determining the full public health insurance cover for medicinal products and the amount of the reimbursement of individual active substances
According to Article 15 (5) of Act No. 48 / 1997 Coll., on Public Health Insurance, and amending and supplementing certain related laws (hereinafter referred to as "the Act"), the Ministry of Health provides:
Medicinal products fully covered by public health insurance and the amount of the payments of individual active substances belonging to anatomical therapeutic chemical (ATC) groups listed in Annex 2 to the Act are listed in the Annex which forms part of this Decree.
This Decree shall take effect on 1 April 1997.
Annex to Decree No 57 / 1997 Coll.
Medicinal products fully covered by health insurance and the amount of individual drug payments
Medicinal products fully covered by health insurance shall be identified in the list of medicinal products fully covered by health insurance and in the list of individual active substances with their level of payment (hereinafter referred to as "the list ') by their code and their name indicating the pharmaceutical form and the package size.
The level of remuneration of each active substance in the crowns for that unit quantity of those active substances is set out in the seventh column of the relevant rows of the list.
In the list, the abbreviations used have the following meaning:
(a) route of administration (application)
| inhal. | inhalační aplikační formy (spraye, prášky a roztoky k inhalaci) |
| intraderm. | aplikační cesta některých alergenů (nitrokožně) |
| lok. | lokální (zevní) aplikační formy |
| parent. | injekční aplikační formy (injekce, suché injekce, infúze) |
| p.o. | perorální aplikační formy (tablety, tobolky, dražé, potahované tablety) |
| p.rect. | rektální aplikační formy |
| PRICK test | k diagnostice |
| subkut. | aplikační cesta některých alergenů |
| sublng | perorální aplikační formy pod jazyk (apikace do dutiny ústní) |
| transd. | transdermální (kožní) aplikační formy (náplasti) |
| vag. | vaginální (poševní) aplikační formy |
| LF | lékové formy |
| aer | aerosol |
| aer dos | aerosol s dávkovačem |
| cap | kapsle, tobolka |
| cap inh | kapsle inhalační (inhaleta) |
| cap ret | kapsle retardovaná |
| crm | krém |
| crm fett | krém mastný |
| crm vag | krém vaginální |
| drg | dražé |
| drg ret | dražé retardované |
| emp | náplast |
| enm | enema, klyzma |
| foa | pěna |
| gel | gel |
| gel oph | gel oční |
| gel vag | gel vaginální |
| glo | globule |
| glo vag | globule vaginální |
| gra | granulát |
| gtt | kapky k vnitřnímu použití |
| gtt oph | kapky oční |
| gít oph+nas | kapky oční a nosní |
| gtt oto | kapky ušní |
| inf | infúze |
| inf sic | lyophilisát pro infúze |
| inh | inhalát |
| inh sol | roztok k inhalaci |
| inj | injekce |
| inj sic | lyophilisát pro injekce |
| kit | kit, souprava |
| lac | lak |
| liq | roztok k zevnímu použití |
| lot | emulze |
| ole | olej |
| pla | náplast |
| plv | prášek (nikoliv zásyp) |
| plv ads | zásyp (pulvis adspersorius) |
| plv por | prášek k perorální aplikaci |
| PRICK sol | roztok diagnostického alergenu |
| pst | pasta |
| sir | sirup |
| sol | roztok k vnitřnímu použití |
| sol nas | roztok nasální |
| sph | šampon |
| spn | houba |
| spr | spray |
| spr nas | spray nasální |
| sup | čípek |
| sus | suspenze |
| sus oph | suspenze oční |
| tab | tableta |
| tab eff | tableta effervescentní |
| tab ent | tableta acidorezistentní obdukovaná |
| tab fc | tableta potahovaná |
| tab obd | tableta obdukovaná (potahovaná) |
| tab ret | tableta retardovaná |
| tab vag | tableta vaginální |
| tct | tinktura |
| ung | mast |
| ung oph | mast oční |
(c) units of quantity of doses of active substances (or international units)
| amp | ampule |
| BA | jedno originální balení |
| C2 | centimetr čtvereční |
| DF | jedna dávka lékové formy |
| Fl | mezinárodní jednotka |
| GM | gram |
| g | gram |
| U | mezinárodní jednotka |
| KU | tisíc U |
| kU | tisíc U |
| MU | milion U |
| MG | miligram |
| mg | miligram |
| ML | mililitr |
| ml | mililitr |
| ks | kus |
| RG | mikrogram |
(d) the name of the columns of Section B:
Column 1 - Group number of active substances
Column 2 - name of the ATC group
column 3 - name of active substance
column 6 - payment in CZK and
Column 7 - Prescription restrictions
Medicinal products fully covered by public health insurance and the amount of individual drug payments
| 1 | A01AA | léčiva k profylaxi zubního kazu (fluorid sodný) | p.o. | |
|---|
| 1.1 | A01AA01 | fluorid sodný | p.o. | 1.1 | MG | 0,88 | |
| 46265 | ZYMAFLUOR 1/4 MG | portblnob200x0.25mg | FAJ | I |
| 64958 | ZYMAFLUOR 1/4 MG | portblnob200x0.25mg | NCH | CH |
| 2 | A01AB | protiinfekční léčiva pro lokální aplikaci | lok. | |
|---|
| 2.1 | A01AB10 | natamycin | lok. | 20 | MG | 7,48 | |
|
| 2.2 | A01AB03 | chlorhexidin | lok. | 1000 | ML | 178,70 | H |
| 3 | A01AC | kortikosteriody pro lokální aplikaci | lok. | |
|---|
| 3.1 | A01AC01 | triamcinolon | lok. | 1 | GM | 13,69 | L/DER,STO,OR L |
| |
| 3.2 | A01AC02 | dexametason | lok. | 1 | GM | 11,68 | L/DER,STO, ORL |
| 4 | A02A | adsorbční antacida | p.o. | |
|---|
| 4.1 | A02AD | kombinace hliníku, vápníku a hořčíku (pevné lékové formy) | p.o. | 10 | DF | 7,44 | |
| 00156 | GASTROGEL SLOVAKOFARMA | tbl 50x500mg | SLO | SK |
| 4.2 | A02AD | kombinace hliníku, vápníku a hořčíku (tekuté lékové formy) | p.o. | 50 | ML | 7,44 | |
| |
| 4.3 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – pevné lékové formy) | p.o. | 10 | DF | 7,44 | |
|
| 4.4 | A02AD01 | kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – tekuté lékové formy) | p.o. | 50 | ML | 7,44 | |
|
| 4.5 | A02AD04 | hydrotalcit (pevné lékové formy) | p.o. | 10 | DF | 7,44 | |
|
| 4.6 | A02AD04 | hydrotalcit (tekuté lékové formy) | p.o. | 50 | ML | 7,44 | |
| 5 | A02BA | antiulceróza ze skupiny H2-antagonistů | p.o. | |
|---|
|
| 5.1 | A02BA01 | cimetidin | p.o. | 0.80 | GM | 4,05 | |
| 64926 | LOCK-2 | tbl obd 100x200mg | CAI | IND |
| 5.2 | A02BA02 | ranitidin nad 75 mg do 150 mg včetně v jedné tabletě | p.o. | 0.30 | GM | 3,80 | |
| 12346 | HISTAC 150 | tbl obd 20x150mg | RXY | IND |
| 45321 | RANISAN 150 MG | por tblflm500x150mg | PMP | CZ |
| 47471 | RANISAN 150 MG | por tblflm60x150mg | PMP | CZ |
| 91280 | RANITAL 150 MG | tbl obd 30x150mg | LEK | SLO |
| 96283 | ULCOSAN | tbl obd 30x150mg | IVX | CZ |
| 5.3 | A02BA02 | ranitidin nad 150 mg v jedné tabletě | p.o. | 0.30 | GM | 3,70 | |
| 76477 | RANITAL 300MG | tbl obd 30x300mg | LEK | SLO |
| 5.4 | A02BA03 | famotidin do 20 mg včetně v 1 tabletě | p.o. | 40 | MG | 3.80 | |
| 75832 | APO-FAMOTIDINE 20 MG | tbl obd 100x20mg | APT | CND |
| 96193 | FAMOSAN 20 MG | por tbl flm 20x20mg | PMP | CZ |
| 59595 | FAMOSAN 20 MG | por tbl flm 50x20mg | PMP | CZ |
| 47862 | FAMOSAN 20 MG | por tbl flm100x20mg | PMP | CZ |
| 66194 | FAMOTIDIN 20-SL | tbl obd 30x20mg | SLO | SK |
| 94207 | ULFAMID 20 | tbl 20x20mg | KRK | SLO |
| 5.5 | A02BA03 | famotidin nad 20 mg v 1 tabletě | p.o. | 40 | MG | 3,70 | |
| 75836 | APO-FAMOTIDINE 40 MG | tbl obd 100x40mg | APT | CND |
| 83206 | FAMOSAN 40 MG | por tbl flm 10x40mg | PMP | CZ |
| 96194 | FAMOSAN 40 MG | por tbl flm 20x40mg | PMP | CZ |
| 59596 | FAMOSAN 40 MG | por tbl flm 50x40mg | PMP | CZ |
| 47863 | FAMOSAN 40 MG | por tbl flm100x40mg | PMP | CZ |
| 47263 | FAMOSAN 40 MG | por tbl flm500x40mg | PMP | CZ |
| 10769 | FAMOTIDIN 40-SL | tbl obd 100x40mg | SLO | SK |
| 66193 | FAMOTIDIN 40-SL | tbl obd 10x40mg | SLO | SK |
| 98035 | ULFAMID 40 | tbl 10x40mg | KRK | SLO |
| 5.6 | A02BA04 | nizatidin | p.o. | 0.30 | GM | 3,80 | |
| |
| 5.7 | A02BA06 | roxatidin | p.o. | 0.15 | GM | 3,80 | |
| | |
| 5.8 | A02BA07 | ranitidin bismut citrát | p.o. | 0.8 | GM | 28,50 | |
| 6 | A02BA | antiulceróza ze skupiny H2-antagonistů | Parent. | |
|---|
| 6.1 | A02BA01 | cimetidin | parent. | 0.80 | GM | 32,06 | H |
| |
| 6.2 | A02BA02 | ranitidin | parent. | 0.30 | GM | 68,43 | H |
|
| 6.3 | A02BA03 | famotidin | parent. | 40 | MG | 68,43 | H |
| 7 | A02BB | antiulceróza ze skupiny prostaglandinů | p.o. | |
|---|
| 7.1 | A02BB01 | misoprostol | p.o. | 0.80 | MG | 47,36 | Z |
| 8 | A02BC | antiulceróza ze skupiny inhibitorů protonové pumpy | p.o. | |
|---|
| 8.1 | A02BC01 | omeprazol (do 10 mg v jedné dávce včetně) | p.o. | 20 | MG | 18,20 | |
| 32174 | OMERA 10 | por cps etd 14x10mg | SLO | SK |
| 32175 | OMERA 10 | por cps etd 28x10mg | SLO | SK |
| 8.2 | A02BC01 | omeprazol (nad 10 mg v jedné dávce) | p.o. | 20 | MG | 9,50 | |
|
| 8.3 | A02BC02 | pantoprazol | p.o. | 40 | MG | 9,50 | |
|
| 8.4 | A02BC03 | lansoprazol | p.o. | 30 | MG | 9,50 | |
|
| 8.5 | A02BC05 | esomeprazol (do 20mg v jedné dávce včetně) | p.o. | 20 | MG | 12,00 | L/GIT,INT, GER |
|
| 8.6 | A02BC05 | esomeprazol (nad 20mg v jedné dávce ) | p.o. | 20 | MG | 6,67 | L/GIT,INT, GER |
|
| 9 | A02BC | antiulceróza ze skupiny inhibitorů protonové pumpy | Parent. | |
|---|
|
| 9.1 | A02BC01 | omeprazol | parent. | 20 | MG | 170,00 | H |
| 31739 | HELICID 40 INF | inf plv sol1x40mg | LEX | CZ |
| 9.2 | A02BC02 | pantoprazol | parent. | 40 | MG | 170,00 | H |
|
| 10 | A02BX | ostatní léčiva peptického vředu | p.o. | |
|---|
| |
| 10.1 | A02BX02 | sukralfát | p.o. | 4 | GM | 9,88 | |
| 84406 | SUCRALAN | tbl 50x1gm | LAR | A |
| 91217 | VENTER | tbl 50x1gm | KRK | SLO |
| 10.2 | A02BX03 | pirenzepin | p.o. | 0.1 | GM | 8,55 | |
|
| 10.3 | A02BX05 | zásaditý citronan bismutitý | p.o. | 0.48 | GM | 23,07 | |
| |
| 10.4 | A02BX | ostatní léčiva peptického vředu (bismut subsalicylat) | p.o. | 3 | DF | 22,29 | |
| |
| 11 | A02BX | ostatní léčiva peptického vředu | Parent. | |
|---|
|
| 11.1 | A02BX03 | pirenzepin | parent. | 20 | MG | 105,58 | H |
|
| 12 | A02DA | antiflatulencia a spasmolytika ATC skupiny A03A | p.o. | |
|---|
|
| 12.1 | A03AA04 | mebeverin | p.o. | 0.30 | GM | 4,94 | |
|
| 12.2 | A03AA05 | trimebutin | p.o. | 0.30 | GM | 4,94 | |
|
| 12.3 | A03AX13 | silikony (pevné lékové formy) | p.o. | 0.50 | GM | 10,91 | |
|
| 12.4 | A03AX13 | silikony (tekuté lékové formy) | p.o. | 0.50 | GM | 18,73 | |
| 93500 | SAB SIMPLEX | sus 1x30ml | PDA | D |
| 12.5 | A03AX58 | alverin (kombinace se silikony) | p.o. | 0.18 | GM | 7,90 | |
| 67269 | METEOSPASMYL | cps 20x60mg | MSR | F |
| 13 | A03AB | anticholinergika s kvarterní oniovou skupinou | p.o. | |
|---|
| 13.1 | A03AB03 | oxyfenon | p.o. | 25 | MG | 2,30 | |
|
| 13.2 | A03AB06 | otilonium bromid | p.o. | 0.12 | GM | 12,42 | |
|
| 13.3 | A03AB11 | poldin | p.o. | 12 | MG | 2,30 | |
|
| 13.4 | A03AB20 | trospium chlorid | p.o. | 40 | MG | 11,84 | |
| 12527 | SPASMEX 15 | tbl 30x15mg | PFL | D |
| 14 | A03AD | muskulotropní spasmolytika | p.o. | |
|---|
| |
| 14.1 | A03AD01 | papaverin | p.o. | 0.1 | GM | 0,68 | |
|
| 14.2 | A03AD02 | drotaverin | p.o. | 0.1 | GM | 4,88 | |
| 46627 | NO-SPA FORTE | tbl 10x80mg | CHN | H |
| 46628 | NO-SPA FORTE | tbl 20x80mg | CHN | H |
| 15 | A03AD | muskulotropní spasmolytika | parent. | |
|---|
|
| 15.1 | A03AD01 | papaverin | parent. | 0.1 | GM | 17,94 | |
|
| 15.2 | A03AD02 | drotaverin | parent. | 0.1 | GM | 25,00 | |
| 59649 | NO-SPA | inj 5x4ml/80mg | CHN | H |
| 16 | A03BA | alkaloidy beladony s terciální aminovou skupinou | p.o. | |
|---|
|
| 16.1 | A03BA01 | atropin | p.o. | 1.5 | MG | 0,49 | |
|
| 17 | A03BA | alkaloidy beladony s terciální aminovou skupinou | parent. | |
|---|
|
| 17.1 | A03BA01 | atropin (do 1mg v 1 ampuli) | parent. | 1.5 | MG | 15,15 | |
|
| 17.2 | A03BA01 | atropin (1 mg a více v 1 ampuli) | parent. | 1.5 | MG | 7,83 | |
| 00394 | ATROPIN BIOTIKA 1MG | inj 10x1ml/1mg | HBS | SK |
| 18 | A03BB | alkaloidy beladony s kvarterní aminovou skupinou | p.o. | |
|---|
|
| 18.1 | A03BB01 | butylskopolamin | p.o. | 60 | MG | 14,10 | |
| 01317 | BUSCOPAN | por tbl obd 20x10mg | BOE | D |
| 19 | A03BB | alkaloidy beladony s kvarterní aminovou skupinou | p.rect. | |
|---|
|
| 19.1 | A03BB01 | butylskopolamin | p.rect. | 60 | MG | 14,66 | |
|
| 20 | A03BB | alkaloidy beladony s kvarterní aminovou skupinou | parent. | |
|---|
|
| 20.1 | A03BB01 | butylskopolamin | parent. | 60 | MG | 37,62 | |
|
| 21 | A03DA | syntetická anticholinergika v kombinaci s analgetiky | p.o. | |
|---|
|
| 21.1 | A03DA | syntetická anticholinergika v komb. s analgetiky | p.o. | 2 | DF | 3,96 | |
|
| 21.2 | A03DA02 | pitofenon kombinace s analgetiky (pevné lékové formy) | p.o. | 2 | DF | 4,11 | |
| 21.3 | A03DA02 | pitofenon kombinace s analgetiky (tekuté lékové formy) | p.o. | 2 | ML | 5,82 | |
|
| 22 | A03DA | syntetická anticholinergika v kombinaci s analgetiky | p.rect. | |
|---|
|
| 22.1 | A03DA02 | pitofenon kombinace s analgetiky | p.rect. | 2 | DF | 13,48 | |
| 91517 | ALGIFEN SUP | rct sup 5 | LEX | CZ |
| 23 | A03DA | syntetická anticholinergika v kombinaci s analgetiky | parent. | |
|---|
|
| 23.1 | A03DA02 | pitofenon kombinace s analgetiky | parent. | 2 | DF | 44,25 | |
| 88709 | ALGIFEN | inj 5x5ml | HBS | SK |
| 24 | A03EA | spasmolytika, psycholeptika, analgetika v kombinaci | p.rect. | |
|---|
|
| 24.1 | A03EA | antispasmodika, psycholeptika, analgetika v komb. | p.rect. | 2 | DF | 12,72 | |
|
| 25 | A03FA | prokinetika (cisaprid) | p.o. | |
|---|
|
| 25.1 | A03FA02 | cisaprid (pevné lékové formy, nad 5 mg do 10 mg včetně v 1 tabletě) | p.o. | 30 | MG | 26,00 | L/GIT,INT,PDD, PSY,GER |
|
| 25.2 | A03FA02 | cisaprid (pevné lékové formy, nad 10 mg v 1 tabletě) | p.o. | 30 | MG | 22,50 | L/GIT,INT,PDD, PSY, GER |
|
| 25.3 | A03FA02 | cisaprid (tekuté lékové formy) s obsahem 1 mg v 1 ml | p.o. | 30 | MG | 57,18 | L/GIT,INT,PDD, PSY, GER |
| 93393 | PREPULSID | por sus 1x100ml | JAN | B |
| 25.4 | A03FA02 | cisaprid (tekuté lékové formy dělené - sáčky) | p.o. | 30 | MG | 26,00 | L/GIT,INT,PDD, PSY, GER |
| 26 | A03FA | prokinetika (ostatní) | p.o. | |
|---|
|
| 26.1 | A03FA01 | metoclopramid hydrochlorid | p.o. | 30 | MG | 4,02 | |
| 56696 | MCP HEXAL 10 | tbl 100x10mg | FST | D |
| 56695 | MCP HEXAL 10 | tbl 50x10mg | FST | D |
| 26.2 | A03FA03 | domperidon | p.o. | 30 | MG | 4,02 | |
|
| 26.3 | A03FA05 | alizaprid | p.o. | 0.15 | GM | 4,02 | |
|
| 26.4 | A03FA | itoprid | p.o. | 0.15 | GM | 28,00 | L/GIT,INT, PDD, PSY,GER |
|
| 26.5 | A03AE02 | tegaserod | p.o. | 12 | MG | 30,00 | |
|
| 27 | A03FA | prokinetika | p.rect. | |
|---|
|
| 27.1 | A03FA01 | metoclopramid | p.rect. | 30 | MG | 41,50 | |
|
| 27.2 | A03FA02 | cisaprid | p.rect. | 30 | MG | 47,57 | |
|
| 27.3 | A03FA03 | domperidon | p.rect. | 0.12 | GM | 41,50 | |
|
| 28 | A03FA | prokinetika | parent. | |
|---|
|
| 28.1 | A03FA01 | metoclopramid | parent. | 30 | MG | 21,10 | O |
|
| 28.2 | A03FA05 | alizaprid | parent. | 0.15 | GM | 16,47 | O |
|
| 29 | A04AA | antiemetika ze skupiny serotoninových antagonistů | p.o. | |
|---|
Nausea and vomiting due to strong serotonin release, i. e. induced by cytotoxic chemotherapy and radiotherapy.
| 29.1 | A04AA01 | ondansetron (pevné lékové formy do 4 mg v jedné tabletě včetně) | p.o. | 16 | MG | 535,50 | P |
| 84794 | EMESET- 4 | tbl obd (10x6)x4mg | CIA | IND |
| 84744 | EMESET- 4 | tbl obd 6x4mg | CIA | IND |
| 04004 | EMETRON 4 MG | por tbl flm 10x4mg | GED | H |
| 81475 | SETRON 4 | por tbl flm 10x4mg | SLO | SK |
| 29.2 | A04AA01 | ondansetron (pevné lékové formy nad 4 mg v jedné tabletě) | p.o. | 16 | MG | 396,90 | P |
| 84793 | EMESET- 8 | tbl obd (10x6)x8mg | CIA | IND |
| 84443 | EMESET- 8 | tbl obd 6x8mg | CIA | IND |
| 04005 | EMETRON 8 MG | por tbl flm 10x8mg | GED | H |
| 03830 | ONDEMET 8 | por tbl flm 10x8mg | LEX | CZ |
| 81476 | SETRON 8 | por tbl flm 10x8mg | SLO | SK |
| 29.3 | A04AA01 | ondansetron (rychle rozpustné pevné lékové formy do 4 mg v jedné tabletě včetně) | p.o. | 16 | MG | 562,30 | P |
|
| 29.4 | A04AA01 | ondansetron ((rychle rozpustné pevné lékové formy nad 4 mg v jedné tabletě) | p.o. | 16 | MG | 416,70 | P |
|
| 29.5 | A04AA01 | ondansetron (tekuté lékové formy) | p.o. | 16 | MG | 754,65 | P |
|
| 29.6 | A04AA01 | ondansetron (léková forma čípků) | p.rect. | 16 | MG | 653,80 | P |
|
| 29.7 | A04AA02 | granisetron | p.o. | 2 | MG | 396,90 | P |
|
| 29.8 | A04AA03 | tropisetron | p.o. | 5 | MG | 396,90 | P |
|
| 29.9 | A04AA04 | dolasetron | p.o. | 200 | MG | 396,90 | P |
|
| 30 | A04AA | antiemetika ze skupiny serotoninových antagonistů | parent. | |
|---|
Nausea and vomiting due to strong serotonin release, i. e. induced by cytotoxic chemotherapy and radiotherapy.
| 30.1 | A04AA01 | ondansetron (do 4 mg v jedné ampuli včetně) | parent. | 16 | MG | 895,70 | P |
| 84441 | EMESET | inj 5x2ml/4mg | CIA | IND |
| 04002 | EMETRON 4 MG | inj sol 5x2ml/4mg | GED | H |
| 30.2 | A04AA01 | ondansetron (nad 4 mg v jedné ampuli) | parent. | 16 | MG | 722,40 | P |
| 84442 | EMESET | inj 5x4ml/8mg | CIA | IND |
| 04003 | EMETRON 8 MG | inj sol 5x4ml/8mg | GED | H |
| 03820 | ONDEMET 8 INJ | inj sol 5x4ml/8mg | LEX | CZ |
| 30.3 | A04AA02 | granisetron | parent. | 3 | MG | 474,20 | P |
|
| 30.4 | A04AA03 | tropisetron (do 2,5 mg včetně v jedné ampuli) | parent. | 5 | MG | 816,20 | P |
|
| 30.5 | A04AA03 | tropisetron (nad 2,5 mg v jedné ampuli) | parent. | 5 | MG | 474.20 | P |
|
| 30.6 | A04AA04 | dolasetron | parent. | 100 | MG | 474,20 | P |
|
| 31 | A04AD | různá antiemetika | p.o. | |
|---|
|
| 31.1 | A04AD | různá antiemetika (theoklát embraminu) | p.o. | 50 | MG | 3,31 | |
|
| 31.2 | A04AD | různá antiemetika (theoklát moxastinu) | p.o. | 0.1 | GM | 3,31 | |
|
| 31.3 | A04AD | různá antiemetika (meklozin) | p.o. | 50 | MG | 3,31 | |
|
| 32 | A04AD | různá antiemetika | p.rect. | |
|---|
|
| 32.1 | A04AD01 | různá antiemetika (theoklát moxastinu) | p.rect. | 0.1 | GM | 9,38 | |
|
| 33 | A05AA | hepatika ze skupiny žlučových kyselin | p.o. | |
|---|
|
| 33.1 | A05AA01 | kyselina chenodeoxycholová | p.o. | 1 | GM | 21,46 | L/GIT,INF |
|
| 33.2 | A05AA02 | kyselina ursodeoxycholová | p.o. | 0.75 | GM | 24,10 | L/GIT,INF |
| 91017 | URSOFALK | cps 100x250mg | FAK | D |
| 97864 | URSOSAN | por cps dur50x250mg | PMP | CZ |
| 34 | A05AX | ostatní hepatika | p.o. | |
|---|
|
| 34.1 | A05AX | jiná léčiva onemocnění žlučníku (fenipentol) | p.o. | 3 | DF | 1,55 | |
|
| 34.2 | A05AX02 | hymekromon | p.o. | 1.20 | GM | 5,96 | |
|
| 35 | A05BA | léčiva onemocnění jater | p.o. | |
|---|
|
| 35.1 | A05BA | léčiva onemocnění jater (fosfolipidy) | p.o. | 4 | DF | 11,73 | |
| 35.2 | A05BA | léčiva onemocnění jater (silymarin v kombinaci) | p.o. | 0.21 | GM | 5,68 | |
|
| 35.3 | A05BA03 | silymarin (do 70 mg včetně v jedné tabletě) | p.o. | 0.21 | GM | 5,68 | |
| 76762 | SILYMARIN AL 50 | drg 30x50mg | APA | D |
| 35.4 | A05BA03 | silymarin (nad 70 mg v jedné tabletě) | p.o. | 0.21 | GM | 4,40 | |
|
| 36 | A05BA | léčiva onemocnění jater | parent. | H |
|---|
|
| 36.1 | A05BA | léčiva onemocnění jater (fosfolipidy) | parent. | 1 | DF | 42,72 | H |
| 92325 | ESSENTIALE N | inj sol 5x5ml | NAJ | D |
| 36.2 | A05BA03 | silymarin | parent. | 0.35 | GM | 2345,13 | H |
| 31341 | LEGALON SIL | inj sic 4x350mg | MAU | D |
| 37 | A06A | osmoticky působící nevstřebatelné cukry | p.o., p.rect. | |
|---|
|
| 37.1 | A06AD10 | kombinace minerálních solí (k přípravě Golytelyho roztoku) | p.o. | 4 | DF | 242,70 | |
|
| 37.2 | A06AD11 | laktulóza | p.o. | 6,7 | GM | 5,18 | L/GIT,INT,GER, PDD,CHI |
|
| 37.3 | A06AD12 | laktitol | p.o. | 10 | GM | 3,71 | L/GIT,INT,GER, CHI |
|
| 37.4 | A06AG10 | sorbitol v kombinaci s kont. laxativem | p.rect. | 2 | DF | 174,01 | |
| 92489 | YAL | sol 10x67.5ml | TRM | D |
| 38 | A07AA | střevní antimykotická léčiva | p.o. | |
|---|
|
| 38.1 | A07AA01 | neomycin | p.o. | 5 | GM | 609,91 | H |
|
| 38.2 | A07AA02 | nystatin | p.o. | 1.5 | MU | 5,96 | |
|
| 38.3 | A07AA03 | natamycin | p.o. | 0.3 | GM | 41,01 | |
|
| 38.4 | A07AA11 | rifaximin | p.o. | 0.8 | GM | 85,00 | P |
Rifaximin is indicated for use in:
1) hepatic encephalopathy
2) Prophylaxis in colorectal surgery
3) pseudomembranose colitis
4) bacterial infections associated with non-specific inflammatory diseases of the bowel (Crohn 's disease and ulcerative colitis) susceptible to rifaximin
5) Proven diverticulitis of the colon, susceptible to rifaximine.
| 39 | A07EA | kortikosteroidy pro rektální aplikaci nebo působíci v tlustém střevu | p.rect., p.o. | |
|---|
|
| 39.1 | A07EA06 | budesonid | p.rect. | 2 | MG | 250,00 | L/GIT,INT,GER |
|
| 39.2 | A07EA06 | budesonid | p.o. | 9 | MG | 105,35 | P |
Treatment with oral budesonide is performed by a gastro-enterologist or an intern in an acute attack or chronic phase of Crohn 's disease, in particular where the need for steroid treatment occurs and the need to minimise their systemic effects.
| 64786 | BUDENOFALK | cps ent 50x3mg | FAK | D |
| 39.3 | A07EB01 | natrium kromoglykát | p.o. | 800 | MG | 73,58 | P |
Diagnosis demonstrates and treatment is indicated by an allergologist and a clinical immunologist based on an allergologic examination of skin possibly exposure tests or a specific IgE antibody: with proven food allergy with severe local or overall symptoms that cannot be fully corrected by elimination of food allergens.
| 93797 | NALCROM | cps 100x100mg | FIS | GB |
| 40 | A07EC | aminosalicylová kyselina a její deriváty | p.o. | |
|---|
|
| 40.1 | A07EC01 | sulfasalazin | p.o. | 2 | GM | 16,34 | L/GIT,INT,REV, GER |
| 02159 | SULFASALAZIN K | por tbl flm50x500mg | KRK | SLO |
| 04304 | SULFASALAZIN K-EN | por tblent100x500mg | KRK | SLO |
| 40.2 | A07EC02 | mesalazin (potahované tablety) | p.o. | 1.5 | GM | 23,43 | L/GIT,INT,GER |
| 76479 | ASACOL 400 | por tblflm 100x400mg | TLT | CH |
| 93235 | SALOFALK 250 | tbl ent 100x250mg | FAK | D |
| 40.3 | A07EC02 | mesalazin (tablety s řízeným uvolňováním) | p.o. | 1.5 | GM | 44,12 | P |
Mesalazine powder - modified-release tablets:
It is a first-choice aminosalicylate in idiopathic intestinal inflammation (Crohn's disease) affecting the upper part of the digestive tract, the small intestine and the adjacent part of the colon (ileocolitis). It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon, it is indicated here if other aminosalicylates fail.
| 40.4 | A07EC02 | mesalazin (léková forma - sáčky) | p.o. | 1.5 | GM | 44,12 | P |
Mesalazine per os - pharmaceutical forma-sachets: It is an aminosalicylate of first choice for idiopathic intestinal inflammation (Crohn 's disease) affecting the upper part of the digestive tract, small intestine and adjacent parts of the colon (ileocolitis) in children under 3 years of age and in patients with swallowing disorder. It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon, it is indicated here if other aminosalicylates fail.
| 41 | A07EC | aminosalicylová kyselina a její deriváty | p.rect. | |
|---|
| |
| 41.1 | A07EC02 | mesalazin (enm.) | p.rect. | 1.5 | GM | 69,31 | L/GIT |
| 76700 | ASACOL ENEMA 4 G | sus rec 1x100ml/4gm | TLT | CH |
| 06250 | ASACOL ENEMA 4 G | sus rec 7x100ml/4gm | TLT | CH |
| 93770 | SALOFALK 4 GM | enm 7x60ml/4gm | FAK | D |
| 41.2 | A07EC02 | mesalazin (čípky do 250 mg včetně) | p.rect. | 1.5 | GM | 118,94 | L/GIT |
| 93239 | SALOFALK 250 | sup 30x250mg | FAK | D |
| 41.3 | A07EC02 | mesalazin (čípky nad 250 mg) | p.rect. | 1.5 | GM | 102,63 | L/GIT |
| 76704 | ASACOL | sup 20x500mg | TLT | CH |
| 75568 | SALOFALK 500 | sup 10x500mg | FAK | D |
| 75569 | SALOFALK 500 | sup 30x500mg | FAK | D |
| 41.4 | A07EC | paraaminosalicylát sodný | p.rect. | 2 | GM | 46,20 | L/GIT |
|
| 42 | A07FA | protiprůjmové mikroorganismy | p.o. | |
|---|
|
| 42.1 | A07FA01 | organismy produkující kyselinu mléčnou, tekuté lékové formy | p.o. | 2 | ML | 3,61 | L/PDD,GIT,GER, INF |
| 09159 | HYLAK FORTE | sol 1x100ml | MCK | D |
| 09158 | HYLAK FORTE | sol 1x30ml | MCK | D |
| 42.2 | A07FA01 | organismy produkující kyselinu mléčnou, pevné lékové formy | p.o. | 4 | DF | 3,86 | L/PDD,GIT,GER, INF |
|
| 42.3 | A07FA02 | saccharomyces boulardii sicatus | p.o. | 1 | DF | 5,50 | P |
The product is indicated for the treatment of infectious diarrhoea, prophylaxis and treatment of diarrhoea in patients fed with gastric or enteral nutrition using a probe. It cannot be prescribed (and covered by public health insurance) for prophylaxis and treatment of travellers' diarrhoea.
| 42.4 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), lékové formy tobolek | p.o. | 2 | DF | 25,14 | P |
The product is indicated for maintenance treatment in non-specific intestinal inflammation.
| 42.5 | A07FA | protiprůjmové mikroorganismy (Escherichia coli), tekuté lékové formy | p.o. | 1 | DF | 43,99 | L/PDD, INF |
|
| 42.6 | A07BC05 | diosmectit (plv. susp.) | p.o. | 1 | DF | 3,86 | L/PDD, INF |
|
| 43 | A09AA | enzymové přípravky | p.o. | |
|---|
|
| 43.1 | A09AA | enzymové přípravky (s pankreatinem, dle lipázy) | p.o. | 5000 | U | 1,03 | |
| 04139 | PANZYNORM FORTE | drg 30 | KRK | SLO |
| 43.2 | A09AA | multienzymy (obsahující pankreatin, trypsin, chymotrypsin, bromelain, papain, amylasu, lipasu, rutosid) | p.o. | 6 | DF | 8,80 | P |
Treatment with multienzyme agents is performed by an oncologist, surgeon, intern or dermatologist in lymphoedema in connection with radical surgery or radiotherapy for malignancy, provided that physical treatment for the control of lymphoedema is insufficient or cannot be administered.
| 43.3 | A09AA02 | multienzymy (dle lipázy, do 10.000 U v 1 tabletě včetně) | p.o. | 5000 | U | 1,47 | |
|
| 43.4 | A09AA02 | multienzymy (dle lipázy, nad 10.000 do 20.000 U včetně v jedné tabletě) | p.o. | 5000 | U | 1,45 | |
| 56167 | PANGROL 20000 | tbl obd 50 | BCE | D |
| 21362 | PANGROL 400 | tbl obd 48 | BCE | D |
| 43.5 | A09AA02 | multienzymy (dle lipázy, nad 10.000 do 20.000 U včetně v jedné tabletě) - formy mikropelet | p.o. | 5000 | U | 1,90 | |
|
| 43.6 | A09AA02 | multienzymy (dle lipázy, nad 20.000 U v jedné tabletě) | p.o. | 5000 | U | 1,61 | |
|
| 44 | A09AC | pepsin a kyselinotvorné látky | p.o. | |
|---|
|
| 44.1 | A09AC01 | pepsin a kyselinotvorné látky | p.o. | 2 | DF | 2,79 | |
|
| 45 | A10A | insuliny (rozpustné humánní) | parent. | |
|---|
|
| 45.1 | A10AB01 | insulin lidský rychle účinkující 100 U/ml, cartridge | parent. | 40 | U | 22,86 | L/DIA |
|
| 45.2 | A10AB01 | insulin lidský rychle účinkující, lahv. | parent. | 40 | U | 18,85 | |
| 44576 | HUMULIN R 100 M.J./ML | inj 1x10ml/1ku | LIL | F |
| 40876 | INSULIN-HM R | inj 1x10ml/1ku | LEX | CZ |
| 45.3 | A10AB01 | insulin lidský rychle účinkující pro aplikaci do insulinových pump | parent. | 40 | U | 27,96 | L/DIA |
| 81496 | VELOSULIN HM (GE) | inj sol1x10ml/100ut | NOO | DK |
| 45.4 | A10AB04 | insulin-lispro krátce působící, lahv. | parent. | 40 | U | 28,28 | |
|
| 45.5 | A10AB04 | insulin-lispro krátce působící, cartridge 100U/ML | parent. | 40 | U | 30,49 | L/DIA |
|
| 45.6 | A10AB05 | insulin-aspart krátce působící, lahv. | parent. | 40 | U | 28,28 | |
|
| 45.7 | A10AB05 | insulin-aspart krátce působící, cartridge 100U/ML | parent. | 40 | U | 30,49 | L/DIA |
|
| 46 | A10A | insuliny (rozpustné monokomponentní) | parent. | |
|---|
|
| 46.1 | A10AB03 | insulin vepřový rychle účinkující - lahv. | parent. | 40 | U | 16,48 | |
| 42366 | HYPURIN PORCINE NEUTRAL | inj 1x10ml/1000ut | CBF | GB |
| 83725 | INSULIN-MONO N | inj 1x10ml/400ut | LEX | CZ |
| 46.2 | A10AB03 | insulin vepřový rychle účinkující - cartridge | parent. | 40 | U | 22,86 | L/DIA |
|
| 47 | A10A | insuliny (suspenzní humánní) | parent. | |
|---|
|
| 47.1 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge | parent. | 40 | U | 22,86 | L/DIA |
|
| 47.2 | A10AC01 | insulin lidský středně dlouze účinkující 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40 | U | 28,00 | P, L/DIA |
Diabetes mellitus treated with intensified insulin regimen in people with defined visual impairment determined by ophthalmologist examination - practical or actual vision: decrease in visual acuity below 3 / 60 inclusive or binocular visual field less than 10 st. around central fixation.
| 47.3 | A10AC01 | insulin lidský středně dlouze účinkující, lahv. | parent. | 40 | U | 18,85 | |
| 44567 | HUMULIN N 100 M.J./ML | inj 1x10ml/1ku | LIL | F |
| 40875 | INSULIN-HM NPH | inj 1x10ml/1ku | LEX | CZ |
| 47.4 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge | parent. | 40 | U | 22,86 | L/DIA |
|
| 47.5 | A10AD01 | insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge v jednorázovém aplikátoru | parent. | 40 | U | 28,00 | P, L/DIA |
Diabetes mellitus treated with intensified insulin regimen in people with defined visual impairment determined by ophthalmologist examination - practical or actual vision: decrease in visual acuity below 3 / 60 inclusive or binocular visual field less than 10 st. around central fixation.
| 47.6 | A10AD01 | insulin lidský kombinace středně a rychle účinného, lahv. | parent. | 40 | U | 18,85 | |
| 40878 | INSULIN-HM MIX 30 | inj 1x10ml/1ku | LEX | CZ |
| 47.7 | A10AE01 | insulin lidský dlouhodobě účinkující | parent. | 40 | U | 18,85 | |
|
| 47.8 | A10AD | insulin aspart, kombinace středně a rychle účinného, cartridge | parent. | 40 | U | 30,49 | L/DIA |
|
| 47.9 | A10AE04 | insulin glargin, dlouhodobě účinný, cartridge | parent. | 40 | U | 30,49 | L/DIA |
|
| 47.10 | A10AE04 | insulin glargin, dlouhodobě účinný, lahv. | parent. | 40 | U | 22,86 | L/DIA |
|
| 48 | A10A | insuliny (suspenzní monokomponentní) | parent. | | |
|---|
|
| 48.1 | A10AC03 | insulin vepřový středně dlouze účinkující | parent. | 40 | U | 12,64 | |
|
| 48.2 | A10AC30 | insulin kombinace zvířecí středně dlouze účinkující | parent. | 40 | U | 12,64 | |
| 83726 | INSULIN-MONO D | inj 1x10ml/400ut | LEX | CZ |
| 83727 | INSULIN-MONO ID | inj 1x10ml/400ut | LEX | CZ |
| 48.3 | A10AE30 | insulin kombinace zvířecí dlouhodobě účinkující | parent. | 40 | U | 12,64 | |
|
| 48.4 | A10AC02 | insulin hovězí středně dlouze účinkující - lahv. | parent. | 40 | U | 11,99 | |
| 42368 | HYPURIN BOVINE ISOPHANE | inj 1x10ml/1000ut | CBF | GB |
| 48.5 | A10AC02 | insulin hovězí středně dlouze účinkující - cartridge | parent. | 40 U | 21,60 | L/DIA |
| 42369 | HYPURIN BOVINE ISOPHANE | inj 5x1.5ml/150ut | CBF | GB |
| 48.6 | A10AE02 | insulin hovězí dlouhodobě účinkující - lahv. | parent. | 40 | U | 11,99 | |
| 42370 | HYPURIN BOVINE PROT.ZINC.SULF. | inj 1x10ml/1000ut | CBF | GB |
| 49 | A10BA | léčiva snižující hladinu cukru ze skupiny derivátů biguanidu a inhibitorů alfa-glukosidáz | p.o. | |
|---|
|
| 49.1 | A10BA02 | metformin hydrochlorid | p.o. | 2 | GM | 6,67 | |
| 64642 | ADIMET | tbl obd 120x850mg | MCK | D |
| 31957 | GLUFORMIN | tbl obd 60x850mg | PLI | CHO |
| 06668 | METFIREX 500 MG | por tbl flm60x500mg | CHN | H |
| 41507 | METFIREX 500 MG | por tblflm120x500mg | CHN | H |
| 06657 | METFIREX 850 MG | por tbl flm60x850mg | CHN | H |
| 41506 | METFIREX 850 MG | por tblflm 120x850mg | CHN | H |
| 32784 | METFOGAMMA 850 | por tblflm 120x850mg | ARN | D |
| 53960 | METFORMIN 500 LÉČIVA | por tblflm 100x500mg | LEX | CZ |
| 53961 | METFORMIN 850 LÉČIVA | por tbl flm50x850mg | LEX | CZ |
| 05643 | METFORMIN 850 LÉČIVA | por tblflm100x850mg | LEX | CZ |
| 30343 | METFORMIN AL 500 | por tbl flm30x500mg | APA | D |
| 30356 | METFORMIN AL 500 | por tbl flm60x500mg | APA | D |
| 30357 | METFORMIN AL 500 | por tblflm 100x500mg | APA | D |
| 30361 | METFORMIN AL 500 | por tblflm120x500mg | APA | D |
| 40001 | METFORMIN AL 850 | por tbl flm30x850mg | APA | D |
| 40155 | METFORMIN AL 850 | por tbl flm60x850mg | APA | D |
| 40172 | METFORMIN AL 850 | por tblflm100x850mg | APA | D |
| 40174 | METFORMIN AL 850 | por tblflm 120x850mg | APA | D |
| 56503 | SIOFOR 500 | por tbl flm60x500mg | BBE | D |
| 56504 | SIOFOR 850 | por tbl flm60x850mg | BBE | D |
| 49.2 | A10BA03 | buformin | p.o. | 0.2 | GM | 3,47 | |
| 02558 | SILUBIN RETARD | tbl obd 60x100mg | GRU | D |
| 49.3 | A10BF01 | akarboza | p.o. | 0.3 | GM | 10,26 | |
|
| 49.4 | A10BG02 | rosiglitason s obsahem 4 mg v jedné tabletě | p.o. | 1 | DF | 38,50 | P |
|
| 49.5 | A10BG03 | pioglitazon s obsahem 15 mg v jedné tabletě | p.o. | 1 | DF | 34,05 | P |
|
| 49.6 | A10BG03 | pioglitazon s obsahem 30 mg v jedné tabletě | p.o. | 1 | DF | 44,27 | P |
Thiazolidinedione derivatives are for the combined treatment of type 2 diabetic patients with insulin resistance. They are indicated in combination with a sulphonylurea, where metformin cannot be used for intolerance, and (b) in combination with metformin, where monotherapy with this preparation has not achieved the desired glycaemic control, while unsatisfactory glycaemic control (fasting glucose greater than 8.0 mmol / l, postprandial glucose greater than 10 mmol / l and glycated haemoglobin greater than 8.5%) persists and an increased risk of cardiovascular disease (arterial hypertension, dyslipidaemia and increased albumin greater than 20 µg / min or 2.5 g / mol creatinine) is present. The daily dose for public health insurance is 4mg (1tbl.) rosiglitazone or 15mg (1tbl.) pioglitazone or 30mg (1tbl.) pioglitazone.
| 50 | A10BB | léčiva snižující hladinu cukru ze skupiny derivátů sulfonylmočoviny | p.o. | |
|---|
| 50.1 | A10BB01 | glibenklamid (do 1 mg v jedné tabletě včetně) | p.o. | 10 | MG | 2,30 | |
|
| 50.2 | A10BB01 | glibenklamid (nad 1 mg v jedné tabletě) | p.o. | 10 | MG | 0,86 | |
| 01791 | BETANASE | tbl 5x(3x10)x5mg | CAI | IND |
| 50.3 | A10BB01 | glibenklamid (mikronizované formy, do 1,75 mg včetně v jedné tabletě) | p.o. | 7 | MG | 1,37 | |
| 94523 | GLUCOBENE 1.75 MG | tbl 120x1.75mg | MCK | D |
| 50.4 | A10BB01 | glibenklamid (mikronizované formy, nad 1,75 mg v jedné tabletě) | p.o. | 7 | MG | 0,86 | |
| 94525 | GLUCOBENE 3.5 MG | tbl 120x3.5mg | MCK | D |
| 50.5 | A10BB02 | chlorpropamid | p.o. | 0.37 | GM | 0,78 | |
|
| 50.6 | A10BB03 | tolbutamid | p.o. | 1.5 | GM | 2,32 | |
| 00120 | DIRASTAN | tbl50 (=5x10)x500mg | SLO | SK |
| 50.7 | A10BB04 | glibornurid | p.o. | 38 | MG | 4,79 | |
|
| 50.8 | A10BB05 | tolazamid | p.o. | 1 | GM | 2,49 | |
|
| 50.9 | A10BB07 | glipizid | p.o. | 10 | MG | 4,00 | |
| 87110 | ANTIDIAB | tbl 30x5mg | KRK | SLO |
| 50.10 | A10BB08 | gliquidon | p.o. | 60 | MG | 5,65 | |
| 99336 | GLURENORM | tbl 30x30mg | SLO | SK |
| 50.11 | A10BB09 | gliklazid | p.o. | 0.16 | GM | 6,55 | |
| 31897 | GLICIREX | por tbl nob 60x80mg | RTT | D |
| 50.12 | A10BB09 | gliklazid, retardované lékové formy | p.o. | 2 | DF | 6,55 | |
|
| 50.13 | A10BB12 | glymepirid do 2 mg v jedné tabletě včetně | p.o. | 2 | MG | 6,55 | |
|
| 50.14 | A10BB12 | glymepirid nad 2 mg v jedné tabletě | p.o. | 2 | MG | 5,45 | |
|
| 50.15 | A10BD02 | metformin a glibenklamid - kombinace | p.o. | 3 | DF | 5,85 | |
|
| 50.16 | A10BX02 | repaglinid | p.o. | 1 | DF | 5,00 | L/DIA |
|
| 50.17 | A10BX03 | nateglinid | p.o. | 1 | DF | 5,00 | L/DIA |
|
| 51 | A11CA | vitamin A a jeho deriváty | p.o. | |
|---|
|
| 51.1 | A11CA01 | retinol (vitamin A) | p.o. | 50 | KU | 1,12 | |
| 00347 | VITAMIN A-SLOVAKOFARMA | cps 50x30ku | SLO | SK |
| 52 | A11CA | vitamin A a jeho deriváty | parent. | |
|---|
| 52.1 | A11CA01 | retinol (vitamin A) | parent. | 50 | KU | 10,40 | |
| 00396 | AXEROPHTHOL BIOTIKA | inj 5x1ml/50ku | BTA | SK |
| 53 | A11CC | vitamin D a jeho deriváty (kalcitriol) | p.o. | |
|---|
Treatment is performed by an internist, endocrinologist, urologist, pediatrician and physician on the dialysis unit:
(a) senile osteoporosis or osteoporotic pathological fracture that developed during vitamin D and calcium-free therapy
(b) glucocorticoids induced by osteoporosis
(c) in patients with a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated levels of PTH resistant to vitamin D and calcium therapy
2. Treatment of renal osteodystrophy in patients with chronic renal insufficiency (mainly in patients on dialysis)
3. Vitamin D resistant curve treatment
4. Treatment of vitamin D resistant osteomalacia
5. Treatment of vitamin D and calcium-resistant hypoparathyroidism.
| 53.1 | A11CC04 | kalcitriol | p.o. | 1 | RG | 35,10 | P |
| 47583 | ROCALTROL 0.25 MCG | por cpsmol30x0.25rg | RPS | D |
| 58255 | ROCALTROL 0.25 MCG | por cpsmol30x0.25rg | RPS | D |
| 54 | A11CC | vitamin D a jeho deriváty (ostatní) | p.o. | |
|---|
|
| 54.1 | A11CC01 | ergokalciferol (tekuté lékové formy, do 200 U/ml včetně) | p.o. | 6 KU | 13,10 |
|
| 54.2 | A11CC01 | ergokalciferol (tekuté lékové formy, nad 200 U/ml) | p.o. | 6 KU | 0,78 |
| 00716 | INFADIN | gtt 1x10ml /100mg | SLO | SK |
| 54.3 | A11CC01 | ergocalciferol (pevné lékové formy) | p.o. | 6 | KU | 0,54 | |
| 00353 | VITAMIN D SLOVAKOFARMA | cps 1x300ku | SLO | SK |
| 54.4 | A11CC02 | dihydrotachysterol | p.o. | 1 | MG | 17,13 | |
| 94445 | TACHYSTIN | gtt 1x20ml/20mg | CHV | D |
| 54.5 | A11CC03 | alfakalcidol do 0,50 rg včetně | p.o. | 1 | RG | 18,60 | P |
|
| 54.6 | A11CC03 | alfakalcidol nad 0,50 rg | p.o. | 1 | RG | 17,55 | P |
Treatment with alfacalcidol is performed by an internist, an endocrinologist, a urologist, a pediatrician and a physician on a dialysis unit in indications:
(a) senile osteoporosis or osteoporotic pathological fracture that developed during vitamin D and calcium-free therapy
(b) glucocorticoids induced by osteoporosis
(c) in patients with a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated levels of PTH resistant to vitamin D and calcium therapy
2. Treatment of renal osteodystrophy in patients with chronic renal insufficiency (mainly in patients on dialysis)
3. Vitamin D resistant curve treatment
4. Treatment of vitamin D resistant osteomalacia
5. Treatment of vitamin D and calcium-resistant hypoparathyroidism.
| 54.7 | A11CC05 | cholekalciferol – tekuté lékové formy | p.o. | 0.5 | MG | 3,84 | |
| 12023 | VIGANTOL | por gtt sol 1x10ml | MEC | D |
| 54.8 | A11CC05 | cholekalciferol - pevné lékové formy | p.o. | 0.5 | MG | 1,04 | |
| 05877 | VITAMIN D 800-SLOVAKOFARMA | cps 30x800rg | SLO | SK |
| 55 | A11CC | vitamin D a jeho deriváty (kalcitriol) | parent. | |
|---|
Treatment with calcitriol is performed by an internist, an endocrinologist, a urologist, a pediatrician and a physician on a dialysis unit in indications:
(a) senile osteoporosis or osteoporotic pathological fracture that developed during vitamin D and calcium-free therapy
(b) glucocorticoids induced by osteoporosis
(c) in patients with a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated levels of PTH resistant to vitamin D and calcium therapy
2. Treatment of renal osteodystrophy in patients with chronic renal insufficiency (mainly in patients on dialysis)
3. Vitamin D resistant curve treatment
4. Treatment of vitamin D resistant osteomalacia
5. Treatment of vitamin D and calcium-resistant hypoparathyroidism.
| 55.1 | A11CC04 | kalcitriol | parent. | 1 | RG | 174,20 | P |
| 56 | A11CC | vitamin D a jeho deriváty (ostatní) | parent. | |
|---|
| 56.1 | A11CC01 | ergokalciferol | parent. | 6 | KU | 0,72 | |
| 00405 | CALCIFEROL BIOTIKA FORTE | inj sol 1x1ml/7.5mg | BTA | SK |
| 56677 | CALCIFEROL BIOTIKA FORTE | ini sol 5x1ml/7.5mg | BTA | SK |
| 56.2 | A11CC05 | cholekalciferol | parent. | 1 | KU | 0,93 | |
| 11093 | VIGANTOL 50000 | inj 5x1ml/1.25mg | MEC | D |
| 57 | A11DA | vitamin B1 a jeho deriváty | parent. | |
|---|
|
| 57.1 | A11DA | thiamin (vit. B1), prostý | parent. | 75 | MG | 5,50 | H |
|
| 57.2 | A11DA01 | thiamin (vit. B1) | parent. | 50 | MG | 5,50 | H |
| 92502 | THIABENE | inj 6x2ml/100mg | MCK | D |
| 58.1 | A11GA01 | kyselina askorbová (vitamin C) | parent. | 0.2 | GM | 3,32 | H |
| 92729 | ACIDUM ASCORBICUM BIOTIKA | inj 5x5ml/500mg | HBS | SK |
| 59 | A11HA | vitamin B2, B6 a E | parent. | |
|---|
| 59.1 | A11HA02 | pyridoxin hydrochlorid (vitamín B6) | parent. | 0.16 | GM | 16,58 | H |
| 00584 | PYRIDOXIN LÉČIVA INJ. | inj sol 5x1ml/50mg | LEX | CZ |
| 59.2 | A11HA03 | tokoferol (vitamin E, do 30 mg/ml včetně) | parent. | 0.2 | GM | 69,90 | H |
|
| 59.3 | A11HA03 | tokoferol (vitamin E, nad 30 mg/ml) | parent. | 0.2 | GM | 7,58 | H |
|
| 59.4 | A11HA04 | riboflavin (vitamin B2) | parent. | 20 | MG | 6,11 | H |
| 60 | A11JA | kombinace vitamínů | parent. | |
|---|
| 60.1 | A11JA | kombinace vitamínů | parent. | 10 | ML | 93,80 | H |
|
| 60.2 | A11DB | kombinace vitamínů (vitamin B1, B6, B12) | parent. | 10 | ML | 93,80 | H |
| 11487 | MILGAMMA N | inj 100x2ml | SLH | D |
| 11486 | MILGAMMA N | inj 25x2ml | SLH | D |
| 11488 | MILGAMMA N | inj 500x2ml | SLH | D |
| 67075 | MILGAMMA N | inj 500x2ml | WGP | D |
| 11485 | MILGAMMA N | inj 5x2ml | SLH | D |
| 61 | A12A | soli vápníku včetně kombinaci vápníku a fluoru | p.o. | |
|---|
| 61.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | p.o. | 0.5 | GM | 0,59 | |
|
| 61.2 | A12AA04 | uhličitan vápenatý (na obsah vápníku) tablety | p.o. | 0.5 | GM | 2,34 | |
| 70536 | TBL.CALCII CARBON.PRAEC.0.5 MVM | portblnob1000x0.5gm | MVM | CZ |
| 61.3 | A12AA04 | uhličitan vápenatý (na obsah vápníku), léková forma šumivé tablety | p.o. | 0.5 | GM | 2,34 | |
|
| 61.4 | A12AA04 | uhličitan vápenatý(na obsah vápníku), léková forma prášky | p.o. | 0.5 | GM | 2,34 | |
|
| 61.5 | A12AA07 | chlorid vápenatý (na obsah vápníku), tekuté lékové formy, | p.o. | 0.2 | GM | 0,64 | |
| 00409 | CALCIUM CHLORATUM BIOTIKA | inj 5x10ml 10% | HBS | SK |
| 61.6 | A12AA12 | octan vápenatý (na obsah vápníku) | p.o. | 0.5 | GM | 10,00 | |
|
| 61.7 | A12AA20 | vápník (kombinace různých solí, na obsah vápníku) | p.o. | 0.5 | GM | 2,54 | |
|
| 61.8 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a do 5 mg cholekalciferolu v 1 dávce včetně | p.o. | 1 | DF | 3,26 | |
|
| 61.9 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a nad 5 mg cholekalciferolu v 1 dávce | p.o. | 1 | DF | 4,00 | |
|
| 61.10 | A12AX | uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) nad 600 mg vápníku v 1 dávce | p.o. | 1 | DF | 6,51 | |
| 46472 | CALTRATE PLUS | tbl obd 30 | JDC | USA |
| 61.11 | A12AX | vápník v kombinaci s fluorem (fluorofosfat sodný) | p.o. | 1 | DF | 5,38 | L/INT,GYN,ORT REV,GER |
| |
| 61.12 | A12AX | vápník v kombinaci s fluorem (levoglutamid fluorofosfat) | p.o. | 1 | DF | 4,01 | L/INT,GYN,ORT REV,GER |
|
| 61.13 | A12CX | jiné minerální produkty (na obsah vápníku) | p.o. | 0.5 | GM | 1,14 | |
| 99808 | BIOMIN H | plv 60x3gm(sÁČky) | BMN | SK |
| 62 | A12AA | soli vápníku | parent. | |
|---|
| 62.1 | A12AA03 | glukonát vápenatý (na obsah vápníku) | parent. | 3 | GM | 59,16 | |
| 00407 | CALCIUM BIOTIKA | inj sol 10x10ml/1gm | HBS | SK |
| 62.2 | A12AA07 | chlorid vápenatý (na obsah vápníku) | parent. | 0.2 | GM | 2,85 | |
| 00409 | CALCIUM CHLORATUM BIOTIKA | inj 5x10ml 10% | HBS | SK |
| 63.1 | A12BA | draslík v kombinaci s hořčíkem (na obsah draslíku) | p.o. | 1 | GM | 9,78 | |
|
| 63.2 | A12BA | draslík (na obsah draslíku) | p.o. | 1.5 | GM | 2,44 | |
|
| 63.3 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | p.o. | 3 | GM | 2,37 | |
| 91600 | KALNORMIN | tbl ret 30x1gm | ICN | H |
| 64 | A12BA | soli draslíku | parent. | |
|---|
| 64.1 | A12BA | draslík v kombinaci s hořčíkem | parent. | 1 | DF | 13,20 | O |
| 02132 | CARDILAN | inj 10x10ml | HBS | SK |
| 64.2 | A12BA01 | chlorid draselný (na obsah chloridu draselného) | parent. | 3 | GM | 52,88 | O |
| 02486 | KALIUM CHLORATUM LÉČIVA 7.5% | inj 5x10ml 7.5% | LEX | CZ |
| 65.1 | A12CC03 | glukonat hořečnatý (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
|
| 65.2 | A12CC04 | citronan hořečnatý (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
|
| 65.3 | A12CC05 | aspartat hořečnatý (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
|
| 65.4 | A12CC06 | mléčnan hořečnatý (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
|
| 65.5 | A12CC09 | orotat hořečnatý (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
|
| 65.6 | A12CC30 | kombinace hořečnatých solí (na obsah hořčíku) | p.o. | 1 | GM | 11,38 | L/INT,NEU,PSY, GYN,GER |
| 99891 | MAGNESIUM 250 MG PHARMAVIT | por tbl eff 20 | CPW | H |
| 66 | A12CC | soli hořčíku | parent. | |
|---|
| 66.1 | A12CC02 | síran hořečnatý (koncentrace do 10 % včetně) | parent. | 1 | GM | 19,72 | O |
| 00498 | MAGNESIUM SULFURICUM BIOT.10% | inj 5x10ml 10% | HBS | SK |
| 66.2 | A12CC02 | síran hořečnatý (koncentrace nad 10%) | parent. | 1 | GM | 8,87 | O |
| 00499 | MAGNESIUM SULFURICUM BIOT.20% | inj 5x10ml 20% | HBS | SK |
| 67.1 | A12CD01 | fluorid sodný | p.o. | 88 | MG | 4,06 | |
| 09495 | OSSIN RETARD | tbl obd 100x40mg | GRU | D |
| 68 | A14A | anabolické steroidy | parent. | |
|---|
| 68.1 | A14AB01 | nandrolon phenpropionát | parent. | 2 | MG | 3,11 | |
| 69 | A16A | ostatní léčiva alimentárního traktu | parent. | |
|---|
| 69.1 | A16AA01 | levokarnitin | parent. | 2 | GM | 356,82 | O |
| 69.2 | A16AX01 | kyselina tioktová | parent. | 0.2 | GM | 84,42 | O |
| 84382 | THIOGAMMA 600 INJECT | inj 1000x20ml/600mg | SLH | D |
| 84381 | THIOGAMMA 600 INJECT | inj 100x20ml/600mg | SLH | D |
| 84379 | THIOGAMMA 600 INJECT | inj 10x20ml/600mg | SLH | D |
| 55380 | THIOGAMMA 600 INJECT | inj 20x20ml/600mg | SLH | D |
| 55381 | THIOGAMMA 600 INJECT | inj 500x20ml/600mg | SLH | D |
| 84380 | THIOGAMMA 600 INJECT | inj 50x20ml/600mg | SLH | D |
| 84378 | THIOGAMMA 600 INJECT | inj 5x20ml/600mg | SLH | D |
| 69.3 | A16AA02 | ademetionin | parent. | 0,5 | GM | 94,66 | Z |
| 12319 | TRANSMETIL 500 MG INJEKCE | inj pso Iqf 5x500mg | ABT | I |
| 69.4 | A16AA02 | ademetionin | p.o. | 1 | GM | 59,83 | Z |
|
| 69.5 | A16AB02 | imiglucerasa | parent. | 200 | U | 40341,80 | Z |
|
| 69.6 | A16AB03 | agalsidáza alfa | parent. | 1 | MG | 17700,00 | Z |
|
| 69.7 | A16AB04 | agalsidáza beta | parent. | 5 | MG | 17700,00 | Z |
|
| 69.8 | A08AA10 | sibutramin s obsahem 10 mg v jedné tabletě | p.o. | 15 | MG | 106,20 | P |
|
| 69.9 | A08AA10 | sibutramin s obsahem 15 mg v jedné tabletě | p.o. | 15 | MG | 80,00 | P |
|
| 69.10 | A08AB01 | orlistat | p.o. | 360 | MG | 80,00 | P |
Sibutramine or orlistat prescribes diabetic patients with type 2 diabetes mellitus and BMI > 35 kg / m2 who are diagnosed with arterial hypertension, hyperlipoproteinaemia or ICHS (for sibutramine see contraindications) requiring pharmacological treatment. The patient must also have a weight decrease of at least 3 kg within 6 weeks, using only dietary and motion measures. Tolerance of treatment is evaluated 4 weeks after initiation of treatment, efficacy after 3 months of treatment with antiobesics. Efficacy criteria for anti-obesity therapy are a decrease of at least 5% of baseline body weight while improving glycaemic control (fasting or glycated haemoglobin HbA1c). If treatment is not effective, administration of the antiobesity medicinal product is discontinued after 3 months. Treatment with antiobesity is indicated for a maximum of 12 months.
| 70 | B01AA | antithrombotika ze skupiny antagonistů vitaminu K | p.o. | |
|---|
|
| 70.1 | B01AA03 | warfarin | p.o. | 7.5 | MG | 3,22 | |
| 12848 | LAWARIN 2 | tbl 100x2mg | PVL | CZ |
| 58161 | LAWARIN 2 | tbl 50x2mg | PVL | CZ |
| 12849 | LAWARIN 5 | tbl 100x5mg | PVL | CZ |
| 58162 | LAWARIN 5 | tbl 50x5mg | PVL | CZ |
| 59674 | WARFARIN 3-SL | por tbl nob 100x3mg | SLO | SK |
| 59675 | WARFARIN 5-SL | por tbl nob 100x5mg | SLO | SK |
| 70.2 | B01AA08 | ethylbiskumacetát (do 75 mg v jedné tabletě včetně) | p.o. | 0.6 | GM | 3,60 | |
|
| 70.3 | B01AA08 | ethylbiskumacetát (nad 75 mg v jedné tabletě) | p.o. | 0.6 | GM | 4,30 | |
| 71 | B01AB | antithrombotika ze skupiny heparinu a jeho derivátů (antithrombin III) | parent. | |
|---|
| 71.1 | B01AB02 | antithrombin (z tuzemské plazmy zakázkovou frakcionací) | parent. | 2.1 | KU | 25440,00 | U |
|
| 71.2 | B01AB02 | antithrombin | parent. | 2.1 | KU | 25440,00 | U |
| 72 | B01AB | antithrombotika ze skupiny heparinu a jeho derivátů (heparin) | parent. | |
|---|
| 72.1 | B01AB01 | heparin | parent. | 10 | KU | 15,35 | O |
| 74999 | HEPARIN BIOCHEMIE 25000UT | inj 100x5ml/25ku | BCA | A |
| 93746 | HEPARIN LÉČIVA | inj 1x10ml/50ku | LEX | CZ |
| 73 | B01AB | antithrombotika ze skupiny heparinu a jeho derivátů (ostatní) | p.o.,parent. | |
|---|
Low molecular heparin for outpatient care in indication:
1) Treatment of deep vein thrombosis confirmed by the dopler examination
2) Treatment of conditions requiring anticoagulant treatment during pregnancy
3) in the period prior to the planned cardiac transplant
4) Prevention and treatment of deep vein thrombosis in patients with evidence of congenital or acquired hypercoagulant conditions in whom the required reduction in coagulation factors by oral anticoagulants cannot be stabilised, or unable to administer these anticoagulants
5) the need for outpatient transfer from oral anticoagulants to low molecular heparin in the short term (maximum 5 days) prior to the scheduled operation
| 73.1 | B01AB04 | dalteparin do 2,5 KU včetně v jedné ampuli | parent. | 3 | KU | 64,45 | P |
|
| 73.2 | B01AB04 | dalteparin nad 2,5 KU do 5 KU včetně v jedné ampuli | parent. | 3 | KU | 64,40 | P |
| |
| 73.3 | B01AB04 | dalteparin nad 5 KU v jedné ampuli | parent. | 3 | KU | 49,60 | P |
|
| 73.4 | B01AB05 | enoxaparin do 20 mg včetně v jedné ampuli | parent. | 3 | KU | 64,45 | P |
| |
| 73.5 | B01AB05 | enoxaparin nad 20 mg do 40 mg včetně v jedné ampuli | parent. | 3 | KU | 64,40 | P |
|
| 73.6 | B01AB05 | enoxaparin nad 40 mg do 80 mg včetně v jedné ampuli | parent. | 3 | KU | 59,74 | P |
|
| 73.7 | B01AB05 | enoxaparin nad 80 mg v jedné ampuli | parent. | 3 | KU | 49,60 | P |
|
| 73.8 | B01AB06 | nadroparin do 2,85 KU včetně v jedné ampuli | parent. | 3 | KU | 64,45 | P |
|
| 73.9 | B01AB06 | nadroparin nad 2,85 do 3,8 KU včetně v jedné ampuli | parent. | 3 | KU | 64,40 | P |
|
| 73.10 | B01AB06 | nadroparin nad 3,8 do 7,6 KU včetně v jedné ampuli | parent. | 3 | KU | 59,74 | P |
|
| 73.11 | B01AB06 | nadroparin nad 7,6 KU do 10 KU v jedné ampuli včetně | parent. | 3 | KU | 49,60 | P |
|
| 73.12 | B01AB06 | nadroparin nad 10 KU v jedné ampuli | parent. | 3 | KU | 44,00 | P |
| |
| 73.13 | B01AB07 | parnaparin do 3,2 KU v jedné ampuli včetně | parent. | 3 | KU | 64,45 | P |
|
| 73.14 | B01AB07 | parnaparin nad 3,2 do 4,250 KU včetně v jedné ampuli | parent. | 3 | KU | 64,40 | P |
| |
| 73.15 | B01AB07 | parnaparin nad 4,250 KU v jedné ampuli | parent. | 3 | KU | 59,74 | P |
| |
| 73.16 | B01AB08 | reviparin do 1,432 KU včetně v jedné ampuli | parent. | 3 | KU | 64,45 | P |
| |
| 73.17 | B01AB08 | reviparin nad 1,432 KU v jedné ampuli | parent. | 3 | KU | 64,40 | P |
|
| 73.18 | B01AB11 | sulodexid | parent. | 600 | U | 63,44 | O |
|
| 73.19 | B01AB11 | sulodexid | p.o. | 250 | U | 12,46 | L/OPH,INT,NEU, DIA,GER |
|
| 73.20 | B01AB | certoparin | parent. | 3 | KU | 76,10 | O |
| 31316 | TROPARIN AMPOULE | inj 10x0.5ml/32mg | BCA | A |
| 74 | B01AC | antiagregancia trombocytů | p.o. | |
|---|
Treatment with ticlopidine and clopidogrel is performed by an internist, cardiologist or neurologist:
(a) allergy and evident intolerance to acetylsalicylic acid,
(b) numbness to acetylsalicylic acid detected by an aggregation test in a haematocoagulation laboratory;
(c) administration to patients following intravascular intervention (stents, PTCA, rotabulation, atherectomy, laser atheroplastics, etc.), usually in combination with acetylsalicylic acid for a limited period of time (usually one month after exercise).
Clopidogrel treatment is indicated by a cardiologist, an intern in patients with acute coronary syndrome without elevations of the ST section (unstable angina or non-Q myocardial infarction) usually in combination with acetylsalicylic acid for 6 months after the event.
Indobufen treatment is administered by an internist, cardiologist or neurologist:
(a) allergy and evident intolerance to acetylsalicylic acid,
(b) the need for only a short-term antiaggregation effect (e.g. prior to surgery).
Treatment with dipyridamol, including combination therapy, indicates a neurologist or intern for the secondary prevention of ischaemic stroke in patients who are intolerant to higher doses of acetylsalicylic acid or failure of antiplatelet therapy that is manifested by stroke.
| 74.1 | B01AC04 | clopidogrel | p.o. | 75 | MG | 39,00 | P |
|
| 74.2 | B01AC05 | ticlopidin | p.o. | 0.5 | GM | 23,00 | P |
| 02984 | APO-TIC | por tbl obd30x250mg | APT | CND |
| 02985 | APO-TIC | por tblobd 100x250mg | APT | CND |
| 02518 | IPATON 250 MG | por tbl flm20x250mg | EGI | H |
| 21023 | IPATON 250 MG | por tbl flm60x250mg | EGI | H |
| 66938 | TAGREN | tbl 30x250mg | KRK | SLO |
| 02973 | TICLOPIDIN-RATIOPHARM 250 MG | tbl obd 30x250mg | MCK | D |
| 02974 | TICLOPIDIN-RATIOPHARM 250 MG | tbl obd 90x250mg | MCK | D |
| 74.3 | B01AC06 | kyselina acetylsalicylová (do 30 mg v jedné tabletě včetně) | p.o. | 1 | DF | 0,51 | |
| 72813 | ANOPYRIN 30MG | tbl 20x30mg | SLO | SK |
| 72812 | ANOPYRIN 30MG | tbl 50x30mg | SLO | SK |
| 74.4 | B01AC06 | kyselina acetylsalicylová (nad 30 mg do 100 mg v jedné tabletě včetně) | p.o. | 1 | DF | 0,51 | |
|
| 74.5 | B01AC06 | kyselina acetylsalicylová (nad 100 do 150 mg v jedné tabletě včetně) | p.o. | 1 | DF | 0,98 | |
|
| 74.6 | B01AC07 | dipyridamol | p.o. | 400 | MG | 8,65 | P |
|
| 74.7 | B01AC10 | indobufen | p.o. | 0.3 | GM | 8,40 | P |
|
| 74.8 | B01AC30 | dipyridamol a kyselina acetylosalicylová v kombinaci | p.o. | 2 | DF | 12,00 | P |
|
| 74.9 | B01AC | lysin acetylosalicylát (do 160 mg ekvivalentu kys. acetylosalicylové včetně v jedné dávce) | p.o. | 1 | DF | 0,68 | |
|
| 74.10 | B01AC | lysin acetylosalicylát (nad 160 mg ekvivalentu kys. acetylosalicylové v jedné dávce) | p.o. | 1 | DF | 0,64 | |
| 75 | B01AC | antiagregancia trombocytů | parent. | |
|---|
| 75.1 | B01AC07 | dipyridamol | parent. | 0.2 | GM | 224,45 | H |
|
| 75.2 | B01AC09 | epoprostenol | parent. | 0.5 | MG | 4956,00 | X |
|
| 75.3 | B01AC10 | indobufen | parent. | 0.3 | GM | 89,35 | H |
|
| 75.4 | B01AC11 | iloprost | parent. | 50 | RG | 660,60 | X |
|
| 75.5 | B01AC13 | abciximab | parent. | 1 | DF | 11131,00 | H |
|
| 75.6 | B01AC16 | eptifibatide injekce | parent. | 1 | DF | 930,27 | H |
|
| 75.7 | B01AC16 | eptifibatide infuze | parent. | 1 | DF | 2930,36 | H |
|
| 75.8 | B01AC17 | tirofiban | parent. | 1 | DF | 5437,00 | H |
| 76 | B01AD | trombolytika | parent. | |
|---|
Alteplase and urokinase at all workplaces:
(a) treatment for acute myocardial infarction who have been treated with streptokinase for the past 12 months or have a history of allergic reactions to streptokinase.
In workplaces which have specialised treatment in the contract with the health insurance company:
(a) intracoronary thrombolysis,
(b) thrombolysis of acute and subacute peripheral vessel closures.
| 76.1 | B01AD01 | streptokináza (do 0,75 MU včetně v jedné dávce) | parent. | 1.5 | MU | 3384,60 | U |
| 10937 | STREPTASE | inj sic 1x750ku | AVN | D |
| 76.2 | B01AD01 | streptokináza (nad 0,75 MU v jedné dávce) | parent. | 1.5 | MU | 3214,40 | U |
| 62461 | STREPTASE | inj sic 1x1.5mu | AVN | D |
| 76.3 | B01AD02 | alteplaza | parent. | 0.1 | GM | 43265,44 | U/P |
|
| 76.4 | B01AD04 | urokináza (do 100 KU v jedné dávce včetně) | parent. | 3 | MU | 53928,40 | U/P |
|
| 76.5 | B01AD04 | urokináza (nad 100 do 500 KU v jedné dávce včetně) | parent. | 3 | MU | 45346,56 | U/P |
|
| 76.6 | B01AD04 | urokináza (nad 500 KU v jedné dávce) | parent. | 3 | MU | 42565,93 | U/P |
|
| 76.7 | B01AD07 | retepláza | parent. | 20 | U | 43265,44 | U/P |
|
| 76.8 | B01AD10 | drotrecogin alfa (aktivovaný) | parent. | 5 | MG | 6882,00 | X |
In patients with an APACHE II score of 25 or more, in failure of two or more organ systems, controlled by a sepsis source, and in patients where there is a presumption that after healing there will be sufficient duration and quality of life for selected workplaces.
| 76.9 | B01AX03 | lepirudin | parent. | 1 | DF | 2300,00 | H |
| 77 | B02AA | antifibrinolytika ze skupiny aminokyselin | p.o. | |
|---|
| 77.1 | B02AA01 | kyselina aminokaproová | p.o. | 16 | GM | 38,86 | |
|
| 77.2 | B02AA02 | kyselina tranexámová (do 250 mg v jedné tabletě včetně) | p.o. | 2 | GM | 40,72 | |
|
| 77.3 | B02AA02 | kyselina tranexámová (nad 250 mg v jedné tabletě) | p.o. | 2 | GM | 38,57 | |
| 42613 | EXACYL | por tblflm20x500mg | SXQ | P |
| 77.4 | B02AA03 | kyselina aminomethylbenzoová | p.o. | 0.25 | GM | 19,31 | |
| 02123 | PAMBA | tbl 10x250mg | ABP | D |
| 78 | B02AA | antifibrinolytika ze skupiny aminokyselin | parent. | |
|---|
| 78.1 | B02AA01 | kyselina aminokaproová | parent. | 16 | GM | 65,01 | |
|
| 78.2 | B02AA02 | kyselina tranexámová | parent. | 2 | GM | 63,74 | |
| 97411 | EXACYL | inj 5x5ml/500mg | SWI | F |
| 78.3 | B02AA03 | kyselina aminomethylbenzoová | parent. | 0.25 | GM | 192,40 | |
| 69793 | PAMBA | inj sol 5x5ml/50mg | BGL | D |
| 79 | B02AB | antifibrinolytika ze skupiny inhibitorů proteináz | parent. | |
|---|
| 79.1 | B02AB01 | aprotinin | parent. | 500 | KU | 664,66 | H |
| 80 | B02BA | vitamin K a jeho deriváty a další lokální hemostyptika | p.o. | |
|---|
| 80.1 | B02BA01 | fytomenadion | p.o. | 20 | MG | 10,38 | |
| 00720 | KANAVIT | gtt 1x5ml/100mg | SLO | SK |
| 80.2 | B02BX01 | etamsylat | p.o. | 0.75 | GM | 11,30 | L/OPH,HEM,ORL |
| 81 | B02B | vitamin K a jeho deriváty a další lokální hemostyptika | parent. | |
|---|
| 81.1 | B02BA | menadiolfosfat sodná sůl | parent. | 10 | MG | 14,27 | |
|
| 81.2 | B02BA01 | fytomenadion | parent. | 20 | MG | 15,68 | |
| 00489 | KANAVIT | inj 5x1ml/10mg | HBS | SK |
| 81.3 | B02BX01 | etamsylat | parent. | 0.75 | GM | 80,51 | O |
| 02213 | DICYNONE 250 | inj 100x2ml/250mg | OMR | CH |
| 82 | B02BB | lidský fibrinogen | parent. | |
|---|
| 82.1 | B02BB01 | lidský fibrinogen | parent. | 5 | GM | 9452,50 | U |
| 32282 | FIBRINOGEN IMMUNO | inf sic 1000mg+solv | BXG | A |
| 62464 | HAEMOCOMPLETTAN P | inj sic 1x1000mg | CTO | D |
| 83 | B02BC | lokální hemostatika | lok. | |
|---|
| 83.1 | B02BC | lokální hemostatika (rektální lékové formy) | lok. | 1 | DF | 7,19 | |
|
| 83.2 | B02BC | lokální hemostatika (pěna) | lok. | 1 | C2 | 1,47 | |
|
| 83.3 | B02BC | lokální hemostatika - karboxycelulosa (zásyp) | lok. | 1 | GM | 15,40 | |
|
| 83.4 | B02BC01 | absorbovatelná želatinová houba | lok. | 1 | C2 | 2,69 | |
|
| 83.5 | B02BC06 | thrombin (houba) | lok. | 1 | DF | 56,80 | |
| 84 | B02BD | koagulační faktory (faktor VIII a faktor IX) | parent. | |
|---|
Treatment with coagulation factor VIII is administered by a haematologist:
prevention and treatment of bleeding conditions in patients with congenital or acquired factor VIII deficiency,
(b) in patients with a low titre (up to 5 Bethesda units) inhibitor
(c) Pigs factor VIII is indicated in patients with high antibody titre against human factor VIII and low antibody titre against swine factor VIII.
Treatment with coagulation factor IX is administered by a haematologist:
prevention and treatment of bleeding conditions in patients with evidence of factor IX deficiency, possibly in patients with factor VIII inhibitor.
A haematologist is responsible for treating the activity of bypassing factor VIII. For the treatment of bleeding conditions caused by a proven inhibitor of coagulation factors.
Treatment with eptacog alfa is performed by a haematologist. For the treatment of acute life-threatening bleeding that is not demonstrably manageable with another medicinal product as well as in patients with evidence of an inhibitor of coagulation factors.
| 84.1 | B02BD01 | kombinace koagulačních faktorů IX,II,VII a X | parent. | 350 | U | 3284,67 | B/P |
|
| 84.2 | B02BD02 | koagulační faktor VIII (středně čištěný) | parent. | 500 | U | 5083,42 | B/P |
|
| 84.3 | B02BD02 | koagulační faktor VIII (vysoce čištěný) | parent. | 500 | U | 5818,70 | B/P |
| 53360 | ANTIHEM.F.(LIDSKÝ)HEMOFIL M | inj sic 1x1000ut+so | BXI | B |
| 53359 | ANTIHEM.F.(LIDSKÝ)HEMOFIL M | inj sic 1x500ut+sol | BXI | B |
| 84.4 | B02BD02 | koagulační faktor VIII rekombinantní | parent. | 500 | U | 5818,70 | B/P |
|
| 84.5 | B02BD02 | koagulační faktor VIII středně čištěný s von Willebrandovým faktorem | parent. | 500 | U | 7820,64 | B/P |
|
| 84.6 | B02BD02 | koagulační faktor VIII vysoce čištěný s von Wilebrandovým faktorem | parent. | 500 | U | 9263,30 | B/P |
| 88337 | HAEMATE P | inj sic 1x1ku+solv. | AVN | D |
| 88335 | HAEMATE P | inj sic 1x250ut+sol | AVN | D |
| 88336 | HAEMATE P | inj sic 1x500ut+sol | AVN | D |
| 84.7 | B02BD03 | aktivata obcházející inhibitor faktoru VIII | parent. | 10 | KU | 297672,00 | B/P |
| 85677 | FEIBA TIM 4 1000 J. | inf pso Iqf 1x1ku | BXG | A |
| 85676 | FEIBA TIM 4 500 J. | inf pso Iqf 1x500ut | BXG | A |
| 84.8 | B02BD04 | koagulační faktor IX (středně čištěný) | parent. | 350 | U | 3284,67 | B/P |
|
| 84.9 | B02BD04 | koagulační faktor IX (vysoce čištěný) | parent. | 350 | U | 4174,27 | B/P |
|
| 84.10 | B02BD08 | eptakog alfa (aktivovaný) | parent. | 2.5 | MU | 1357785,42 | B/P |
| 89826 | NOVOSEVEN 120KIU (2.4MG) | inj pso Iqf 1x2.4mg | NOO | DK |
| 92641 | NOVOSEVEN 240KIU (4.8MG) | inj pso Iqf 1x4.8mg | NOO | DK |
| 89825 | NOVOSEVEN 60KIU (1.2MG) | inj pso Iqf 1x1.2mg | NOO | DK |
| 85 | B02BD | koagulační faktory (ostatní koagulační faktory) | parent. | |
|---|
| 85.1 | B02BD | srážecí faktory | parent. | 350 | U | 2975,02 | X |
|
| 85.2 | B02BD05 | koagulační faktor VII | parent. | 6 | KU | 87982,20 | X |
|
| 85.3 | B02BD07 | koagulační faktor XIII | parent. | 350 | U | 2975,02 | X |
| 86 | B03AA | soli dvojmocného železa | p.o. | |
|---|
| 86.1 | B03AA02 | fumarát železnatý (pevné lékové formy) | p.o. | 0.1 | GM | 1,12 | |
|
| 86.2 | B03AA02 | fumarát železnatý (tekuté lékové formy) | p.o. | 0.1 | GM | 2,98 | |
| 00677 | FERRONAT | sus 1x100ml/3gm | GNO | CZ |
| 86.3 | B03AA03 | glukonát železnatý (pevné lékové formy) | p.o. | 0.1 | GM | 1,12 | |
|
| 86.4 | B03AA03 | glukonát železnatý (tekuté lékové formy) | p.o. | 0.1 | GM | 3,20 | |
|
| 86.5 | B03AA05 | chlorid železnatý (pevné lékové formy) | p.o. | 0.1 | GM | 1,12 | |
|
| 86.6 | B03AA05 | chlorid železnatý (tekuté lékové formy) | p.o. | 0.1 | GM | 3,20 | |
|
| 86.7 | B03AA07 | síran železnatý (pevné lékové formy) | p.o. | 0.1 | GM | 1,12 | |
|
| 86.8 | B03AA07 | síran železnatý (tekuté lékové formy) | p.o. | 0.1 | GM | 3,20 | |
|
| 86.9 | B03AB | soli trojmocného železa (tekuté lékové formy) | p.o. | 0.1 | GM | 3,20 | |
|
| 86.10 | B03AB02 | polymaltosum ferricum (tekuté lékové formy) | p.o. | 0.1 | GM | 10,80 | |
| 02946 | MALTOFER | por gtt sol 30 ml | VII | CH |
| 87 | B03AC | soli trojmocného železa | parent. | |
|---|
| 87.1 | B03AC02 | hydroxid železitý se sacharózou | parent. | 0.1 | GM | 41,70 | O |
| 04084 | FERRUM LEK I.M. | inj sol50x2ml/100mg | LEK | SLO |
| 87.2 | B03AC03 | komplex železo-sorbitol-citronová kyselina | parent. | 0.1 | GM | 25,56 | O |
|
| 87.3 | B03AC07 | glukonát železito-sodný | parent. | 0.1 | GM | 41,70 | O |
| 03418 | FERRLECIT | inj sol 5x5ml | NAJ | D |
| 70425 | FERRLECIT | inj sol5x5ml/62.5mg | AVT | GB |
| 88 | B03AD | soli dvojmocného železa v kombinaci s kyselinou listovou | p.o. | |
|---|
| 88.1 | B03AD | chlorid železnatý/kyselina listová | p.o. | 0.1 | GM | 4,30 | L/GYN,HEM |
|
| 88.2 | B03AD | glukonat železnatý/kyselina listová | p.o. | 0.1 | GM | 4,30 | L/GYN,HEM |
|
| 88.3 | B03AD02 | fumarat železnatý/kyselina listová | p.o. | 0.1 | GM | 4,30 | L/GYN,HEM,INT, GER |
|
| 88.4 | B03AD03 | síran železnatý/kyselina listová | p.o. | 0.1 | GM | 4,30 | L/GYN,HEM |
| 89 | B03AE | soli dvojmocného železa v ostatních kombinacích | p.o. | |
|---|
| 89.1 | B03AE01 | dvojmocné soli železa/kyselina listová/vitamin B12 | p.o. | 0.1 | GM | 3,90 | |
|
| 89.2 | B03AE02 | dvojmocné soli železa/kyselina listová/vitaminy | p.o. | 0.1 | GM | 3,90 | |
|
| 89.3 | B03AE10 | chlorid železnatý/kyselina listová | p.o. | 0.1 | GM | 3,90 | |
| 89.4 | B03AE10 | fumarat železnatý/kyselina listová | p.o. | 0.1 | GM | 3,90 | |
|
| 89.5 | B03AE10 | glukonat železnatý/kyselina listová | p.o. | 0.1 | GM | 3,90 | |
|
| 89.6 | B03AE10 | různé kombinace bez kyseliny listové | p.o. | 0.1 | GM | 3,20 | |
| 97402 | SORBIFER DURULES | tbl obd 50x100mg | EGI | H |
| 89.7 | B03AE10 | síran železnatý/kyselina listová | p.o. | 0.1 | GM | 3,90 | |
|
| 89.8 | B03AE10 | síran železnatý/serin -pevné lékové formy | p.o. | 0.1 | GM | 3,20 | |
|
| 89.9 | B03AE10 | síran železnatý/serin -tekuté lékové formy | p.o. | 0.1 | GM | 10,80 | |
| 90 | B03BA | vitamin B12 a jeho deriváty | parent. | |
|---|
| 90.1 | B03BA01 | cyanokobalamin (do 0,3 mg v jedné ampuli včetně) | parent. | 0.02 | MG | 0,51 | |
| 00641 | VITAMIN B12 LÉČIVA 300MCG | inj 5x1ml/300rg | LEX | CZ |
| 90.2 | B03BA01 | cyanokobalamin (nad 0,3 mg v jedné ampuli) | parent. | 0.02 | MG | 0,20 | |
| 92503 | NEUROBENE | inj 6x1ml/1000rg | MCK | D |
| 91 | B03BB | kyselina listová a její deriváty | p.o. | |
|---|
| 91.1 | B03BB01 | kyselina listová | p.o. | 10 | MG | 1,39 | |
| 92 | B03XA | ostatní protianemická léčiva | parent. | |
|---|
Treatment with erythropoietin is indicated by an oncologist, a hematologist, an intern or a pediatrician:
(a) treatment of clinically significant anaemia (with haemoglobin levels below 90 g / l, with higher manifestations of anaemia) in patients on dialysis, chronic renal failure patients, cancer patients following radical cytostatic therapy or radiation therapy,
(b) the treatment of anaemia in patients with aplastic anaemia, erythroblastophysis, myelodysplastic syndrome and bone marrow transplantation anaemia,
(c) the treatment of severe anaemia of immature children.
| 92.1 | B03XA01 | erythropoetin do 500 IU v jedné ampuli včetně | parent. | 1 | KU | 497,40 | K/P |
| 64814 | NEORECORMON 500 IU | injsol6x0.3ml/500ut | ROC | D |
| 92.2 | B03XA01 | erythropoetin více než 500 IU do 10 KU v jedné ampuli včetně | parent. | 1 | KU | 455,00 | K/P |
|
| 92.3 | B03XA01 | erythropoetin více než 10 KU v jedné ampuli | parent. | 1 | KU | 430,00 | K/P |
| 93 | B05AA | substituenty plazmy a plazmatické proteiny (albumin) | parent. | |
|---|
| 93.1 | B05AA01 | albumin (z tuzemské plazmy zakázkovou frakcionací) | parent. | 20 | GM | 2676,90 | B |
|
| 93.2 | B05AA01 | albumin | parent. | 20 | GM | 2676,90 | B |
| 10124 | HUMAN ALBUMIN 20% BIOTEST | inf 1x100ml | BTP | D |
| 10117 | HUMAN ALBUMIN 20% BIOTEST | inf 1x50ml | BTP | D |
| 62471 | HUMAN ALBUMIN 20% IMMUNO | inf sol 1x100ml 20% | BXG | A |
| 62470 | HUMAN ALBUMIN 20% IMMUNO | inf sol 1x50ml 20% | BXG | A |
| 62472 | HUMAN ALBUMIN 5% IMMUNO | inj 1x250ml 5% | BXG | A |
| 97910 | HUMAN ALBUMIN GRIFOLS 20% | inf sol 1x100ml | GFO | E |
| 42144 | HUMAN ALBUMIN GRIFOLS 20% | inf sol 1x10ml | GFO | E |
| 97909 | HUMAN ALBUMIN GRIFOLS 20% | inf sol 1x50ml | GFO | E |
| 97907 | HUMAN ALBUMIN GRIFOLS 5% | inf sol 1x250ml | GFO | E |
| 97908 | HUMAN ALBUMIN GRIFOLS 5% | inf sol 1x500ml | GFO | E |
| 93.3 | B05AA02 | ostatní bílkoviny plasmy užívané jako její náhrady | parent. | 100 | ML | 952,16 | B |
| 94 | B05AA | substituenty plazmy a plazmatické proteiny (ostatní) | parent. | |
|---|
| 94.1 | B05AA05 | dextran (koncentrace 10%) | parent. | 500 | ML | 185,84 | O |
|
| 94.2 | B05AA05 | dextran (koncentrace 6%) | parent. | 500 | ML | 108,80 | O |
|
| 94.3 | B05AA05 | dextran (koncentrace 6% v hyperosmolárním roztoku) | parent. | 500 | ML | 123,86 | O |
|
| 94.4 | B05AA06 | želatinové přípravky | parent. | 500 | ML | 173,90 | O |
| 56412 | GELOFUSINE | inf 1x500ml | BME | CH |
| 94.5 | B05AA07 | hydroxyethylškrob | parent. | 500 | ML | 291,60 | O |
| 44467 | HEMOHES 10% | inf sol1x500ml(pe) | BMM | D |
| 44431 | HEMOHES 6% | inf sol 1x500ml-pe | BMM | D |
| 55897 | HEMOHES 6% | inf sol10x500ml-pe | BMM | D |
| 95 | B05BA | roztoky k parenterální výživě (glukóza až do 40% koncentrace) | parent. | |
|---|
| 95.1 | B05BA03 | glukóza 10% (nad 100 do 250 ml v jednom balení včetně) | parent. | 100 | ML | 12,71 | O |
| 31433 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 16x250ml-sk | FKI | I |
| 31432 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x250ml-skl | FKI | I |
| 43919 | 10% DEXTROSE IN WATER USP SIFRA | inf 16x250ml-sklo | SFR | I |
| 92531 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x250ml-sklo | SFR | I |
| 97735 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x250ml(sklo) | BFF | I |
| 59433 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x250ml(vak) | BFF | I |
| 59437 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x250ml(vak) | BFH | E |
| 62376 | INFUSIO GLUCOSI 10 IMUNA | inf 1x250ml(sklo) | IMA | SK |
| 66872 | INFUSIO GLUCOSI 10% INFUSIA | inf sol 1x250ml-skl | IHO | CZ |
| 95.2 | B05BA03 | glukóza 10% (nad 250 do 500 ml v jednom balení včetně) | parent. | 100 | ML | 6,04 | O |
| 31437 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x500ml-pp | FKI | I |
| 92534 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x500ml-pp | SFR | I |
| 97736 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x500ml(sklo) | BFF | I |
| 59419 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x500ml(vak) | BFH | E |
| 97737 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x500ml(vak) | BFF | I |
| 47000 | GLUKÓZA 10 BRAUN | inf 1x500ml-pe | BME | E |
| 47017 | GLUKÓZA 10 BRAUN | inf 1x500ml-pe | BME | CH |
| 96877 | GLUKÓZA 10 BRAUN | inf 1x500ml-pe | BMM | D |
| 71735 | INFUSIO GLUCOSI 100 G/L MVM G10 | inf sol 1x500ml | MVM | CZ |
| 95.3 | B05BA03 | glukóza 10% (do 100 ml v jednom balení včetně) | parent. | 100 | ML | 28,00 | O |
| 31430 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x100ml-skl | FKI | I |
| 03433 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 20x100ml-sk | FKI | I |
| 31431 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 49x100ml-sk | FKI | I |
| 92530 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x100ml-sklo | SFR | I |
| 43918 | 10% DEXTROSE IN WATER USP SIFRA | inf 49x100ml-sklo | SFR | I |
| 59432 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x100ml(vak) | BFF | I |
| 59436 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x100ml(vak) | BFH | E |
| 95.4 | B05BA03 | glukóza 10% (nad 500 ml v jednom balení) | parent. | 100 | ML | 5,82 | O |
| 31439 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x1000ml-pp | FKI | I |
| 31436 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x1000ml-sk | FKI | I |
| 31447 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x1000ml-va | FKI | I |
| 31449 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 1x2000ml-va | FKI | I |
| 31450 | 10% DEXTROSE IN WATER FRESENIUS | inf sol 4x2000ml-va | FKI | I |
| 31440 | 10% DEXTROSE IN WATER FRESENIUS | inf sol12x1000ml-pp | FKI | I |
| 43922 | 10% DEXTROSE IN WATER USP SIFRA | inf 12x1000ml-pp | SFR | I |
| 92535 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x1000ml-pp | SFR | I |
| 92533 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x1000ml-sklo | SFR | I |
| 92539 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x1000ml-vak | SFR | I |
| 92540 | 10% DEXTROSE IN WATER USP SIFRA | inf 1x2000ml-vak | SFR | I |
| 43927 | 10% DEXTROSE IN WATER USP SIFRA | inf 4x2000ml-vak | SFR | I |
| 59434 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x1000ml(vak) | BFF | I |
| 59438 | GLUCOSE 10%W/V I.V.B.P.BIEFFE | inf 1x1000ml(vak) | BFH | E |
| 47001 | GLUKÓZA 10 BRAUN | inf 1x1000ml-pe | BME | E |
| 47018 | GLUKÓZA 10 BRAUN | inf 1x1000ml-pe | BME | CH |
| 96878 | GLUKÓZA 10 BRAUN | inf 1x1000ml-pe | BMM | D |
| 92772 | INFUSIO GLUCOSI 10 MEDIEKOS G10 | inf 1x2000ml(vak) | INK | CZ |
| 95.5 | B05BA03 | glukóza 20% (do 100 ml v jednom balení včetně) | parent. | 100 | ML | 29,10 | O |
| 57750 | GLUCOSE 20% INFUSION-HUMAN | inf 1x100ml | HUA | H |
| 95.6 | B05BA03 | glukóza 20% (nad 100 ml v jednom balení) | parent. | 100 | ML | 6,46 | O |
| 59422 | GLUCOSE 20%W/V I.V.B.P.BIEFFE | inf 1x1000ml(vak) | BFH | E |
| 95.7 | B05BA03 | glukóza 5% (nad 100 do 250 ml v jednom balení včetně) | parent. | 100 | ML | 12,90 | O |
| 31454 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 16x250ml-sk | FKI | I |
| 31453 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x250ml-skl | FKI | I |
| 31464 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x250ml-vak | FKI | I |
| 31465 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 30x250ml-va | FKI | I |
| 43929 | 5% DEXTROSE IN WATER USP SIFRA | inf 16x250ml-sklo | SFR | I |
| 92520 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x250ml-sklo | SFR | I |
| 43934 | 5% DEXTROSE IN WATER USP SIFRA | inf 30x250ml-vak | SFR | I |
| 97729 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x250ml(sklo) | BFF | I |
| 59414 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x250ml(vak) | BFH | E |
| 97732 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x250ml(vak) | BFF | I |
| 46995 | GLUKÓZA 5 BRAUN | inf 1x250ml-pe | BME | E |
| 47012 | GLUKÓZA 5 BRAUN | inf 1x250ml-pe | BME | CH |
| 96872 | GLUKÓZA 5 BRAUN | inf 1x250ml-pe | BMM | D |
| 98894 | GLUKÓZA 5% VIAFLO | inf sol 30x250ml | BFH | E |
| 98893 | GLUKÓZA 5% VIAFLO | inf sol 35x150ml | BFH | E |
| 62372 | INFUSIO GLUCOSI 5 IMUNA | inf 1x250ml(sklo) | IMA | SK |
| 53818 | INFUSIO GLUCOSI 5% INFUSIA | inf sol 1x250ml-pvc | IHO | CZ |
| 66866 | INFUSIO GLUCOSI 5% INFUSIA | inf sol 1x250ml-skl | IHO | CZ |
| 95.8 | B05BA03 | glukóza 5% (nad 250 do 500 ml v jednom balení včetně) | parent. | 100 | ML | 6,89 | O |
| 31456 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 12x500ml-sk | FKI | I |
| 31458 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x500ml-pp | FKI | I |
| 31455 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x500ml-skl | FKI | I |
| 31466 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x500ml-vak | FKI | I |
| 31459 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 20x500ml-pp | FKI | I |
| 31467 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 20x500ml-va | FKI | I |
| 43930 | 5% DEXTROSE IN WATER USP SIFRA | inf 12x500ml-sklo | SFR | I |
| 92523 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x500ml-pp | SFR | I |
| 92521 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x500ml-sklo | SFR | I |
| 92527 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x500ml-vak | SFR | I |
| 43931 | 5% DEXTROSE IN WATER USP SIFRA | inf 20x500ml-pp | SFR | I |
| 43935 | 5% DEXTROSE IN WATER USP SIFRA | inf 20x500ml-vak | SFR | I |
| 97730 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x500ml(sklo) | BFF | I |
| 59415 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x500ml(vak) | BFH | E |
| 97733 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x500ml(vak) | BFF | I |
| 46996 | GLUKÓZA 5 BRAUN | inf 1x500ml-pe | BME | E |
| 47013 | GLUKÓZA 5 BRAUN | inf 1x500ml-pe | BME | CH |
| 96873 | GLUKÓZA 5 BRAUN | inf 1x500ml-pe | BMM | D |
| 98901 | GLUKÓZA 5% VIAFLO | inf sol 20x500ml | BFH | E |
| 86341 | INFUSIO GLUCOSI 5% INFUSIA | inf sol 1x500ml-pe | IHO | CZ |
| 71734 | INFUSIO GLUCOSI 50 G/L MVM G5 | inf sol 1x500ml | MVM | CZ |
| 95.9 | B05BA03 | glukóza 5% (do 100 ml v jednom balení včetně) | parent. | 100 | ML | 27,76 | O |
| 31451 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x100ml-skl | FKI | I |
| 31462 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x100ml-vak | FKI | I |
| 03432 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 20x100ml-sk | FKI | I |
| 31463 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 40x100ml-va | FKI | I |
| 31452 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 49x100ml-sk | FKI | I |
| 92519 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x100ml-sklo | SFR | I |
| 92525 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x100ml-vak | SFR | I |
| 43933 | 5% DEXTROSE IN WATER USP SIFRA | inf 40x100ml-vak | SFR | I |
| 43928 | 5% DEXTROSE IN WATER USP SIFRA | inf 49x100ml-sklo | SFR | I |
| 43933 | 5% DEXTROSE IN WATER USP SIFRA | inf 40x100ml-vak | SFR | I |
| 97728 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x100ml(sklo) | BFF | I |
| 59413 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x100ml(vak) | BFH | E |
| 97731 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x100ml(vak) | BFF | I |
| 46994 | GLUKÓZA 5 BRAUN | inf 1x100ml-sklo | BME | E |
| 47011 | GLUKÓZA 5 BRAUN | inf 1x100ml-sklo | BME | CH |
| 96871 | GLUKÓZA 5 BRAUN | inf 1x100ml-sklo | BMM | D |
| 98886 | GLUKÓZA 5% VIAFLO | inf sol 50x100ml | BFH | E |
| 62370 | INFUSIO GLUCOSI 5 IMUNA | inf 1x100ml(sklo) | IMA | SK |
| 86200 | INFUSIO GLUCOSI 5% INFUSIA | inf sol 1x100ml-skl | IHO | CZ |
| 95.10 | B05BA03 | glukóza 5% (nad 500 ml v jednom balení) | parent. | 100 | ML | 3,96 | O |
| 31468 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x1000ml-va | FKI | I |
| 31470 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 1x2000ml-va | FKI | I |
| 31471 | 5% DEXTROSE IN WATER FRESENIUS | inf sol 4x2000ml-va | FKI | I |
| 31469 | 5% DEXTROSE IN WATER FRESENIUS | inf sol10x1000ml-va | FKI | I |
| 43936 | 5% DEXTROSE IN WATER USP SIFRA | inf 10x1000ml-vak | SFR | I |
| 92528 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x1000ml-vak | SFR | I |
| 92529 | 5% DEXTROSE IN WATER USP SIFRA | inf 1x2000ml-vak | SFR | I |
| 43937 | 5% DEXTROSE IN WATER USP SIFRA | inf 4x2000ml-vak | SFR | I |
| 98902 | GLUKÓZA 5% VIAFLO | inf sol 10x1000ml | BFH | E |
| 97734 | GLUCOSE 5%W/V I.V.B.P.BIEFFE | inf 1x1000ml(vak) | BFF | I |
| 95.11 | B05BA03 | glukóza do 10% včetně (do 10 ml v jedné ampuli včetně) | parent. | 100 | ML | 23,90 | O |
| 47241 | GLUKÓZA 5 BRAUN | inf 20x10ml-pla.amp | BMM | D |
| 95.12 | B05BA03 | glukóza nad 10% do 39 % (do 10 ml v jedné ampuli včetně) | parent. | 100 | ML | 98,74 | O |
|
| 95.13 | B05BA03 | glukóza nad 20% (nad 100 do 250 ml v jednom balení včetně) | parent. | 100 | ML | 18,18 | O |
| 86972 | ARDEANUTRISOL G 33 | inf 1x250ml | ARD | CZ |
| 55630 | INFUSIO GLUCOSI 40 IMUNA | inf 1x250ml | IMA | SK |
| 95.14 | B05BA03 | glukóza nad 20% (do 100 ml v jednom balení včetně) | parent. | 100 | ML | 31,97 | O |
| 55628 | INFUSIO GLUCOSI 40 IMUNA | inf 1x100ml | IMA | SK |
| 95.15 | B05BA03 | glukóza nad 20% (nad 250 ml v jednom balení) | parent. | 100 | ML | 8,26 | O |
|
| 95.16 | B05BA03 | glukóza inj. 40% (do 10 ml včetně v jedné ampuli ) | parent. | 100 | ML | 83,15 | O |
| 02587 | GLUKÓZA 40 BRAUN | inf 20x10ml-pla.amp | BMM | D |
| 02589 | GLUKÓZA 40 BRAUN | inf 20x10ml-pla.amp | BME | CH |
| 96 | B05BA | roztoky k parenterální výživě (ostatní) | parent. | |
|---|
| 96.1 | B05BA01 | aminokyseliny (koncentrace do 6% včetně) | parent. | 100 | ML | 38,76 | H |
| 31989 | CLINIMIX N9G20E | inf sol 4x2000ml | BXF | GB |
| 96.2 | B05BA01 | aminokyseliny (koncentrace nad 14%) | parent. | 100 | ML | 63,44 | H |
| 75521 | AMINOPLASMAL 15% E | inf 1x1000ml | BME | D |
| 96.3 | B05BA01 | aminokyseliny (koncentrace nad 10% do 14% včetně) | parent. | 100 | ML | 70,48 | H |
| 55971 | SALVIAMIN 12.5 E | inf 1x1000ml | CTT | F |
| 55969 | SALVIAMIN 12.5 E | inf 1x500ml | CTT | F |
| 96.4 | B05BA01 | aminokyseliny (koncentrace nad 6% do 10 % včetně) | parent. | 100 | ML | 47,42 | H |
| 31985 | CLINIMIX N14G30E | inf sol 4x2000ml | BXF | GB |
| 31987 | CLINIMIX N17G35E | inf sol 4x2000ml | BXF | GB |
| 92631 | SALVIAMIN 10 E | inf 1x1000ml | CTT | F |
| 96.5 | B05BA02 | tukové emulze (do 10% včetně do 100 ml v jednom balení včetně) | parent. | 100 | ML | 173,20 | H |
| 32004 | INTRALIPID 10 % | inf 10x100ml-vak | FRK | S |
| 04299 | INTRALIPID 10 % | inf 12x100ml-sklo | FRK | S |
| 45303 | INTRALIPID 10 % | inf 1x100ml-sklo | FRK | S |
| 20909 | INTRALIPID 10 % | inf 1x100ml-vak | FRK | S |
| 31526 | SOYACAL 10% | inf eml 20x100ml | GFL | E |
| 96.6 | B05BA02 | tukové emulze (nad 10% do 100 ml v jednom balení včetně) | parent. | 100 | ml | 196,40 | H |
| 31529 | SOYACAL 20% | inf eml 20x100ml | GFL | E |
| 96.7 | B05BA02 | tukové emulze (do 10% včetně nad 100 ml v jednom balerní) | parent. | 100 | ML | 53,83 | H |
| 75442 | INTRALIPID 10 % | inf 12x500ml-sklo | FRK | S |
| 59154 | IVELIP 10% | inf 6x1000ml | CTT | F |
| 96.8 | B05BA02 | tukové emulze (nad 10% nad 100 ml v jednom balení) | parent. | 100 | ML | 67,58 | H |
| 57162 | INTRALIPID 20 % | inf 1x1000ml-sklo | FRK | S |
| 57247 | INTRALIPID 20 % | inf 6x1000ml-sklo | FRK | S |
| 59158 | IVELIP 20% | inf 6x1000ml | CTT | F |
| 96.9 | B05BA03 | fruktóza (koncentrace do 5% včetně) | parent. | 100 | ML | 14,47 | H |
|
| 96.10 | B05BA03 | fruktóza (koncentrace nad 10%) | parent. | 100 | ML | 17,74 | H |
|
| 96.11 | B05BA03 | fruktóza (koncentrace nad 5% do 10% včetně) | parent. | 100 | ML | 15,54 | H |
|
| 96.12 | B05BA03 | sorbitol (koncentrace do 5% včetně) | parent. | 100 | ML | 7,66 | H |
|
| 96.13 | B05BA03 | sorbitol (koncentrace nad 10%) | parent. | 100 | ML | 11,10 | H |
|
| 96.14 | B05BA03 | sorbitol (koncentrace nad 5% do 10% včetně) | parent. | 100 | ML | 8,14 | H |
|
| 96.15 | B05BA03 | xylitol (koncentrace do 5% včetně) | parent. | 100 | ML | 16,62 | H |
|
| 96.16 | B05BA03 | xylitol (koncentrace nad 5%) | parent. | 100 | ML | 22,83 | H |
|
| 96.17 | B05BA10 | kombinace bez obsahu aminokyselin | parent. | 100 | ML | 13,20 | H |
|
| 96.18 | B05BA10 | kombinace s obsahem aminokyselin | parent. | 100 | ML | 55,76 | H |
| 40178 | AMINOPLASMAL 10% E | inf 1x1000ml | BME | D |
| 45377 | AMINOROZTOK NEO SX 4% INFUSIA | inf 1x500ml | IHO | CZ |
| 45383 | AMINOROZTOK NEO SX 8% INFUSIA | inf 1x500ml | IHO | CZ |
| 47482 | CLINOMEL N4-550 | inf 2x2500ml pe vak | CTT | F |
| 46805 | CLINOMEL N4-550 | inf 4x1500ml pe vak | CTT | F |
| 46804 | CLINOMEL N4-550 | inf 4x2000ml pe vak | CTT | F |
| 47479 | CLINOMEL N5-800 | inf 2x2500ml pe vak | CTT | F |
| 46808 | CLINOMEL N5-800 | inf 4x1500ml pe vak | CTT | F |
| 46807 | CLINOMEL N5-800 | inf 4x2000ml pe vak | CTT | F |
| 47481 | CLINOMEL N6-900 | inf 2x2500ml pe vak | CTT | F |
| 46811 | CLINOMEL N6-900 | inf 4x1500ml pe vak | CTT | F |
| 46810 | CLINOMEL N6-900 | inf 4x2000ml pe vak | CTT | F |
| 47480 | CLINOMEL N7-1000 | inf 2x2500ml pe vak | CTT | F |
| 46814 | CLINOMEL N7-1000 | inf 4x1500ml pe vak | CTT | F |
| 46813 | CLINOMEL N7-1000 | inf 4x2000ml pe vak | CTT | F |
| 02460 | NUTRIFLEX BASAL | inf 5x1000ml | BMB | CH |
| 02461 | NUTRIFLEX BASAL | inf 5x2000ml | BMB | CH |
| 02454 | NUTRIFLEX PERI | inf 5x1000ml | BMB | CH |
| 02455 | NUTRIFLEX PERI | inf 5x2000ml | BMB | CH |
| 02458 | NUTRIFLEX PLUS | inf 5x1000ml | BMB | CH |
| 02459 | NUTRIFLEX PLUS | inf 5x2000ml | BMB | CH |
| 02452 | NUTRIFLEX SPECIAL | inf 5x1000ml | BMB | CH |
| 02453 | NUTRIFLEX SPECIAL | inf 5x1500ml | BMB | CH |
| 42557 | OLICLINOMEL N5-800E | inf eml 6x1000ml | BXI | B |
| 98055 | OLICLINOMEL N5-800E | inf eml 6x1000ml | CTT | F |
| 97 | B05BB | roztoky ovlivňující elektrolytovou rovnováhu (chlorid sodný 0,9%) | parent. | |
|---|
| 97.1 | B05BB01 | chlorid sodný 0.9% (nad 100 ml do 250 ml včetně) | parent. | 100 | ML | 7,40 | O |
| 97749 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x250ml(sklo) | BFF | I |
| 57683 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x250ml(vak ii) | BFH | E |
| 97752 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x250ml(vak ii) | BFF | I |
| 97.2 | B05BB01 | chlorid sodný 0.9% (do 100 ml v balení včetně) | parent. | 100 | ML | 21,08 | O |
| 46065 | CHLORID SODNY 0.9% BRAUN | inf sol 1x100ml-sk | BMR | E |
| 96882 | CHLORID SODNY 0.9% BRAUN | inf sol 1x100ml-sk | BMM | D |
| 46075 | CHLORID SODNY 0.9% BRAUN | inf sol1x100ml-skl | BME | CH |
| 46079 | CHLORID SODNY 0.9% BRAUN | infsol20x20ml-plamp | BME | CH |
| 96887 | CHLORID SODNY 0.9% BRAUN | infsol20x20mlpl.amp | BMM | D |
| 98864 | FYZIOLOGICKÝ ROZTOK VIAFLO | inf sol 50x100ml | BFH | E |
| 97748 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x100ml(sklo) | BFF | I |
| 57681 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x100ml(vak ii) | BFH | E |
| 97751 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x100ml(vak ii) | BFF | I |
| 97.3 | B05BB01 | chlorid sodný 0.9% (nad 250 ml v balení) | parent. | 100 | ML | 3,77 | O |
| 75611 | 0.9% SODIUM CHLOR.I.V.BP BAXTER | inf 1x1000ml(vak) | BXF | GB |
| 31487 | 0.9%SODIUM CHL.IN WAT.FRESENIUS | inf sol1x1000ml-skl | FKI | I |
| 31500 | 0.9%SODIUM CHL.IN WAT.FRESENIUS | inf sol1x2000ml-vak | FKI | I |
| 31501 | 0.9%SODIUM CHL.IN WAT.FRESENIUS | inf sol4x2000ml-vak | FKI | I |
| 92511 | 0.9%SODIUM CHL.IN WAT.USP SIFRA | inf sol1x1000ml-skl | SFR | I |
| 92518 | 0.9%SODIUM CHL.IN WAT.USP SIFRA | inf sol1x2000ml-vak | SFR | I |
| 43915 | 0.9%SODIUM CHL.IN WAT.USP SIFRA | inf sol4x2000ml-vak | SFR | I |
| 46077 | CHLORID SODNY 0.9% BRAUN | infsol1x1000mlpelah | BME | CH |
| 96885 | CHLORID SODNY 0.9% BRAUN | infsol1x1000mlpelah | BMM | D |
| 98880 | FYZIOLOGICKÝ ROZTOK VIAFLO | inf sol 10x1000ml | BFH | E |
| 03122 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x1000ml(vak i) | BFH | E |
| 57687 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1 x1000ml(vak ii | BFH | E |
| 97754 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x1000ml(vak ii | BFF | I |
| 57672 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x1500ml(vak ii | BFH | E |
| 69180 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1 x1500ml(vak ii | BFF | I |
| 03126 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x2000ml(vak i) | BFH | E |
| 57673 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x2000ml(vak ii | BFH | E |
| 69181 | SODIUM CHLORIDE 0.9%W/V I.V.INF | inf 1x2000ml(vak ii | BFF | I |
| 97.4 | B05BB01 | chlorid sodný 0.9% (do 10 ml včetně v jedné ampuli) | parent. | 100 | ML | 39,65 | O |
| 46078 | CHLORID SODNY 0.9% BRAUN | infsol20x10ml-plamp | BME | CH |
| 96886 | CHLORID SODNY 0.9% BRAUN | infsol20x10ml-plamp | BMM | D |
| 98 | B05BB | roztoky ovlivňující elektrolytovou rovnováhu (ostatní) | parent. | |
|---|
| 98.1 | B05BB | roztoky ovlivňující rovnováhu elektrolytů | parent. | 100 | ML | 10,46 | H |
| 98.2 | B05BB01 | elektrolyty | parent. | 100 | ML | 8,07 | H |
| 44103 | HARTMANNUV ROZTOK BRAUN BP | inf 10x1000ml-plast | BMM | D |
| 44102 | HARTMANNUV ROZTOK BRAUN BP | inf 10x500ml-plast | BMM | D |
| 44101 | HARTMANNUV ROZTOK BRAUN BP | inf 1x1000ml-plast | BMM | D |
| 44100 | HARTMANNUV ROZTOK BRAUN BP | inf 1x500ml-plast | BMM | D |
| 70527 | INFUSIO DARROWI MEDICAMEN.D1/1 | inf sol 1x500ml | MVM | CZ |
| 85887 | INFUSIO HARTMANNI IMUNA | inf 1x1000ml(vak) | IMA | SK |
| 92580 | INFUSIO HARTMANNI IMUNA | inf 1x2000ml(vak) | IMA | SK |
| 92581 | INFUSIO HARTMANNI IMUNA | inf 1x3000ml(vak) | IMA | SK |
| 99168 | INFUSIO HARTMANNI IMUNA | inf 1x500ml(sklo) | IMA | SK |
| 87250 | INFUSIO HARTMANNI INFUSIA | inf 1x500ml-sklo | IHO | CZ |
| 70524 | INFUSIO HARTMANNI MEDICAM.H1/1 | inf sol 1x500ml | MVM | CZ |
| 92778 | INFUSIO HARTMANNI MEDIEKOS H1/1 | inf 1x2000ml(vak) | INK | CZ |
| 05870 | INFUSIO HARTMANNI MEDIEKOS H1/1 | inf 1x5000ml(vak) | INK | CZ |
| 92585 | INFUSIO NATR.CHLOR.ISOT.IMUNA | inf 1x3000ml(vak) | IMA | SK |
| 70530 | INFUSIO RINGERI C.NATR.LACT.MVM | inf sol 1x500ml | MVM | CZ |
| 85578 | INFUSIO RINGERI IMUNA | inf 1x1000ml(vak) | IMA | SK |
| 55616 | INFUSIO RINGERI IMUNA | inf 1x2000ml(vak) | IMA | SK |
| 55617 | INFUSIO RINGERI IMUNA | inf 1x3000ml(vak) | IMA | SK |
| 72793 | INFUSIO RINGERI IMUNA | inf 1x500ml(sklo) | IMA | SK |
| 89861 | INFUSIO RINGERI INFUSIA | inf 1x500ml-sklo | IHO | CZ |
| 70529 | INFUSIO RINGERI MEDICAMENTAR1/1 | inf sol 1x500ml | MVM | CZ |
| 92801 | INFUSIO RINGERI MEDIEKOS R1/1 | inf 1x1000ml(vak) | INK | CZ |
| 92802 | INFUSIO RINGERI MEDIEKOS R1/1 | inf 1x2000ml(vak) | INK | CZ |
| 05860 | INFUSIO RINGERI MEDIEKOS R1/1 | inf 1x3000ml(vak) | INK | CZ |
| 05869 | INFUSIO RINGERI MEDIEKOS R1/1 | inf 1x5000ml(vak) | INK | CZ |
| 66833 | PLASMA-LYTE 148 ELECTROLYT.SOL. | inf 1x1000ml | BXF | GB |
| 97015 | RINGER INFUSION-HUMAN | inf 1x500ml | HUA | H |
| 96892 | RINGER'S BRAUN | inj 1x1000ml(plast) | BMM | D |
| 96891 | RINGER'S BRAUN | inj 1x500ml(plast) | BMM | D |
| 11305 | RINGER'S INJECTION FRESENIUS | inf 10x1000ml-vak | FKI | I |
| 95571 | RINGER'S INJECTION FRESENIUS | inf 12x1000ml-pe | FKI | I |
| 11380 | RINGER'S INJECTION FRESENIUS | inf 12x1000ml-sklo | FKI | I |
| 11376 | RINGER'S INJECTION FRESENIUS | inf 12x500ml-sklo | FKI | I |
| 95579 | RINGER'S INJECTION FRESENIUS | inf 1x1000ml-f | FKI | I |
| 95569 | RINGER'S INJECTION FRESENIUS | inf 1x1000ml-pe | FKI | I |
| 11328 | RINGER'S INJECTION FRESENIUS | inf 1x1000ml-sklo | FKI | I |
| 11222 | RINGER'S INJECTION FRESENIUS | inf 1x1000ml-vak | FKI | I |
| 11323 | RINGER'S INJECTION FRESENIUS | inf 1x500ml-sklo | FKI | I |
| 59369 | RINGER'S INJECTION U.S.P.BIEFFE | inf 1x1000ml(vak) | BFF | I |
| 59375 | RINGER'S INJECTION U.S.P.BIEFFE | inf 1x1000ml(vak) | BFH | E |
| 69235 | RINGER'S INJECTION U.S.P.BIEFFE | inf 1x500ml(sklo) | BFF | I |
| 59374 | RINGER'S INJECTION U.S.P.BIEFFE | inf 1x500ml(vak) | BFH | E |
| 93047 | RINGER'S INJECTION U.S.P.SIFRA | inf 10x1000ml-vak | SFR | I |
| 93055 | RINGER'S INJECTION U.S.P.SIFRA | inf 12x1000ml-sklo | SFR | I |
| 93054 | RINGER'S INJECTION U.S.P.SIFRA | inf 12x500ml-sklo | SFR | I |
| 93051 | RINGER'S INJECTION U.S.P.SIFRA | inf 1x1000ml-sklo | SFR | I |
| 12610 | RINGER'S INJECTION U.S.P.SIFRA | inf 1x1000ml-vak | SFR | I |
| 93050 | RINGER'S INJECTION U.S.P.SIFRA | inf 1x500ml-sklo | SFR | I |
| 59358 | RINGERUV ROZTOK BRAUN | inf 10x1000ml(Idpe) | BMM | D |
| 59362 | RINGERUV ROZTOK BRAUN | inf 10x1000ml(Idpe) | BME | E |
| 59366 | RINGERUV ROZTOK BRAUN | inf 10x1000ml(Idpe) | BME | CH |
| 59357 | RINGERUV ROZTOK BRAUN | inf 10x500ml(ldpe) | BMM | D |
| 59361 | RINGERUV ROZTOK BRAUN | inf 10x500ml(ldpe) | BME | E |
| 59365 | RINGERUV ROZTOK BRAUN | inf 10x500ml(ldpe) | BME | CH |
| 98.3 | B05BB02 | elektrolyty se sacharidy | parent. | 100 | ML | 9,04 | H |
| 69660 | ARDEAELYTOSOL F 1/2 | inf 1x500ml | ARD | CZ |
| 85566 | INFUS.NACL ISOT.1/2C.GL.5 IMUNA | inf 1x1000ml(vak) | IMA | SK |
| 92624 | INFUS.NACL ISOT.1/2C.GL.5 IMUNA | inf 1x2000ml(vak) | IMA | SK |
| 92625 | INFUS.NACL ISOT.1/2C.GL.5 IMUNA | inf 1x3000ml(vak) | IMA | SK |
| 62369 | INFUS.NACL ISOT.1/2C.GL.5 IMUNA | inf 1x500ml(sklo) | IMA | SK |
| 56702 | INFUSIO F 1/2 INFUSIA | inf 1x500ml(sklo) | IHO | CZ |
| 70552 | INFUSIO HRS MEDICAMENTA HRS | inf sol 1x500ml | MVM | CZ |
| 71732 | INFUSIO NATR.CHL.+GLUC.F1/2 MVM | inf sol 1x500ml | MVM | CZ |
| 71733 | INFUSIO NATR.CHL.+GLUC.F1/3 MVM | inf sol 1x500ml | MVM | CZ |
| 56706 | INFUSIO R 1/2 INFUSIA | inf 1x500ml(sklo) | IHO | CZ |
| 98.4 | B05BB03 | trometamol | parent. | 100 | ML | 23,02 | H |
| 99 | B05BC | roztoky k osmotické diuréze | parent. | |
|---|
| 99.1 | B05BC01 | mannitol (koncentrace do 10% včetně, nad 250 ml v jednom balení) | parent. | 100 | ML | 12,17 | H |
| 97744 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x500ml(sklo) | BFF | I |
| 46027 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x500ml(vak) | BFH | E |
| 74984 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x500ml(vak) | BFF | I |
| 46028 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x1000ml(vak) | BFH | E |
| 31365 | MANNISOL A INFUSION HUMAN | inf 1x500ml | HUA | H |
| 89155 | INFUSIO MANNITOLI 10% INFUSIA | inf sol1x500ml | IHO | CZ |
| 75517 | INFUSIO MANNITOLI 10 IMUNA | inf 1x500ml(sklo) | IMA | SK |
| 99.2 | B05BC01 | mannitol (koncentrace do 10% včetně, do 250 ml v jednom balení včetně) | parent. | 100 | ML | 19,31 | H |
| 97743 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x250ml(sklo) | BFF | I |
| 46026 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x250ml(vak) | BFH | E |
| 74983 | MANNITOL 10% I.V.INF.BP BIEFFE | inf 1x250ml(vak) | BFF | I |
| 80494 | INFUSIO MANNITOLI 100 G/L MVM | inf sol 1x250ml | MVM | CZ |
| 89154 | INFUSIO MANNITOLI 10% INFUSIA | inf sol1x250ml | IHO | CZ |
| 90530 | INFUSIO MANNITOLI 10 IMUNA | inf 1x250ml(sklo) | IMA | SK |
| 99.3 | B05BC01 | mannitol (koncentrace nad 10%, nad 250 ml v jednom balení) | parent. | 100 | ML | 13,78 | H |
| 97746 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x500ml(sklo) | BFF | I |
| 46025 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x500ml(vak) | BFH | E |
| 97747 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x500ml(vak) | BFF | I |
| 59743 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x1000ml(vak) | BFH | E |
| 44383 | INFUSIO MANNITOLI 20% INFUSIA | inf 1x500ml(sklo) | IHO | CZ |
| 43765 | 20% MANNITOL IN WATER USP SIFRA | inf 1x500ml-sklo | SFR | I |
| 44584 | 20% MANNITOL IN WATER USP SIFRA | inf 6x1000ml-sklo | SFR | I |
| 43766 | 20% MANNITOL IN WATER USP SIFRA | inf 1x1000ml-sklo | SFR | I |
| 31477 | 20% MANNITOL IN WATER FRESENIUS | inf 1x500ml-sklo | FKI | I |
| 31480 | 20% MANNITOL IN WATER FRESENIUS | inf 6x1000ml-sklo | FKI | I |
| 44583 | 20% MANNITOL IN WATER USP SIFRA | inf 12x500ml-sklo | SFR | I |
| 31479 | 20% MANNITOL IN WATER FRESENIUS | inf 1x1000ml-sklo | FKI | I |
| 31478 | 20% MANNITOL IN WATER FRESENIUS | inf 12x500ml-sklo | FKI | I |
| 99.4 | B05BC01 | mannitol (koncentrace nad 10%, do 250 ml v jednom balení včetně) | parent. | 100 | ML | 21,70 | H |
| 97745 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x250ml(sklo) | BFF | I |
| 59741 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x250ml(vak) | BFH | E |
| 59742 | MANNITOL 20% I.V.INF.BP BIEFFE | inf 1x250ml(vak) | BFF | I |
| 80497 | INFUSIO MANNITOLI 200 G/L MVM | inf sol 1x250ml | MVM | CZ |
| 44382 | INFUSIO MANNITOLI 20% INFUSIA | inf 1x250ml(sklo) | IHO | CZ |
| 43764 | 20% MANNITOL IN WATER USP SIFRA | inf 1x250ml-sklo | SFR | I |
| 44582 | 20% MANNITOL IN WATER USP SIFRA | inf 16x250ml-sklo | SFR | I |
| 31475 | 20% MANNITOL IN WATER FRESENIUS | inf 1x250ml-sklo | FKI | I |
| 31476 | 20% MANNITOL IN WATER FRESENIUS | inf 16x250ml-sklo | FKI | I |
| 99.5 | B05BC02 | karbamid | parent. | 90 | GM | 1133,11 | H |
| 100 | B05C | roztoky k irigaci | lok. | |
|---|
| 100.1 | B05CB01 | chlorid sodný | lok. | 1000 | ML | 37,29 | H |
|
| 100.2 | B05CX02 | sorbitol | lok. | 1000 | ML | 37,29 | H |
|
| 100.3 | B05CX03 | glycin | lok. | 1000 | ML | 54,04 | H |
|
| 100.4 | B05CX10 | kombinované roztoky k irigaci | lok. | 1000 | ML | 54,04 | H |
| 101 | B05D | roztoky k peritoneální dialýze | parent. | |
|---|
| 101.1 | B05DA | přípravky pro peritoneální dialýzu isotonické | parent. | 1000 | ML | 138,04 | H |
|
| 101.2 | B05DB | přípravky pro peritoneální dialýzu hypertonické | parent. | 1000 | ML | 138,04 | H |
| 03208 | CAPD/DPCA 17 | sol1x2000ml-stay | FMC | D |
| 03209 | CAPD/DPCA 18 | sol1x2000ml-stay | FMC | D |
| 03210 | CAPD/DPCA 19 | sol1x2000ml-stay | FMC | D |
| 97361 | CAPD/DPCA 2 | sol 1x2000ml-andy | FMC | D |
| 97353 | CAPD/DPCA 2 | sol 1x2000ml-stand | FMC | D |
| 97369 | CAPD/DPCA 2 | sol 1x2000ml-stay | FMC | D |
| 97362 | CAPD/DPCA 2 | sol 1x2500ml-andy | FMC | D |
| 97370 | CAPD/DPCA 2 | sol 1x2500ml-stay | FMC | D |
| 97371 | CAPD/DPCA 2 | sol 1x3000ml-stay | FMC | D |
| 95426 | CAPD/DPCA 2 | sol 1x5000ml-sleep | FMC | D |
| 97355 | CAPD/DPCA 2 | sol 1x5000ml-stand | FMC | D |
| 95427 | CAPD/DPCA 2 | sol 2x5000ml-sleep | FMC | D |
| 97356 | CAPD/DPCA 2 | sol 2x5000ml-stand | FMC | D |
| 97372 | CAPD/DPCA 2 | sol 3x3000ml-stay | FMC | D |
| 97366 | CAPD/DPCA 2 | sol 4x2000ml-andy | FMC | D |
| 97357 | CAPD/DPCA 2 | sol 4x2000ml-stand | FMC | D |
| 95424 | CAPD/DPCA 2 | sol 4x2000ml-stay | FMC | D |
| 97367 | CAPD/DPCA 2 | sol 4x2500ml-andy | FMC | D |
| 95425 | CAPD/DPCA 2 | sol 4x2500ml-stay | FMC | D |
| 97359 | CAPD/DPCA 2 | sol 6x1500ml-stand | FMC | D |
| 30828 | CAPD/DPCA 2 BALANCE | sol 4x2500ml-stay | FMC | D |
| 95428 | CAPD/DPCA 3 | sol 1x1500ml-stand | FMC | D |
| 95437 | CAPD/DPCA 3 | sol 1x2000ml-andy | FMC | D |
| 95429 | CAPD/DPCA 3 | sol 1x2000ml-stand | FMC | D |
| 95445 | CAPD/DPCA 3 | sol 1x2000ml-stay | FMC | D |
| 95438 | CAPD/DPCA 3 | sol 1x2500ml-andy | FMC | D |
| 95430 | CAPD/DPCA 3 | sol 1x2500ml-stand | FMC | D |
| 95446 | CAPD/DPCA 3 | sol 1x2500ml-stay | FMC | D |
| 95447 | CAPD/DPCA 3 | sol 1x3000ml-stay | FMC | D |
| 95491 | CAPD/DPCA 3 | sol 1x5000ml-sleep | FMC | D |
| 95431 | CAPD/DPCA 3 | sol 1x5000ml-stand | FMC | D |
| 95492 | CAPD/DPCA 3 | sol 2x5000ml-sleep | FMC | D |
| 95432 | CAPD/DPCA 3 | sol 2x5000ml-stand | FMC | D |
| 95487 | CAPD/DPCA 3 | sol 3x3000ml-stay | FMC | D |
| 95442 | CAPD/DPCA 3 | sol 4x2000ml-andy | FMC | D |
| 95433 | CAPD/DPCA 3 | sol 4x2000ml-stand | FMC | D |
| 95489 | CAPD/DPCA 3 | sol 4x2000ml-stay | FMC | D |
| 95443 | CAPD/DPCA 3 | sol 4x2500ml-andy | FMC | D |
| 95490 | CAPD/DPCA 3 | sol 4x2500ml-stay | FMC | D |
| 95435 | CAPD/DPCA 3 | sol 6x1500ml-stand | FMC | D |
| 30848 | CAPD/DPCA 3 BALANCE | sol 4x2500ml-stay | FMC | D |
| 95501 | CAPD/DPCA 4 | sol 1x2000ml-andy | FMC | D |
| 95494 | CAPD/DPCA 4 | sol 1x2000ml-stand | FMC | D |
| 95509 | CAPD/DPCA 4 | sol 1x2000ml-stay | FMC | D |
| 95502 | CAPD/DPCA 4 | sol 1x2500ml-andy | FMC | D |
| 95495 | CAPD/DPCA 4 | sol 1x2500ml-stand | FMC | D |
| 95510 | CAPD/DPCA 4 | sol 1x2500ml-stay | FMC | D |
| 95511 | CAPD/DPCA 4 | sol 1x3000ml-stay | FMC | D |
| 95516 | CAPD/DPCA 4 | sol 1x5000ml-sleep | FMC | D |
| 95496 | CAPD/DPCA 4 | sol 1x5000ml-stand | FMC | D |
| 95517 | CAPD/DPCA 4 | sol 2x5000ml-sleep | FMC | D |
| 95497 | CAPD/DPCA 4 | sol 2x5000ml-stand | FMC | D |
| 95512 | CAPD/DPCA 4 | sol 3x3000ml-stay | FMC | D |
| 95506 | CAPD/DPCA 4 | sol 4x2000ml-andy | FMC | D |
| 95498 | CAPD/DPCA 4 | sol 4x2000ml-stand | FMC | D |
| 95514 | CAPD/DPCA 4 | sol 4x2000ml-stay | FMC | D |
| 95507 | CAPD/DPCA 4 | sol 4x2500ml-andy | FMC | D |
| 95515 | CAPD/DPCA 4 | sol 4x2500ml-stay | FMC | D |
| 95499 | CAPD/DPCA 4 | sol 6x1500ml-stand | FMC | D |
| 30852 | CAPD/DPCA 4 BALANCE | sol 4x2500ml-stay | FMC | D |
| 46907 | DIANEAL PD1 GL.1.36%/13.6MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 46909 | DIANEAL PD1 GL.1.36%/13.6MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 46916 | DIANEAL PD1 GL.2.27%/22.7MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 46918 | DIANEAL PD1 GL.2.27%/22.7MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 46925 | DIANEAL PD1 GL.3.86%/38.6MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 46927 | DIANEAL PD1 GL.3.86%/38.6MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 76614 | DIANEAL PD4 GL.1.36%/13.6MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 76616 | DIANEAL PD4 GL.1.36%/13.6MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 76623 | DIANEAL PD4 GL.2.27%/22.7MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 76625 | DIANEAL PD4 GL.2.27%/22.7MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 76632 | DIANEAL PD4 GL.3.86%/38.6MG/ML | sol 1x2500ml(vak) | BXI | IRL |
| 76634 | DIANEAL PD4 GL.3.86%/38.6MG/ML | sol 1x5000ml(vak) | BXI | IRL |
| 45640 | GAMBROSOL 10 H | sol 2x4500ml(sy10) | BJS | I |
| 68515 | GAMBROSOL 10 H | sol 2x5000ml(sy10) | BJS | I |
| 69318 | GAMBROSOL 10 H | sol 3x3000ml(ge10) | BJS | I |
| 68321 | GAMBROSOL 10 H | sol 3x3000ml(sy10) | BJS | I |
| 45645 | GAMBROSOL 10 H | sol 4x2500ml(ge10) | BJS | I |
| 45638 | GAMBROSOL 10 H | sol 4x2500ml(sy10) | BJS | I |
| 69304 | GAMBROSOL 10 H | sol 5x2000ml(ge10) | BJS | I |
| 68460 | GAMBROSOL 10 H | sol 5x2000ml(sy10) | BJS | I |
| 45632 | GAMBROSOL 10 H | sol 6x1500ml(sy10) | BJS | I |
| 45706 | GAMBROSOL 10 L | sol 2x4500ml(sy10) | BJS | l |
| 65959 | GAMBROSOL 10 L | sol 2x5000ml(sy10) | BJS | I |
| 65967 | GAMBROSOL 10 L | sol 3x3000ml(ge10) | BJS | I |
| 65956 | GAMBROSOL 10 L | sol 3x3000ml(sy10) | BJS | I |
| 45711 | GAMBROSOL 10 L | sol 4x2500ml(ge10) | BJS | I |
| 45704 | GAMBROSOL 10 L | sol 4x2500ml(sy10) | BJS | I |
| 65963 | GAMBROSOL 10 L | sol 5x2000ml(ge10) | BJS | I |
| 65962 | GAMBROSOL 10 L | sol 5x2000ml(sy10) | BJS | I |
| 45700 | GAMBROSOL 10 L | sol 6x1500ml(sy10) | BJS | I |
| 45674 | GAMBROSOL 10 M | sol 2x4500ml(sy10) | BJS | I |
| 65950 | GAMBROSOL 10 M | sol 2x5000ml(sy10) | BJS | I |
| 65936 | GAMBROSOL 10 M | sol 3x3000ml(ge10) | BJS | I |
| 65946 | GAMBROSOL 10 M | sol 3x3000ml(sy10) | BJS | I |
| 45677 | GAMBROSOL 10 M | sol 4x2500ml(ge10) | BJS | I |
| 45672 | GAMBROSOL 10 M | sol 4x2500ml(sy10) | BJS | I |
| 65937 | GAMBROSOL 10 M | sol 5x2000ml(ge10) | BJS | I |
| 65949 | GAMBROSOL 10 M | sol 5x2000ml(sy10) | BJS | I |
| 45668 | GAMBROSOL 10 M | sol 6x1500ml(sy10) | BJS | I |
| 01186 | GAMBROSOL TRIO 10 | sol 2x5000ml(sy10) | BJS | I |
| 01198 | GAMBROSOL TRIO 10 | sol 4x2500ml(ge10) | BJS | I |
| 01184 | GAMBROSOL TRIO 10 | sol 4x2500ml(sy10) | BJS | I |
| 01218 | GAMBROSOL TRIO 40 | sol 2x5000ml(sy10) | BJS | I |
| 01236 | GAMBROSOL TRIO 40 | sol 4x2500ml(ge10) | BJS | I |
| 01215 | GAMBROSOL TRIO 40 | sol 4x2500ml(sy10) | BJS | I |
| 59059 | NUTRINEAL PD4 WITH 1.1%AMINOAC. | dlp prn sol4x2500ml | BXI | IRL |
| 52992 | PERITON.DIAL.+DEXT.1.5%+0.18CA | sol 4x2000ml | BFF | I |
| 52993 | PERITON.DIAL.+DEXT.1.5%+0.18CA | sol 4x2500ml | BFF | I |
| 52994 | PERITON.DIAL.+DEXT.2.5%+0.18CA | sol 4x2000ml(vak) | BFF | I |
| 52995 | PERITON.DIAL.+DEXT.2.5%+0.18CA | sol 4x2500ml(vak) | BFF | I |
| 55847 | PERITON.DIAL.SOL+DEXT.BFF 1.5% | sol 2500ml(vak-Šr.) | BFF | I |
| 69183 | PERITON.DIAL.SOL+DEXT.BFF 1.5% | sol 5000ml(vak-Šr.) | BFF | I |
| 55848 | PERITON.DIAL.SOL+DEXT.BFF 2.5% | sol 2500ml(vak-Šr.) | BFF | I |
| 85924 | PERITON.DIAL.SOL+DEXT.BFF 2.5% | sol 5000ml(vak-Šr.) | BFF | I |
| 55846 | PERITON.DIAL.SOL+DEXT.BFF4.25% | sol 2500ml(vak-Šr.) | BFF | I |
| 85926 | PERITON.DIAL.SOL+DEXT.BFF4.25% | sol 5000ml(vak-Šr.) | BFF | I |
| 102 | B05X | přídavky do nitrožilně podávaných roztoků (hydrogenuhličitan sodný) | parent. | |
|---|
| 102.1 | B05XA02 | hydrogenuhličitan sodný (do 20 ml v jedné ampuli včetně) | parent. | 100 | ML | 124,74 | O |
|
| 102.2 | B05XA02 | hydrogenuhličitan sodný (nad 20 ml v jedné ampuli) | parent. | 100 | ML | 10,65 | O |
| 103 | B05X | přídavky do nitrožilně podávaných roztoků (ostatní) | parent. | |
|---|
| 103.1 | B05XA01 | chlorid draselný (koncentrace 7,45%) | parent. | 100 | ML | 17,40 | H |
| 70523 | INFUSIO KALII CHL.CONC.MVM 7.45 | inf sol 1x250ml | MVM | CZ |
| 103.2 | B05XA03 | chlorid sodný (koncentrace do 5,85% včetně) | parent. | 100 | ML | 20,30 | H |
| 44171 | CHLORID SODNY 5.85% BRAUN | inf 1x100ml | BME | D |
| 103.3 | B05XA03 | chlorid sodný (koncentrace nad 5,85%) | parent. | 100 | ML | 18,55 | H |
| 01695 | NATRII CHLORIDI 10% MEDVIR | inf 1x100ml | VYS | CZ |
| 103.4 | B05XA04 | chlorid amonný | parent. | 100 | ML | 11,68 | H |
|
| 103.5 | B05XA06 | fosforečnan draselný, vč. kombinací | parent. | 100 | ML | 52,35 | H |
|
| 103.6 | B05XA30 | kombinace elektrolytů (stopové prvky) | parent. | 10 | ML | 12,46 | H |
|
| 103.7 | B05XA31 | elektrolyty v kombinaci s jinými léčivy | parent. | 100 | ML | 33,26 | H |
| 75101 | KALIUM-L-MALATLÖS.ELO-MEL INF. | inf cnc sol 10x20ml | LPD | A |
| 103.8 | B05XB01 | chlorid argininu (koncentrace 21%) | parent. | 100 | ML | 233,08 | H |
| 86797 | ARDEAELYTOSOL L-ARGININCHL.21% | inf 1x200ml | ARD | CZ |
| 86798 | ARDEAELYTOSOL L-ARGININCHL.21% | inf 1x250ml | ARD | CZ |
| 69596 | ARDEAELYTOSOL L-ARGININCHL.21% | inf 1x300ml | ARD | CZ |
| 86799 | ARDEAELYTOSOL L-ARGININCHL.21 % | inf 1x400ml | ARD | CZ |
| 69597 | ARDEAELYTOSOL L-ARGININCHL.21% | inf 1x500ml | ARD | CZ |
| 103.9 | B05XB02 | alanylglutamin | parent. | 1 | ML | 4,39 | H |
|
| 103.10 | B05XC | vitamíny | parent. | 1 | DF | 43,99 | H |
|
| 103.11 | B05XX | ostatní i.v. roztoky | parent. | 100 | ML | 7,63 | H |
| 104 | B05Z | roztoky k hemodialýze a hemofiltraci | lok. | |
|---|
| 104.1 | B05Z | hemodialytika a hemofiltráty | lok. | 1000 | ML | 94,50 | H |
|
| 104.2 | B05ZA | hemodialytika, koncentráty | lok. | 1000 | ML | 125,72 | H |
|
| 104.3 | B05ZB | hemofiltráty | lok. | 1000 | ML | 94,50 | H |
| 98825 | ROZTOK PRO HEMOFILTRACI HF 11 | sol 2x4500ml | FMC | D |
| 89174 | SOLUTION FOR HAEMOFILTRATION E2 | sol 1x5000ml | BFF | I |
| 105 | C01AA | kardioglykosidy z náprstníku | p.o. | |
|---|
| 105.1 | C01AA02 | acetyldigoxin | p.o. | 0.5 | MG | 1,03 | |
| |
| 105.2 | C01AA04 | digitoxin | p.o. | 0.1 | MG | 1,03 | |
|
| 105.3 | C01AA05 | digoxin | p.o. | 0.25 | MG | 1,27 | |
| 83318 | DIGOXIN 0.125 LÉČIVA | tbl 30x0.125mg | LEX | CZ |
| 03542 | DIGOXIN 0.250 LÉČIVA | tbl 30x0.25mg | LEX | CZ |
| 00705 | DIGOXIN-GALENA | porgttsol1x10ml/5mg | IVX | CZ |
| 105.4 | C01AA08 | metildigoxin | p.o. | 0.2 | MG | 1,03 | |
| 106 | C01AA | kardioglykosidy z náprstníku | parent. | |
|---|
| 106.1 | C01AA05 | digoxin | parent. | 0.25 | MG | 7,32 | |
|
| 106.2 | C01AA08 | metildigoxin | parent. | 0.2 | MG | 6,99 | |
|
| 106.3 | C01AC01 | g-strofantin | parent. | 0.25 | MG | 23,46 | |
| 107 | C01BA | antiarytmika, třída la | p.o. | |
|---|
| 107.1 | C01BA | detajmii bitartras | p.o. | 75 | MG | 14,07 | |
| 23113 | TACHMALCOR | por tbl obd 50x25mg | AWD | D |
| 107.2 | C01BA01 | chinidin (neretardované lékové formy) | p.o. | 1.2 | GM | 10,80 | |
|
| 107.3 | C01BA01 | chinidin (retardované lékové formy) | p.o. | 1.2 | GM | 17,40 | |
|
| 107.4 | C01BA02 | prokainamid | p.o. | 3 | GM | 38,61 | |
|
| 107.5 | C01BA03 | disopyramid | p.o. | 0.4 | GM | 12,37 | |
|
| 107.6 | C01BA08 | prajmalin | p.o. | 30 | MG | 10,80 | |
|
| 107.7 | C01CA | ipratropium | p.o. | 30 | MG | 53,77 | |
| 88433 | ITROP | tbl obd 20x10mg | BOE | F |
| 108 | C01BA | antiarytmika, třída la | parent. | |
|---|
| 108.1 | C01B | ipratropium | parent. | 3 | MG | 782,94 | O |
|
| 108.2 | C01BA02 | prokainamid | parent. | 3 | GM | 251,87 | O |
|
| 108.3 | C01BA03 | disopyramid | parent. | 0.4 | GM | 251,87 | O |
|
| 108.4 | C01BA05 | ajmalin | parent. | 0.3 | GM | 251,87 | O |
| 109 | C01BB | antiarytmika, třída Ib | p.o. | |
|---|
| 109.1 | C01BB02 | mexiletin | p.o. | 0.8 | GM | 9,41 | |
| 93311 | KATEN RETARD 400MG | tbl ret 50x400mg | SLO | SK |
| 109.2 | C01BB03 | tocainid | p.o. | 1.2 | GM | 10,22 | |
| 110 | C01BB | antiarytmika, třída Ib | parent. | |
|---|
| 110.1 | C01BB01 | lidokain | parent. | 1 | ML | 1,22 | O/INT,KAR,GER |
|
| 110.2 | C01BB02 | mexiletin | parent. | 0.8 | GM | 351,64 | O/INT,KAR,GER |
|
| 110.3 | C01BB03 | tocainid | parent. | 1.2 | GM | 351,64 | O/INT,KAR,GER |
| 111 | C01BC | antiarytmika, třída Ic | p.o. | |
|---|
| 111.1 | C01BC03 | propafenon (méně než 100 mg v jedné tabletě) | p.o. | 0.3 | GM | 17,16 | |
|
| 111.2 | C01BC03 | propafenon (od 100 mg do 150 mg včetně v jedné tabletě) | p.o. | 0.3 | GM | 6,40 | |
|
| 111.3 | C01BC03 | propafenon (nad 150 mg v jedné tabletě) | p.o. | 0.3 | GM | 5,40 | |
| 112 | C01BC | antiarytmika, třída Ic | parent. | |
|---|
| 112.1 | C01BC03 | propafenon | parent. | 0.3 | GM | 174,00 | O/INT,KAR,GER |
|
| 112.2 | C01BC07 | lorcainid | parent. | 0.2 | GM | 139,01 | O/INT,KAR,GER |
| 113 | C01BD | antiarytmika, třída III | p.o. | |
|---|
| 113.1 | C01BD01 | amiodaron | p.o. | 0.2 | GM | 4,00 | |
| 59286 | AMIOHEXAL 200 | tbl 100x200mg | SFS | D |
| 59284 | AMIOHEXAL 200 | tbl 20x200mg | SFS | D |
| 59285 | AMIOHEXAL 200 | tbl 50x200mg | SFS | D |
| 114 | C01BD | antiarytmika, třída III a adenosin | parent. | |
|---|
| 114.1 | C01BD01 | amiodaron | parent. | 0.2 | GM | 19,28 | O/INT,KAR,GER |
| 59659 | AMIOKORDIN | inj sol 5x3ml/150mg | KRK | SLO |
| 96600 | SEDACORON | inj sol 5x3ml/150mg | EBP | A |
| 114.2 | C01BD02 | bretylium tosilát | parent. | 100 | MG | 139,01 | O/INT,KAR,GER |
|
| 114.3 | C01EB10 | adenosin | parent. | 15 | MG | 695,63 | O/INT,KAR,GER |
| 91615 | ADENOCOR | inj 6x2ml/6mg | SWJ | F |
| 55662 | ADENOSIN EBEWE | inj sol 6x2ml/6mg | EBP | A |
| 115 | C01CA | adrenergní a dopaminergní léčiva (norepinefrin a dopamin) | parent. | |
|---|
| 115.1 | C01CA03 | norepinefrin | parent. | 6 | MG | 79,56 | O |
| 00536 | NORADRENALIN LÉČIVA | inj 5x1ml/1mg | LEX | CZ |
| 115.2 | C01CA04 | dopamin | parent. | 0.5 | GM | 114,50 | O |
| 116 | C01CA | adrenergní a dopaminergní léčiva (ostatní) | parent. | |
|---|
| 116.1 | C01CA02 | isoprenalin | parent. | 90 | MG | 15620,16 | H |
| | |
| 116.2 | C01CA05 | norfenefrin | parent. | 25 | MG | 23,76 | H |
| | |
| 116.3 | C01CA07 | dobutamin | parent. | 0.5 | GM | 324,00 | H |
| 01639 | DOBUTAMIN GIULINI | inj sic 10x250mg | WAU | D |
| 84361 | DOBUTAMIN GIULINI | inj sic 1x250mg | WAU | D |
| 116.4 | C01CA09 | metaraminol | parent. | 50 | MG | 191,26 | H |
| |
| 116.5 | C01CA10 | metoxamin | parent. | 30 | MG | 40,91 | H |
|
| 116.6 | C01CA11 | mepentermin | parent. | 30 | MG | 101,67 | H |
| 116.7 | C01CA17 | midodrin | parent. | 7.5 | MG | 83,44 | H |
|
| 116.8 | C01CA24 | epinefrin (lékové formy autoinjektoru) | parent. | 1 | DF | 684,31 | P |
Medicinal product containing epinephrine in autoinjector formulations is prescribed by an allergologist and a clinical immunologist in patients with a history of anaphylactic shock caused by an insect allergy.
| 116.9 | C01CA24 | epinefrin | parent. | 0.5 | MG | 4,50 | O |
|
| 116.10 | C01CA14 | dopexamin | parent. | 500 | MG | 109,39 | H |
|
| 116.11 | C01CX08 | levosimendan | parent. | 11 | MG | 20280,00 | H |
| 117 | C01CE | léčiva ze skupiny inhibitorů fosfodiesterázy | parent. | |
|---|
| 117.1 | C01CE01 | amrinon | parent. | 0.5 | GM | 4059,95 | H |
| 91980 | WINCORAM | inj 10x20ml 5mg/ml | SWI | F |
| 117.2 | C01CE02 | milrinon | parent. | 50 | MG | 3980,00 | H |
| 118 | C01DA | vazodilatancia ze skupiny organických nitrátů | p.o. | |
|---|
| 118.1 | C01DA02 | glycerol trinitrát (do 2,5 mg v jedné tabletě včetně, lékové formy tablet) | p.o. | 5 | MG | 2,00 | |
|
| 118.2 | C01DA02 | glycerol trinitrát (do 2,5 mg v jedné tabletě včetně, lékové formy tobolek s peletami) | p.o. | 5 | MG | 3,00 | |
|
| 118.3 | C01DA02 | glycerol trinitrát (nad 2,5 mg v jedné tabletě) | p.o. | 5 | MG | 2,12 | |
| 31089 | NITROMINT 2.6MG | tbl ret 60x2.6mg | EGI | H |
| 118.4 | C01DA08 | isosorbid dinitrát (do 20 mg v jedné tabletě včetně) | p.o. | 60 | MG | 3,50 | |
| 02405 | DINISAN RETARD 20MG | por cps pro 30x20mg | ETS | F |
| 32840 | DINISAN RETARD 20MG | por cps pro 30x20mg | PMP | CZ |
| 118.5 | C01DA08 | isosorbid dinitrát (nad 20 do 80 mg v jedné tabletě včetně) neretardované lékové formy | p.o. | 60 | MG | 1,25 | |
|
| 118.6 | C01DA08 | isosorbid dinitrát (nad 20 do 80 mg v jedné tabletě včetně) retardované lékové formy | p.o. | 60 | MG | 2,50 | |
| 02379 | DINISAN RETARD 40MG | por cps pro 30x40mg | ETS | F |
| 32843 | DINISAN RETARD 40MG | por cps pro 30x40mg | PMP | CZ |
| 118.7 | C01DA08 | isosorbid dinitrát (nad 80 mg v jedné tabletě) | p.o. | 60 | MG | 4,20 | |
| 91591 | CARDIKET RETARD 120 | cps ret 20x120mg | SWP | D |
| 118.8 | C01DA14 | isosorbid mononitrát do 20 mg včetně v jedné tabletě | p.o. | 40 | MG | 2,75 | |
| 47685 | ISMIN AL 20 | por tbl nob 30x20mg | APA | D |
| 47686 | ISMIN AL 20 | por tbl nob 60x20mg | APA | D |
| 47687 | ISMIN AL 20 | por tbl nob100x20mg | APA | D |
| 59898 | ISMN AL 20 | por tbl nob 30x20mg | APA | D |
| 92568 | ISMN AL 20 | por tbl nob 60x20mg | APA | D |
| 61467 | ISMN AL 20 | por tbl nob100x20mg | APA | D |
| 87184 | MONO MACK 20MG | por tbl nob 30x20mg | ICS | CZ |
| 96190 | MONOSAN 20 MG | por tbl nob 30x20mg | PMP | CZ |
| 96187 | MONOSAN 20 MG | por tbl nob 50x20mg | PMP | CZ |
| 23305 | MONOSAN 20 MG | por tbl nob100x20mg | PMP | CZ |
| 76402 | SORBIMON 20 MG | tbl 100x20mg | MCK | D |
| 76400 | SORBIMON 20 MG | tbl 20x20mg | MCK | D |
| 76401 | SORBIMON 20 MG | tbl 50x20mg | MCK | D |
| 118.9 | C01DA14 | isosorbid mononitrát nad 20 mg v jedné tabletě | p.o. | 40 | MG | 2,49 | |
| 47688 | ISMIN AL 40 | por tbl nob 30x40mg | APA | D |
| 47689 | ISMIN AL 40 | por tbl nob 60x40mg | APA | D |
| 47690 | ISMIN AL 40 | por tbl nob100x40mg | APA | D |
| 59899 | ISMN AL 40 | por tbl nob 30x40mg | APA | D |
| 92569 | ISMN AL 40 | por tbl nob 60x40mg | APA | D |
| 61469 | ISMN AL 40 | por tbl nob100x40mg | APA | D |
| 87185 | MONO MACK 40MG | por tbl nob 30x40mg | ICS | CZ |
| 96191 | MONOSAN 40 MG | por tbl nob 30x40mg | PMP | CZ |
| 96188 | MONOSAN 40 MG | por tbl nob 50x40mg | PMP | CZ |
| 23306 | MONOSAN 40 MG | por tbl nob100x40mg | PMP | CZ |
| 76405 | SORBIMON 40 MG | tbl 100x40mg | MCK | D |
| 76403 | SORBIMON 40 MG | tbl 20x40mg | MCK | D |
| 76404 | SORBIMON 40 MG | tbl 50x40mg | MCK | D |
| 119 | C01DA | vazodilatancia ze skupiny organických nitrátů | parent. | |
|---|
| 119.1 | C01DA02 | glycerol trinitrát | parent. | 2.5 | MG | 13,18 | H |
| 02640 | NITRO MACK AMPULE | inj 10x5ml/5mg | PHH | D |
| 04307 | NITRO POHL INFUS. | inf 10x10ml/10mg | PLB | D |
| 83538 | NITRO POHL INFUS. | inf 1x50ml/50mg | PLB | D |
| 119.2 | C01DA08 | isosorbid dinitrát | parent. | 20 | MG | 123,96 | H |
| 120 | C01DA | vazodilatancia ze skupiny organických nitrátů | spr. | |
|---|
| 120.1 | C01DA02 | glycerol trinitrát | spr. | 5 | DF | 2,36 | |
|
| 120.2 | C01DA08 | isosorbid dinitrát (mimo přípravků určených k transdermální aplikaci) | spr. | 20 | MG | 8,80 | |
| 121 | C01DA | vazodilatancia ze skupiny organických nitrátů | sublng. | |
|---|
| 121.1 | C01DA02 | glycerol trinitrát | sublng. | 2.5 | MG | 5,93 | |
| 00231 | NITROGLYCERIN-SLOVAKOFARMA | tbl 20x0.5mg | SLO | SK |
| 121.2 | C01DA08 | isosorbid dinitrát | sublng. | 20 | MG | 3,03 | |
| 122 | C01DX | ostatní vazodilatancia | p.o. | |
|---|
| 122.1 | C01DX03 | oxifedrin | p.o. | 40 | MG | 4,79 | |
|
| 122.2 | C01DX12 | molsidomin (do 2 mg v jedné tabletě včetně) | p.o. | 6 | MG | 4,46 | |
| 49553 | MOLSIHEXAL 2 MG | tbl 100x2mg | SFS | D |
| 122.3 | C01DX12 | molsidomin (nad 2 do 4 mg v jedné tabletě včetně) | p.o. | 6 | MG | 2,72 | |
| 49554 | MOLSIHEXAL 4 MG | tbl 100x4mg | SFS | D |
| 122.4 | C01DX12 | molsidomin (nad 4 mg v jedné tabletě) | p.o. | 6 | MG | 2,10 | |
| 49559 | MOLSIHEXAL RETARD | tbl ret 100x8mg | SFS | D |
| 49560 | MOLSIHEXAL RETARD | tbl ret 30x8mg | SFS | D |
| 49561 | MOLSIHEXAL RETARD | tbl ret 60x8mg | SFS | D |
| 122.5 | C01EB15 | trimetazidin | p.o. | 40 | MG | 6,50 | L/INT, KAR,GER |
| 123 | C01DX | ostatní vazodilatancia | parent. | |
|---|
| 123.1 | C01DX03 | oxifedrin | parent. | 40 | MG | 13,78 | H |
|
| 123.2 | C01DX12 | molsidomin | parent. | 6 | MG | 105,38 | H |
| 124 | C01EA | prostaglandiny | parent. | |
|---|
| 124.1 | C01EA01 | alprostadil | parent. | 0,5 | MG | 3090,40 | X |
| 92305 | ALPROSTAN | inf sol 10x0.2ml | LEX | CZ |
| 44169 | ALPROSTAPINT 500 MCG/ML | inf cnc sol 5x1ml | BGD | D |
| 124.2 | C01EA01 | alprostadil (vázaný na cyklodextrin) | parent. | 20 | RG | 634,27 | X |
| 91731 | PROSTAVASIN | inj sic 10x5ml | SWP | D |
| 125 | C02 | antihypertenziva působící na centrální alfa-2 receptory a jejich kombinace s diuretiky | p.o. | |
|---|
| 125.1 | C02AB01 | methyldopa (levotočivá) | p.o. | 1 | GM | 6,80 | |
|
| 125.2 | C02AC01 | klonidin | p.o. | 0.45 | MG | 7,00 | |
|
| 125.3 | C02AC02 | guanfacin | p.o. | 3 | MG | 7,00 | |
|
| 125.4 | C02AC05 | moxonidin do 0,2 mg v 1 tabletě včetně | p.o. | 0.3 | MG | 7,80 | |
|
| 125.5 | C02AC05 | moxonidin nad 0,2 mg v 1 tabletě | p.o. | 0.3 | MG | 7,00 | |
|
| 125.6 | C02AC06 | rilmenidin | p.o. | 1 | MG | 7,00 | |
|
| 125.7 | C02LA51 | reserpin a diuretika | p.o. | 1 | DF | 1,63 | |
| 02629 | CRYSTEPIN | drg 30 | LEX | CZ |
| 125.8 | C02LB01 | methyldopa/hydrochlorothiazid (do 15 mg v jedné tabletě včetně) | p.o. | 3 | DF | 4,94 | |
|
| 125.9 | C02LB01 | methyldopa/hydrochlorothiazid (nad 15 mg v jedné tabletě) | p.o. | 2 | DF | 3,42 | |
| 126 | C02A | antihypertenziva působící na centrální alfa-2 receptory | parent. | |
|---|
| 126.1 | C02AC01 | klonidin | parent. | 0.45 | MG | 70,09 | H |
| 11823 | CATAPRESAN | inj 5x1ml/0.15mg | BOE | E |
| 92074 | CATAPRESAN | inj 5x1ml/0.15mg | BGP | D |
| 127 | C02CA | antihypertenziva působící na periferní alfa-1 receptory | p.o. | |
|---|
| 127.1 | C02CA | metazosin | p.o. | 20 | MG | 5,96 | |
|
| 127.2 | C02CA01 | prazosin (do 1 mg v jedné tabletě včetně) | p.o. | 5 | MG | 12,59 | |
| 58259 | DEPRAZOLIN MITE | tbl 15x1mg | LEX | CZ |
| 127.3 | C02CA01 | prazosin (nad 1 mg v jedné tabletě) | p.o. | 5 | MG | 3,33 | |
| 88173 | DEPRAZOLIN | tbl 30x2mg | LEX | CZ |
| 127.4 | C02CA04 | doxazosin-retardované formy do 4 mg v jedné tabletě včetně | p.o. | 4 | MG | 18,90 | L/URN |
|
| 127.5 | C02CA04 | doxazosin-retardované formy nad 4 mg v jedné tabletě | p.o. | 4 | MG | 10,20 | L/URN |
|
| 127.6 | C02CA04 | doxazosin – neretardované formy | p.o. | 4 | MG | 16,80 | L/URN |
| 64798 | KAMIREN 2 | tbl 30x2mg | KRK | SLO |
| 64797 | KAMIREN 4 | tbl 30x4mg | KRK | SLO |
| 45215 | ZOXON 4 | por tbl nob 30x4mg | LEX | CZ |
| 95243 | ZOXON 4 | por tbl nob100x4mg | LEX | CZ |
| 127.7 | C02CA06 | urapidil | p.o. | 50 | MG | 6,89 | |
| 128 | C02CA | antihypertenziva působící na periferní alfa-1 receptory | parent. | O |
|---|
| 128.1 | C02CA06 | urapidil | parent. | 50 | MG | 217,84 | O |
| 90763 | EBRANTIL I.V. 25 | inj sol 5x5ml/25mg | AKZ | D |
| 90765 | EBRANTIL I.V. 50 | inj sol 5x10ml/50mg | AKZ | D |
| 129 | C02D | antihypertenziva působící přímou vazodilataci | p.o. | |
|---|
| 129.1 | C02DB01 | dihydralazin | p.o. | 75 | MG | 2,00 | |
|
| 129.2 | C02DB03 | endralazin | p.o. | 10 | MG | 9,43 | |
|
| 129.3 | C02DC01 | minoxidil | p.o. | 20 | MG | 20,14 | L/INT,KAR, GER |
| 130 | C02D | antihypertenziva působící přímou vazodilataci | parent. | |
|---|
| 130.1 | C02DA01 | diazoxid | parent. | 300 | MG | 283,99 | H |
|
| 130.2 | C02DB01 | dihydralazin | parent. | 25 | MG | 29,88 | H |
|
| 130.3 | C02DD01 | nitroprusid sodný | parent. | 50 | MG | 265,63 | H |
| 21221 | NIPRUSS | inf plv sol 5x60mg | SWP | D |
| 131 | C03AA | thiazidová diuretika | p.o. | |
|---|
| 131.1 | C03AA03 | hydrochlorothiazid | p.o. | 25 | MG | 0,94 | |
| 132 | C03B | sulfonamidová diuretika a antihypertenziva | p.o. | |
|---|
| 132.1 | C03BA04 | chlortalidon | p.o. | 25 | MG | 0,61 | |
|
| 132.2 | C03BA10 | xipamid | p.o. | 20 | MG | 1,03 | |
|
| 132.3 | C03BA11 | indapamid | p.o. | 2.5 | MG | 1,12 | |
| 96696 | INDAP | por cps dur30x2.5mg | PMP | CZ |
| 46635 | INDAPAMID HF | tbl obd 30x2.5mg | HMF | YU |
| 132.4 | C03BA11 | indapamid s řízeným uvolňováním | p.o. | 1,5 | MG | 1,12 | |
|
| 132.5 | C03BA | metipamid | p.o. | 2.5 | MG | 1,03 | |
|
| 132.6 | C03B | cikletanin | p.o. | 50 | MG | 1,03 | |
| 133 | C03CA | kličková diuretika | p.o. | |
|---|
| 133.1 | C03CA01 | furosemid (méně než 125 mg v jedné tabletě) | p.o. | 40 | MG | 0,88 | |
| 56347 | APO-FUROSEMIDE 40MG | tbl 100x40mg | APT | CND |
| 96738 | APO-FUROSEMIDE 80MG | tbl 100x80mg | APT | CND |
| 98219 | FURON 40 MG | por tbl nob 50x40mg | MCK | D |
| 56805 | FURORESE 40 | tbl 100x40mg | FST | D |
| 56802 | FURORESE 40 | tbl 20x40mg | FST | D |
| 56804 | FURORESE 40 | tbl 50x40mg | FST | D |
| 02079 | FUROSEMID-SLOVAKOFARMA | tbl 20x40mg | SLO | SK |
| 133.2 | C03CA01 | furosemid (125 mg a více v jedné tabletě) | p.o. | 40 | MG | 1,08 | |
| 56809 | FURORESE 125 | tbl 100x125mg | FST | D |
| 56807 | FURORESE 125 | tbl 30x125mg | FST | D |
| 56808 | FURORESE 125 | tbl 50x125mg | FST | D |
| 98937 | FURORESE 250 | por tbl nob10x250mg | FST | D |
| 56810 | FURORESE 250 | por tbl nob20x250mg | FST | D |
| 56811 | FURORESE 250 | por tbl nob50x250mg | FST | D |
| 56812 | FURORESE 250 | por tblnob100x250mg | FST | D |
| 56815 | FURORESE 500 | tbl 100x500mg | FST | D |
| 68632 | FURORESE 500 | tbl 20x500mg | FST | D |
| 56814 | FURORESE 500 | tbl 50x500mg | FST | D |
| 81497 | FUROSEMID AL 500 | por tbl nob20x500mg | APA | D |
| 81498 | FUROSEMID AL 500 | por tbl nob50x500mg | APA | D |
| 81499 | FUROSEMID AL 500 | por tblnob100x500mg | APA | D |
| 02785 | FUROSEMID SLOVAKOFARMA FORTE | tbl 10x250mg | SLO | SK |
| 133.3 | C03CA04 | torasemid (do 10 mg v jedné tabletě včetně) | p.o. | 15 | MG | 0,88 | |
|
| 133.4 | C03CA04 | torasemid (nad 10 mg v jedné tabletě) | p.o. | 15 | MG | 1,08 | |
| 134 | C03CA | kličková diuretika | parent. | |
|---|
| 134.1 | C03CA01 | furosemid (méně než 125 mg v jedné ampuli) | parent. | 40 | MG | 15,04 | O |
| 56818 | FURORESE 20 INJEKT | inj 25x2ml/20mg | PHH | D |
| 56817 | FURORESE 20 INJEKT | inj 5x2ml/20mg | PHH | D |
| 02133 | FUROSEMID BIOTIKA | inj 5x2ml/20mg | HBS | SK |
| 134.2 | C03CA01 | furosemid (125 mg a více v jedné ampuli) | parent. | 40 | MG | 7,36 | O |
| 56820 | FURORESE ROZTOK | inf 25x25ml/250mg | PHH | D |
| 56819 | FURORESE ROZTOK | inf 5x25ml/250mg | PHH | D |
| 99333 | FUROSEMID BIOTIKA FORTE | inj 10x10ml/125mg | HBS | SK |
| 134.3 | C03CA04 | torasemid (do 10 mg v jedné ampuli včetně) | parent. | 15 | MG | 16,03 | O |
|
| 134.4 | C03CA04 | torasemid (nad 10 mg v jedné ampuli) | parent. | 15 | MG | 7,72 | O |
|
| 134.5 | C03C | kyselina etakrynová | parent. | 50 | MG | 543,63 | O |
| 135 | C03D | kalium šetřící diuretika | p.o. | |
|---|
| 135.1 | C03DA01 | spironolakton | p.o. | 75 | MG | 4,84 | |
|
| 135.2 | C03DB01 | amilorid | p.o. | 10 | MG | 1,56 | |
| 87662 | AMICLARAN | tbl 50x5mg | SLO | SK |
| 135.3 | C03DB02 | triamteren | p.o. | 100 | MG | 1,22 | |
| 136 | C03EA | kombinace thiazidových a kalium šetřících diuretik | p.o. | |
|---|
| 136.1 | C03EA06 | chlorthalidon a kalium šetřící látky | p.o. | 1 | DF | 1,17 | |
| 88518 | AMICLOTON | tbl 30 | SLO | SK |
| 136.2 | C03EA01 | hydrochlorothiazid a kalium šetřící látky | p.o. | 0.5 | DF | 0,54 | |
| 83718 | AMILORID/HCT AL | tbl 100 | APA | D |
| 83717 | AMILORID/HCT AL | tbl 50 | APA | D |
| 47478 | LORADUR MITE | por tbl nob 50 | MCK | D |
| 76380 | RHEFLUIN | tbl 30 | LEX | CZ |
| 136.3 | C03EA14 | spironolakton/butizid | p.o. | 1 | DF | 9,78 | |
| 137 | C04AB | periferní vazodilatancia ze skupiny derivátů imidazolu | parent. | |
|---|
| 137.1 | C04AB01 | fentolamin | parent. | 10 | MG | 20,82 | O |
|
| 137.2 | C04AB02 | tolazolin | parent. | 75 | MG | 87,00 | O |
| 138 | C04A | periferní vazodilatancia ze skupiny derivátů purinu a kyseliny nikotinové | p.o. | |
|---|
| 138.1 | C04AC01 | kyselina nikotinová | p.o. | 0.2 | GM | 0,44 | |
|
| 138.2 | C04AD02 | xantinol nikotinát | p.o. | 0.9 | GM | 4,30 | |
|
| 138.3 | C04AD03 | pentoxifyllin (do 100 mg v jedné tabletě včetně) | p.o. | 1 | GM | 4,30 | |
|
| 138.4 | C04AD03 | pentoxifyllin (nad 100 mg do 400 mg v jedné tabletě včetně) | p.o. | 1 | GM | 6,70 | |
| 54247 | APO-PENTOXIFYLLINE SR | por tblpro100x400mg | APT | CND |
| 47085 | PENTOMER RETARD 400MG | tbl ret 100x400mg | MCK | D |
| 89992 | PENTOXIFYLLIN AL 400 RETARD | tbl ret 100x400mg | APA | D |
| 66513 | PENTOXIFYLLIN AL 400 RETARD | tbl ret 30x400mg | APA | D |
| 89991 | PENTOXIFYLLIN AL 400 RETARD | tbl ret 50x400mg | APA | D |
| 53479 | TRENTAL 400 | por tbl ret20x400mg | HBS | SK |
| 53480 | TRENTAL 400 | por tblret100x400mg | HBS | SK |
| 138.5 | C04AD03 | pentoxifyllin (nad 400 mg v jedné tabletě) | p.o. | 1 | GM | 7,50 | |
| 49600 | PENTOHEXAL 600 | tbl ret 30x600mg | SFS | D |
| 49601 | PENTOHEXAL 600 | tbl ret 50x600mg | SFS | D |
| 97702 | PENTOMER RETARD 600MG | tbl ret 20x600mg | MCK | D |
| 84413 | VASONIT RETARD 600MG | tbl obd 20x600mg | LAR | A |
| 138.6 | C04AD04 | etophyllin nikotinát | p.o. | 0.3 | GM | 1,65 | |
| 00243 | OXYPHYLLIN | tbl 50x100mg | SLO | SK |
| 139 | C04A | periferní vazodilatancia ze skupiny derivátů purinu a kyseliny nikotinové | parent. | |
|---|
| 139.1 | C04AC | olamin nikotinát | parent. | 0.9 | GM | 20,04 | |
|
| 139.2 | C04AD | etophyllin/theophyllin | parent. | 0.3 | GM | 11,05 | |
| 57351 | OXANTIL | inj 5x2ml | HBS | SK |
| 139.3 | C04AD02 | xantinol nikotinát | parent. | 0.9 | GM | 4,25 | |
|
| 139.4 | C04AD03 | pentoxifyllin | parent. | 0.3 | GM | 28,40 | |
| 53200 | AGAPURIN | inj 5x5ml/100mg | SLO | SK |
| 69241 | PENTILIN INJEKCE 100MG/5ML | inj 5x5ml/100mg | KRK | SLO |
| 49603 | PENTOHEXAL 300 | inf 10x15ml/300mg | PHH | D |
| 43709 | TRENTAL | inf 10x15ml/300mg | HBS | SK |
| 140 | C04AE | periferní vazodilatancia ze skupiny derivátů námelových alkaloidů | p.o. | |
|---|
| 140.1 | C04AE01 | hydrogenované ergotové alkaloidy | p.o. | 3 | MG | 2,11 | |
| 91032 | SECATOXIN FORTE | por gtt sol 1x25ml | IVX | CZ |
| 140.2 | C04AE02 | nicergolin | p.o. | 30 | MG | 8,50 | |
| 05742 | ERGOTOP 30 | por tbl flm 28x30mg | IVX | CZ |
| 140.3 | C04AE54 | dihydroergokristin, kombinace | p.o. | 2 | ML | 1,87 | |
| 88088 | ERSILAN | gtt 1x50ml | GNO | CZ |
| 141 | C04AE | periferní vazodilatancia ze skupiny derivátů námelových alkaloidů | parent. | |
|---|
| 141.1 | C04AE01 | hydrogenované ergotové alkaloidy | parent. | 3 | MG | 69,21 | |
| 142 | C04AX | jiná periferní vasodilatancia | p.o. |
|---|
| 142.1 | C04AX | jiná periferní vasodilatancia | p.o. | 3 | DF | 5,66 | |
|
| 142.2 | C04AX02 | fenoxybenzamin | p.o. | 30 | MG | 15,54 | |
| 142.3 | C04AX19 | sulkotidil | p.o. | 0.3 | GM | 5,66 | |
| | |
| 142.4 | C04AX20 | buflomedil | p.o. | 0.6 | GM | 5,66 | |
| | |
| 142.5 | C04AX21 | naftidrofuryl | p.o. | 0.2 | GM | 5,66 | |
| 66015 | ENELBIN 100 RETARD | por tblret100x100mg | LEX | CZ |
| 143 | C04AX | jiná periferní vasodilatancia | parent. | |
|---|
| 143.1 | C04AX | jiná periferní vasodilatancia | parent. | 2 | DF | 14,86 | |
|
| 143.2 | C04AX11 | bencyklan | parent. | 0.6 | GM | 51,52 | |
|
| 143.3 | C04AX21 | naftidrofuryl | parent. | 0.2 | GM | 53,95 | |
| 98049 | ENELBIN | inj 10x5ml/40mg | LEX | CZ |
| 144 | C05AD | antihemorhoidalia obsahující lokální anestetika | lok. | |
|---|
| 144.1 | C05AD | přípravky obsahující lokální anestetika (lékové formy čípků) | lok. | 1 | DF | 0,98 | |
|
| 144.2 | C05AD | přípravky obsahující lokální anestetika (lékové formy mastí) | lok. | 1 | GM | 0,81 | |
|
| 144.3 | C05AD01 | lidokain (lékové formy čípků) | lok. | 1 | DF | 0,98 | |
|
| 144.4 | C05AD01 | lidokain (lékové formy mastí) | lok. | 1 | GM | 0,81 | |
|
| 144.5 | C05AD04 | cinchokain (lékové formy čípků) | lok. | 1 | DF | 0,98 | |
| |
| 144.6 | C05AD04 | cinchokain (lékové formy mastí) | lok. | 1 | GM | 0,84 | |
| 145 | C05AX | jiná antihemorrhoidalia k zevnímu použití | lok. | |
|---|
| 145.1 | C05AX02 | bismutové přípravky, kombinace (lékové formy mastí) | lok. | 1 | GM | 0,78 | |
| |
| 145.2 | C05AX02 | bismutové přípravky, kombinace (lékové formy čípků) | lok. | 1 | DF | 0,98 | |
|
| 145.3 | C05AX03 | jiná antihemorrhoidalia k zevnímu použití (lékové formy mastí) | lok. | 1 | GM | 0,78 | |
| |
| 145.4 | C05AX03 | jiná antihemorrhoidalia k zevnímu použití (lékové formy čípků) | lok. | 1 | DF | 0,98 | |
| 146 | C05BA | lokální léčiva s heparinem nebo heparinoidy k zevnímu použití | lok. | |
|---|
| 146.1 | C05BA01 | organo-heparinoidy | lok. | 1 | GM | 0,87 | |
| | |
| 146.2 | C05BA03 | heparin k zevnímu použití | lok. | 1 | GM | 0,87 | |
| 86044 | HEPARIN AL GEL 30000 | gel 1x100gm | APA | D |
| 86042 | HEPARIN AL MAST 30000 | ung 1x100gm | APA | D |
| 146.3 | C05BA53 | heparin, kombinace k zevnímu použití | lok. | 1 | GM | 0,87 | |
| 147 | C05CA | kapiláry stabilizující léčiva ze skupiny flavonoidů | p.o. | |
|---|
| 147.1 | C05CA04 | troxerutin | p.o. | 3 | DF | 4,50 | |
| |
| 147.2 | C05CA51 | rutosidy (kombinace, pevné lékové formy) | p.o. | 3 | DF | 1,30 | |
| 96303 | ASCORUTIN | tbl obd 50 | SLO | SK |
| 147.3 | C05CA51 | rutosidy (kombinace, tekuté lékové formy) | p.o. | 2 | ML | 3,03 | |
| 02635 | ANAVENOL | por gtt sol 1x25ml | IXP | CZ |
| 147.4 | C05CA53 | diosmin, kombinace | p.o. | 2 | DF | 4,50 | |
| |
| 147.5 | C05CA54 | troxerutin, kombinace | p.o. | 2 | DF | 4,50 | |
| 148 | C05 | jiné kapiláry stabilizující látky | p.o. |
|---|
| 148.1 | C05BX01 | dobesilat vápenatý | p.o. | 0.75 | GM | 4,50 | |
|
| 148.2 | C05CX01 | tribenosid | p.o. | 0.8 | GM | 4,50 | |
|
| 148.3 | C05CX | jiné kapiláry stabilizující látky (escin) | p.o. | 60 | MG | 6,33 | |
| 31000 | YELLON | cps 30x20mg-bli | SLO | SK |
| 94327 | YELLON | cps 30x20mg-lah | SLO | SK |
| 149 | C05 | jiné kapiláry stabilizující látky | parent. | |
|---|
| 149.1 | C05CX | jiné kapiláry stabilizující látky (escin) | parent. | 5 | MG | 54,26 | H |
|
| 149.2 | C05BB02 | polidokanol (do 0,5% včetně) | parent. | 1 | ML | 14,16 | O |
| 08512 | AETHOXYSKLEROL 0.5% | inj 1x30ml | KRS | D |
| 08510 | AETHOXYSKLEROL 0.5% | inj 5x2ml | KRS | D |
| 149.3 | C05BB02 | polidokanol (nad 0,5 do 1 % včetně) | parent. | 1 | ML | 16,30 | O |
| 20034 | AETHOXYSKLEROL 1% | inj 1x30ml | KRS | D |
| 20033 | AETHOXYSKLEROL 1% | inj 5x2ml | KRS | D |
| 149.4 | C05BB02 | polidokanol (nad 1% do 3 % včetně) | parent. | 1 | ML | 18,16 | O |
| 08511 | AETHOXYSKLEROL 2% | inj 5x2ml | KRS | D |
| 02529 | AETHOXYSKLEROL 3% | inj 5x2ml | KRS | D |
| 149.5 | C05BB02 | polidokanol (více než 3 %) | parent. | 1 | ML | 19,64 | O |
| 90799 | AETHOXYSKLEROL 4% | inj 5x2ml | KRS | D |
| 149.6 | C05BB04 | natrium tetradecyl sulfat (koncentrace do 1% včetně) | parent. | 1 | ML | 14,16 | O |
| |
| 149.7 | C05BB04 | natrium tetradecyl sulfat (koncentrace nad 1% ) | parent. | 1 | ML | 19,64 | O |
| 150 | C07AA | beta-blokátory, bez beta-1 selektivity (sotalol) | p.o. | |
|---|
| 150.1 | C07AA07 | sotalol | p.o. | 0.16 | GM | 4,75 | L/KAR,INT, GER |
| 83481 | SOTAHEXAL 160 | tbl 20x160mg | HEX | D |
| 83670 | SOTAHEXAL 160 | tbl 50x160mg | HEX | D |
| 83480 | SOTAHEXAL 80 | tbl 20x80mg | HEX | D |
| 151 | C07AA | beta-blokátory, bez beta-1 selektivity (ostatní) | p.o. | |
|---|
| 151.1 | C07AA | metipranolol (do 5 mg včetně v 1 tabletě) | p.o. | 10 | MG | 0,78 | |
|
| 151.2 | C07AA | metipranolol (nad 5 do 10 mg včetně v 1 tabletě) | p.o. | 10 | MG | 0,66 | |
| 02483 | TRIMEPRANOL 10MG | tbl 50x10mg | SLO | SK |
| 151.3 | C07AA | metipranolol (nad 10 mg v 1 tabletě) | p.o. | 10 | MG | 0,29 | |
|
| 151.4 | C07AA02 | oxprenolol | p.o. | 0.1 | GM | 2,74 | |
|
| 151.5 | C07AA03 | pindolol | p.o. | 15 | MG | 2,74 | |
|
| 151.6 | C07AA05 | propranolol | p.o. | 0.16 | GM | 2,74 | |
|
| 151.7 | C07AA12 | nadolol | p.o. | 0.16 | GM | 2,74 | |
|
| 151.8 | C07AA16 | tertatolol | p.o. | 5 | MG | 2,74 | |
|
| 151.9 | C07AA17 | bopindolol | p.o. | 1 | MG | 4,00 | |
|
| 151.10 | C07AA23 | penbutolol | p.o. | 40 | MG | 2,74 | |
|
| 151.11 | C07AA27 | kloranolol | p.o. | 20 | MG | 2,74 | |
| 152 | C07AA | beta-blokátory, bez beta-1 selektivity | parent. | |
|---|
| 152.1 | C07AA | metipranolol | parent. | 10 | MG | 62,70 | O |
| 85886 | TRIMEPRANOL | inj 10x1ml/1mg | HBS | SK |
| 152.2 | C07AA | talinolol | parent. | 50 | MG | 93,65 | O |
|
| 152.3 | C07AA02 | oxprenolol | parent. | 0.1 | GM | 99,13 | O |
|
| 152.4 | C07AA03 | pindolol | parent. | 15 | MG | 99,13 | O |
|
| 152.5 | C07AA07 | sotalol | parent. | 0.16 | GM | 900,64 | O |
| 153 | C07AB | beta-blokátory, s beta-1 selektivitou | p.o. | |
|---|
| 153.1 | C07AB02 | metoprolol (do 50 mg včetně v jedné tabletě) | p.o. | 0.15 | GM | 2,93 | |
| 96753 | APO-METOPROLOL 50 | tbl 100x50mg | APT | CND |
| 54152 | EGILOK 50MG | tbl 200x50mg | EGI | H |
| 54151 | EGILOK 50MG | tbl 60x50mg | EGI | H |
| 50080 | VASOCARDIN 50 | tbl 50x50mg | SLO | SK |
| 153.2 | C07AB02 | metoprolol (nad 50 mg v jedné tabletě) | p.o. | 0.15 | GM | 2,74 | |
| 96755 | APO-METOPROLOL 100 | tbl 100x100mg | APT | CND |
| 45555 | BETALOC 100 MG | tbl 100x100mg | AZC | S |
| 59894 | EGILOK 100 MG | tbl 200x100mg | EGI | H |
| 59893 | EGILOK 100 MG | tbl 60x100mg | EGI | H |
| 32674 | METOPROLOL AL 100 | por tbl nob20x100mg | SDB | D |
| 47673 | METOPROLOL AL 100 | por tbl nob20x100mg | APA | D |
| 47674 | METOPROLOL AL 100 | por tbl nob60x100mg | APA | D |
| 32675 | METOPROLOL AL 100 | por tblnob100x100mg | SDB | D |
| 47675 | METOPROLOL AL 100 | por tblnob100x100mg | APA | D |
| 45592 | VASOCARDIN 100 | tbl 50x100mg-blistr | SLO | SK |
| 153.3 | C07AB02 | metoprolol - retardované lékové formy | p.o. | 0.15 | GM | 3,52 | |
| 46980 | BETALOC SR 200MG | tbl ret 100x200mg | AZC | S |
| 46981 | BETALOC SR 200MG | tbl ret 30x200mg | AZC | S |
| 03201 | EMZOK 200 MG | por tbl pro30x200mg | IXP | CZ |
| 32673 | METOPROLOL AL 200 RETARD | por tbl pro50x200mg | APA | D |
| 47501 | METOPROLOL AL 200 RETARD | por tblpro100x200mg | APA | D |
| 32707 | VASOCARDIN SR 200 | por tbl pro30x0.2gm | SLO | SK |
| 32711 | VASOCARDIN SR 200 | por tblpro100x0.2gm | SLO | SK |
| 153.4 | C07AB02 | metoprolol (léková forma tablety s řízeným uvolňováním) do 25 mg v jedné tabletě včetně | p.o. | 0.15 | GM | 26,20 | P |
Metoprolol as modified-release tablets is indicated for the treatment of heart failure; 25 mg is indicated for initiation of therapy, only if the patient does not tolerate a higher dose, can 25 mg be administered over a long period of time. The target dose of metoprolol as modified-release tablets in the indication of heart failure is 200 mg daily and 100 mg tablets can be prescribed for this maintenance dose. In the indication of the treatment of hypertension, arrhythmias and secondary prevention, health insurance cannot be covered.
| 31536 | BETALOC ZOK 25 MG | tbl ret 100x25mg | AZC | S |
| 49935 | BETALOC ZOK 25 MG | tbl ret 100x25mg | AZC | D |
| 153.5 | C07AB02 | metoprolol (léková forma tablety s řízeným uvolňováním) nad 25 mg v jedné tabletě | p.o. | 0.15 | GM | 8,00 | P |
|
| 153.6 | C07AB03 | atenolol do 50 mg v jedné tabletě včetně | p.o. | 75 | MG | 3,35 | |
| 42453 | ATEHEXAL 25 | por tbl flm 30x25mg | SFS | D |
| 83638 | ATEHEXAL 25 | por tbl flm 30x25mg | HEX | D |
| 42454 | ATEHEXAL 25 | por tbl flm 50x25mg | SFS | D |
| 83639 | ATEHEXAL 25 | por tbl flm 50x25mg | HEX | D |
| 42455 | ATEHEXAL 25 | por tbl flm100x25mg | SFS | D |
| 83640 | ATEHEXAL 25 | por tbl flm100x25mg | HEX | D |
| 42456 | ATEHEXAL 50 | por tbl flm 30x50mg | SFS | D |
| 83642 | ATEHEXAL 50 | por tbl flm 30x50mg | HEX | D |
| 42457 | ATEHEXAL 50 | por tbl flm 50x50mg | SFS | D |
| 83643 | ATEHEXAL 50 | por tbl flm 50x50mg | HEX | D |
| 42458 | ATEHEXAL 50 | por tbl flm100x50mg | SFS | D |
| 83644 | ATEHEXAL 50 | por tbl flm100x50mg | HEX | D |
| 62861 | ATENOBENE 25 MG | por tbl flm 30x25mg | MCK | D |
| 62856 | ATENOBENE 50 MG | por tbl flm 20x50mg | MCK | D |
| 62857 | ATENOBENE 50 MG | por tbl flm 50x50mg | MCK | D |
| 58659 | ATENOLOL AL 25 | por tbl nob 30x25mg | APA | D |
| 58660 | ATENOLOL AL 25 | por tbl nob 50x25mg | APA | D |
| 58661 | ATENOLOL AL 25 | por tbl nob100x25mg | APA | D |
| 89254 | ATENOLOL AL 25 | tbl obd 100x25mg | APA | D |
| 89253 | ATENOLOL AL 25 | tbl obd 50x25mg | APA | D |
| 89252 | ATENOLOL AL 25 | tblobd 30x25mg | APA | D |
| 02949 | ATENOLOL AL 50 | por tbl nob 30x50mg | APA | D |
| 02950 | ATENOLOL AL 50 | por tbl nob 50x50mg | APA | D |
| 02951 | ATENOLOL AL 50 | por tbl nob100x50mg | APA | D |
| 89257 | ATENOLOL AL 50 | tbl obd 100x50mg | APA | D |
| 89255 | ATENOLOL AL 50 | tbl obd 30x50mg | APA | D |
| 89256 | ATENOLOL AL 50 | tbl obd 50x50mg | APA | D |
| 153.7 | C07AB03 | atenolol nad 50 mg v jedné tabletě | p.o. | 75 | MG | 3,10 | |
| 54419 | ATEBLOCOR 100 | por tbl flm30x100mg | PMP | CZ |
| 42459 | ATEHEXAL 100 | por tbl flm30x100mg | SFS | D |
| 83646 | ATEHEXAL 100 | por tbl flm30x100mg | HEX | D |
| 42460 | ATEHEXAL 100 | por tbl flm50x100mg | SFS | D |
| 83647 | ATEHEXAL 100 | por tbl flm50x100mg | HEX | D |
| 42461 | ATEHEXAL 100 | por tblflm100x100mg | SFS | D |
| 83648 | ATEHEXAL 100 | por tblflm100x100mg | HEX | D |
| 02710 | ATENOLOL AL 100 | por tblnob 50x100mg | APA | D |
| 02720 | ATENOLOL AL 100 | por tblnob100x100mg | APA | D |
| 89260 | ATENOLOL AL 100 | tbl obd 100x100mg | APA | D |
| 89259 | ATENOLOL AL 100 | tbl obd 50x100mg | APA | D |
| 65389 | TENORMIN 100 | tbl obd 28x100mg | AZC | GB |
| 153.8 | C07AB04 | acebutolol | p.o. | 0.4 | GM | 5,12 | |
| 75939 | ACECOR 400 | por tbl flm30x400mg | DAQ | I |
| 153.9 | C07AB05 | betaxolol | p.o. | 20 | MG | 5,12 | |
| |
| 153.10 | C07AB07 | bisoprolol | p.o. | 10 | MG | 5,12 | |
| 32970 | BISOPROLOL-RATIOPHARM 10 MG | por tbl nob 30x10mg | MCK | D |
| 32974 | BISOPROLOL-RATIOPHARM 10 MG | por tbl nob100x10mg | MCK | D |
| 32967 | BISOPROLOL-RATIOPHARM 5 MG | por tbl nob 100x5mg | MCK | D |
| 32963 | BISOPROLOL-RATIOPHARM 5 MG | por tbl nob 30x5mg | MCK | D |
| 153.11 | C07AB07 | bisoprolol hemifumarát do 2,5 mg v jedné tabletě včetně | p.o. | 10 | MG | 13,37 | P |
| 03801 | CONCOR COR 2.5 MG | tbl obd 28x2.5mg | MEC | D |
| 153.12 | C07AB07 | bisoprolol hemifumarát nad 2,5 mg v jedné tabletě | p.o. | 10 | MG | 8,00 | P |
Bisoprolol is used to treat heart failure; 2.5 mg is indicated for initiation of therapy, only when the patient is not tolerated at a higher dose can 2.5 mg be given for a long time. The target dose of bisoprolol in this indication is 10 mg daily and it is possible to prescribe bisoprolol in 10 mg tablets for maintenance treatment. In the indication of the treatment of hypertension, arrhythmias and secondary prevention, health insurance cannot be covered.
| 153.13 | C07AB08 | celiprolol | p.o. | 0.2 | GM | 5,12 | |
| 59761 | TENOLOC 200 | tbl obd 30x200mg | LEX | CZ |
| 153.14 | C07AB12 | nebivolol | p.o. | 5 | MG | 5,12 | |
| 154 | C07AB | beta-blokátory, s beta-1 selektivitou | parent. | |
|---|
| 154.1 | C07AB02 | metoprolol | parent. | 0.15 | GM | 1398,18 | O |
| | |
| 154.2 | C07AB03 | atenolol | parent. | 75 | MG | 1840,83 | O |
| 65387 | TENORMIN | inj sol 10x10ml/5mg | AZC | GB |
| 154.3 | C07AB04 | acebutolol | parent. | 0.4 | GM | 1398,18 | O |
| | |
| 154.4 | C07AB09 | esmolol | parent. | 2,5 | GM | 4205,00 | O |
| 58412 | BREVIBLOC 250 MG/ML | inf cnc sol 1x10ml | BXT | GB |
| 155 | C07AG | alfa, beta-blokátory | p.o. | |
|---|
| 155.1 | C07AG01 | labetalol | p.o. | 0.6 | GM | 19,50 | L/KAR,INT,GER |
| |
| 155.2 | C07AG02 | karvedilol (do 6,25 mg v 1 tabletě včetně) | p.o. | 37.5 | MG | 21,00 | P |
| 98922 | ATRAM 6.25 | por tblnob30x6.25mg | LEX | CZ |
Carvedilol therapy is initiated by a cardiologist or an intern to treat heart failure with evidence of reduced left ventricular ejection fraction to 35% and below. Karvedilol 6,25 mg is indicated for the introduction of treatment for an absolute period of time and can be prescribed in a maximum of 3 patient packs. Only if a higher dose is not tolerated can a dose of 6,25 mg be administered for a long time. The target dose of carvedilol in this indication is 25-50 mg daily. The indication of the treatment of hypertension cannot be covered by health insurance.
| 155.3 | C07AG02 | karvedilol (nad 6,25 mg v 1 tabletě) | p.o. | 37.5 | MG | 16,00 | P |
| 98925 | ATRAM 25 | por tblnob30x25mg | LEX | CZ |
| 156 | C07AG | alfa, beta-blokátory | parent. | |
|---|
| 156.1 | C07AG01 | labetalol | parent. | 0.6 | GM | 1027,60 | H |
| 157 | C07F | beta-blokátory v kombinaci s jinými antihypertenzivy | p.o. | |
|---|
| 157.1 | C07BB03 | atenolol a thiazidy | p.o. | 1 | DF | 4,34 | |
| 76715 | TENORETIC | por tbl flm 28 | AZC | GB |
| 157.2 | C07CA17 | bopindolol a thiazidy | p.o. | 1 | DF | 4,34 | |
| |
| 157.3 | C07FA | beta-blokátory, neselektivní, a jiná antihypertensiva | p.o. | 0.5 | DF | 0,73 | |
| |
| 157.4 | C07BB07 | bisoprolol a thiazidy | p.o. | 1 | DF | 3,71 | |
| 158 | C08CA | antagonisté vápníku dihydropyridinové řady | p.o. | |
|---|
| 158.1 | C08CA01 | amlodipin | p.o. | 5 | MG | 5,53 | |
| 02954 | AGEN 10 | por tbl nob 30x10mg | LEX | CZ |
| 02945 | AGEN 5 | por tbl nob 30x5mg | LEX | CZ |
| 58876 | AMLOZEK 10 | por tbl nob 30x10mg | ADD | PL |
| 58874 | AMLOZEK 5 | por tbl nob 30x5mg | ADD | PL |
| 03999 | CARDILOPIN 10 MG | por tbl nob 30x10mg | EGI | H |
| 03997 | CARDILOPIN 2.5 MG | por tbl nob30x2.5mg | EGI | H |
| 03998 | CARDILOPIN 5 MG | por tbl nob 30x5mg | EGI | H |
| 03994 | NORMODIPINE 10 MG | por tbl nob 30x10mg | GED | H |
| 03993 | NORMODIPINE 5 MG | por tbl nob 30x5mg | GED | H |
| 58417 | ORCAL 10MG | tbl 30x10mg | LEK | SLO |
| 58415 | ORCAL 5MG | tbl 30x5mg | LEK | SLO |
| 158.2 | C08CA02 | felodipin | p.o. | 5 | MG | 5,53 | |
| 03965 | AURONAL 10 MG RETARD | por tbl ret 30x10mg | EGI | H |
| 03961 | AURONAL 2.5 MG RETARD | por tbl ret30x2.5mg | EGI | H |
| 03963 | AURONAL 5 MG RETARD | por tbl ret30x5mg | EGI | H |
| 02959 | PRESID 10 MG | por tbl ret 30x10mg | IVX | CZ |
| 02961 | PRESID 2.5 MG | por tbl ret30x2.5mg | IVX | CZ |
| 02957 | PRESID 5 MG | por tbl ret 30x5mg | IVX | CZ |
| 158.3 | C08CA03 | isradipin | p.o. | 5 | MG | 5,28 | |
| | |
| 158.4 | C08CA03 | isradipin (retardované lékové formy) | p.o. | 5 | MG | 5,53 | |
| | |
| 158.5 | C08CA05 | nifedipin | p.o. | 30 | MG | 1,45 | |
| 91634 | CORDAFEN | por tbl flm 50x10mg | ZPF | PL |
| 158.6 | C08CA05 | nifedipin (retardované lékové formy s obsahem 20 mg) | p.o. | 30 | MG | 2,10 | |
| 93460 | CORDIPIN RETARD | tbl ret 30x20mg | KRK | SLO |
| 47490 | CORINFAR 20 RETARD | por tbl pro 30x20mg | AWD | D |
| 158.7 | C08CA05 | nifedipin (retardované lékové formy s obsahem 40 mg) | p.o. | 30 | MG | 1,37 | |
| | |
| 158.8 | C08CA05 | nifedipin (lékové formy s retardací 24 hodin) | p.o. | 1 | DF | 5,53 | |
| 03033 | CORDIPIN XL | tbl ret 30x40mg | KRK | SLO |
| 53372 | NIFECARD XL 30MG | tbl ret 30x30mg | LEK | SLO |
| 158.9 | C08CA06 | nimodipin | p.o. | 0.3 | GM | 136,08 | X |
| 94189 | DILCEREN | tbl obd 50x30mg | SLO | SK |
| 158.10 | C08CA07 | nisoldipin | p.o. | 20 | MG | 5,53 | |
| | | |
| 158.11 | C08CA08 | nitrendipin | p.o. | 20 | MG | 5,53 | |
| 94688 | NITRENDIPIN-RATIOPHARM 20MG | por tbl nob 30x20mg | MCK | D |
| 30965 | NITRENDIPIN-RATIOPHARM 20MG | por tbl nob100x20mg | MCK | D |
| 66469 | NITREPRESS 10 | por tbl nob 20x10mg | HHO | D |
| 95584 | NITREPRESS 10 | por tbl nob 28x10mg | HHO | D |
| 95585 | NITREPRESS 10 | por tbl nob 30x10mg | HHO | D |
| 66495 | NITREPRESS 10 | por tbl nob 50x10mg | HHO | D |
| 66496 | NITREPRESS 10 | por tbl nob100x10mg | HHO | D |
| 66499 | NITREPRESS 20 | por tbl nob 20x20mg | HHO | D |
| 95586 | NITREPRESS 20 | por tbl nob 28x20mg | HHO | D |
| 95587 | NITREPRESS 20 | por tbl nob 30x20mg | HHO | D |
| 66498 | NITREPRESS 20 | por tbl nob 50x20mg | HHO | D |
| 66497 | NITREPRESS 20 | por tbl nob100x20mg | HHO | D |
| 03079 | UNIPRES 10 | tbl 30x10mg | KRK | SLO |
| 03078 | UNIPRES 20 | tbl 30x20mg | KRK | SLO |
| 158.12 | C08CA09 | lacidipin | p.o. | 4 | MG | 5,53 | |
|
| 158.13 | C08CA10 | nilvadipin | p.o. | 8 | MG | 5,53 | |
|
| 158.14 | C08CA12 | barnidipin | p.o. | 10 | MG | 5,53 | |
|
| 158.15 | C08CA13 | lercanidipin | p.o. | 10 | MG | 5,53 | |
| 158.16 | C08CX01 | mibefradil | p.o. | 50 | MG | 13,20 | L/INT,KAR,GER |
| 159 | C08CA | antagonisté vápníku dihydropyridinové řady | parent. | |
|---|
| 159.1 | C08CA03 | isradipin | parent. | 5 | MG | 3074,59 | H |
|
| 159.2 | C08CA05 | nifedipin | parent. | 30 | MG | 3074,59 | H |
|
| 159.3 | C08CA06 | nimodipin | parent. | 50 | MG | 3066,90 | X |
| 94535 | NIMOTOP S | inf sol 5x50ml/10mg | BAY | D |
| 160 | C08DA | antagonisté vápníku fenylalkylaminové řady | p.o. | |
|---|
| 160.1 | C08DA01 | verapamil neretardované lékové formy do 240 mg v jedné tabletě včetně | p.o. | 0.24 | GM | 5,00 | |
| 56160 | VERAHEXAL 120 | tbl obd 100x120mg | FST | D |
| 56158 | VERAHEXAL 120 | tbl obd 30x120mg | FST | D |
| 56159 | VERAHEXAL 120 | tbl obd 50x120mg | FST | D |
| 56154 | VERAHEXAL 40 | tbl obd 100x40mg | FST | D |
| 56152 | VERAHEXAL 40 | tbl obd 30x40mg | FST | D |
| 56153 | VERAHEXAL 40 | tbl obd 50x40mg | FST | D |
| 56157 | VERAHEXAL 80 | tbl obd 100x80mg | FST | D |
| 56155 | VERAHEXAL 80 | tbl obd 30x80mg | FST | D |
| 56156 | VERAHEXAL 80 | tbl obd 50x80mg | FST | D |
| 56163 | VERAHEXAL KHK RETARD | tbl ret 100x120mg | FST | D |
| 56161 | VERAHEXAL KHK RETARD | tbl ret 30x120mg | FST | D |
| 56162 | VERAHEXAL KHK RETARD | tbl ret 50x120mg | FST | D |
| 99305 | VERAPAMIL 40-SLOVAKOFARMA | tbl obd 30x40mg | SLO | SK |
| 99306 | VERAPAMIL 80-SLOVAKOFARMA | tbl obd 30x80mg | SLO | SK |
| 86045 | VERAPAMIL AL 120 | por tbl flm50x120mg | APA | D |
| 86046 | VERAPAMIL AL 120 | por tblflm100x120mg | APA | D |
| 77034 | VERAPAMIL AL 40 | por tbl flm50x40mg | APA | D |
| 77035 | VERAPAMIL AL 40 | por tblflm100x40mg | APA | D |
| 77036 | VERAPAMIL AL 80 | por tbl flm50x80mg | APA | D |
| 77037 | VERAPAMIL AL 80 | por tblflm100x80mg | APA | D |
| 160.2 | C08DA01 | verapamil (retardované lékové formy s obsahem 240 mg v jedné tabletě včetně) | p.o. | 0.24 | GM | 5,53 | |
| 93679 | LEKOPTIN RETARD | tbl ret 20x240mg | LEK | SLO |
| 56166 | VERAHEXAL RR | tbl ret 100x240mg | FST | D |
| 56164 | VERAHEXAL RR | tbl ret 30x240mg | FST | D |
| 56165 | VERAHEXAL RR | tbl ret 50x240mg | FST | D |
| 54032 | VERAPAMIL AL 240 RETARD | por tbl ret50x240mg | APA | D |
| 54034 | VERAPAMIL AL 240 RETARD | por tblret100x240mg | APA | D |
| 43877 | VEROGALID ER 240 MG | por tblpro 30x240mg | IVX | CZ |
| 43879 | VEROGALID ER 240 MG | portblpro 100x240mg | IVX | CZ |
| 160.3 | C08DA02 | gallopamil | p.o. | 0.1 | GM | 5,00 | |
| 161 | C08DA | antagonisté vápníku fenylalkylaminové řady | parent. | |
|---|
| 161.1 | C08DA01 | verapamil | parent. | 0.24 | GM | 355,24 | H |
| 162 | C08DB | antagonisté vápníku benzothiazepinové řady | p.o. | |
|---|
| 162.1 | C08DB01 | diltiazem | p.o. | 0.24 | GM | 5,28 | |
| 93186 | BLOCALCIN 60 | por tbl nob 50x60mg | PVL | CZ |
| 94321 | BLOCALCIN 90 RETARD | por tbl ret 30x90mg | PVL | CZ |
| 162.2 | C08DB01 | diltiazem (retardované lékové formy s obsahem 120 mg a více) | p.o. | 0.24 | GM | 5,53 | |
| 163 | C08DB | antagonisté vápníku benzothiazepinové řady | parent. | |
|---|
| 163.1 | C08DB01 | diltiazem | parent. | 25 | MG | 319,18 | H |
| 164 | C09AA | inhibitory angiotenzin konvertujícího enzymu | p.o. | |
|---|
| 164.1 | C09AA01 | kaptopril (do 12,5 mg v 1 tabletě včetně) | p.o. | 50 | MG | 4,29 | |
| 97873 | ALKADIL 25MG | tbl 40x25mg | ALK | MAC |
| 96903 | APO-CAPTO 12.5 MG | tbl 100x12.5mg | APT | CND |
| 68839 | APO-CAPTO 25 MG | tbl 100x25mg | APT | CND |
| 56200 | CAPOTEN 12.5MG | tbl 90x12.5mg | BMS | AUS |
| 12150 | CAPTOPRIL AL 12.5 | tbl 100x12.5mg | APA | D |
| 12148 | CAPTOPRIL AL 12.5 | tbl 30x12.5mg | APA | D |
| 12149 | CAPTOPRIL AL 12.5 | tbl 50x12.5mg | APA | D |
| 164.2 | C09AA01 | kaptopril (nad 12,5 mg do 25 mg v 1 tabletě včetně) | p.o. | 50 | MG | 4,00 | |
| 59381 | CAPTOPRIL 25 SVUS | tbl 100x25mg | SVS | CZ |
| 32253 | CAPTOPRIL AL 25 | tbl 100x25mg | APA | D |
| 32251 | CAPTOPRIL AL 25 | tbl 30x25mg | APA | D |
| 32252 | CAPTOPRIL AL 25 | tbl 50x25mg | APA | D |
| 164.3 | C09AA01 | kaptopril (nad 25 mg v 1 tabletě) | p.o. | 50 | MG | 3,80 | |
| 59386 | CAPTOPRIL 50 SVUS | tbl 100x50mg | SVS | CZ |
| 59384 | CAPTOPRIL 50 SVUS | tbl 30x50mg | SVS | CZ |
| 59385 | CAPTOPRIL 50 SVUS | tbl 50x50mg | SVS | CZ |
| 84143 | CAPTOPRIL AL 50 | tbl 100x50mg | APA | D |
| 84141 | CAPTOPRIL AL 50 | tbl 30x50mg | APA | D |
| 84142 | CAPTOPRIL AL 50 | tbl 50x50mg | APA | D |
| 49563 | TENSIOMIN 50MG | tbl 90x50mg | EGI | H |
| 164.4 | C09AA02 | enalapril hydrogenmaleát (do 5 mg v jedné tabletě včetně) | p.o. | 10 | MG | 4,95 | |
| 83503 | APO-ENALAPRIL 5 MG | tbl 100x5mg | APQ | MEX |
| 59108 | BERLIPRIL 5 | tbl 100x5mg | BCE | D |
| 84651 | BERLIPRIL 5 | tbl 30x5mg | BCE | D |
| 32179 | E-COR 2.5 | por tbl nob30x2.5mg | SLO | SK |
| 32183 | E-COR 5 | por tbl nob 100x5mg | SLO | SK |
| 32182 | E-COR 5 | por tbl nob 30x5mg | SLO | SK |
| 11991 | EDNYT 2.5 MG | tbl 30x2.5mg | GED | H |
| 32277 | EDNYT 5 MG | tbl 100x5mg-blistr | GED | H |
| 12087 | EDNYT 5 MG | tbl 30x5mg-blistr | GED | H |
| 66115 | ENALAPRIL 2.5-SL | tbl 100x2.5mg(bli.) | SLO | SK |
| 66067 | ENALAPRIL 2.5-SL | tbl 30x2.5mg(blis.) | SLO | SK |
| 66197 | ENALAPRIL 5-SL | tbl 100x5mg(blis.) | SLO | SK |
| 66148 | ENALAPRIL 5-SL | tbl 30x5mg(blistr) | SLO | SK |
| 32758 | ENALEK 5 MG | por tbl nob 30x5mg | LEK | SLO |
| 06550 | ENAP 2.5MG | tbl 100x2.5mg | KRK | SLO |
| 59976 | ENAP 2.5MG | tbl 30x2.5mg | KRK | SLO |
| 45273 | ENAP 5 MG | por tbl nob 30x5mg | KRK | SLO |
| 59643 | ENAP 5 MG | por tbl nob100x5mg | KRK | SLO |
| 30478 | ENAPIREX 5 MG | por tbl nob 28x5mg | CHN | H |
| 42632 | ENAPIREX 5 MG | por tbl nob 70x5mg | CHN | H |
| 59879 | ENAPRIL 5 | tbl 100x5mg | SFS | D |
| 59877 | ENAPRIL 5 | tbl 30x5mg | SFS | D |
| 59878 | ENAPRIL 5 | tbl 50x5mg | SFS | D |
| 164.5 | C09AA02 | enalapril hydrogenmaleát (nad 5 do 10 mg v jedné tabletě včetně) | p.o. | 10 | MG | 3,90 | |
| 64839 | APO-ENALAPRIL 10 MG | tbl 100x10mg | APQ | MEX |
| 32185 | E-COR 10 | por tbl nob 30x10mg | SLO | SK |
| 32186 | E-COR 10 | por tblnob100x10mg | SLO | SK |
| 32276 | EDNYT 10 MG | tbl 100x10mg-blistr | GED | H |
| 12156 | EDNYT 10 MG | tbl 30x10mg-blistr | GED | H |
| 58052 | ENALAPRIL 10-SL | tbl 100x10mg(blis.) | SLO | SK |
| 58055 | ENALAPRIL 10-SL | tbl 30x10mg(blistr) | SLO | SK |
| 58367 | ENALAPRIL-RATIOPHARM 10 MG | tbl 50x10mg | MCK | D |
| 32759 | ENALEK 10 MG | por tbl nob 30x10mg | LEK | SLO |
| 45274 | ENAP 10 MG | por tbl nob 30x10mg | KRK | SLO |
| 59642 | ENAP 10 MG | por tbl nob100x10mg | KRK | SLO |
| 30479 | ENAPIREX 10 MG | por tbl nob 28x10mg | CHN | H |
| 42636 | ENAPIREX 10 MG | por tbl nob 70x10mg | CHN | H |
| 59882 | ENAPRIL 10 | tbl 100x10mg | SFS | D |
| 59880 | ENAPRIL 10 | tbl 30x10mg | SFS | D |
| 59881 | ENAPRIL 10 | tbl 50x10mg | SFS | D |
| 164.6 | C09AA02 | enalapril hydrogenmaleát (nad 10 mg v jedné tabletě) | p.o. | 10 MG | 2,85 | |
| 64840 | APO-ENALAPRIL 20 MG | tbl 100x20mg | APQ | MEX |
| 32188 | E-COR 20 | por tbl nob 30x20mg | SLO | SK |
| 32189 | E-COR 20 | por tblnob100x20mg | SLO | SK |
| 12212 | EDNYT 20 MG | tbl 30x20mg | GED | H |
| 58061 | ENALAPRIL 20-SL | tbl 30x20mg(blistr) | SLO | SK |
| 58369 | ENALAPRIL-RATIOPHARM 20 MG | tbl 30x20mg | MCK | D |
| 32760 | ENALEK 20 MG | por tbl nob 30x20mg | LEK | SLO |
| 45275 | ENAP 20 MG | por tbl nob 30x20mg | KRK | SLO |
| 30480 | ENAPIREX 20 MG | por tbl nob 28x20mg | CHN | |
| 42640 | ENAPIREX 20 MG | por tbl nob 70x20mg | CHN | |
| 59885 | ENAPRIL 20 | tbl 100x20mg | SFS | D |
| 59883 | ENAPRIL 20 | tbl 30x20mg | SFS | D |
| 59884 | ENAPRIL 20 | tbl 50x20mg | SFS | D |
| 164.7 | C09AA03 | lisinopril | p.o. | 10 | MG | 5,13 | |
| 10685 | LISINOPRIL-RATIOPHARM 10 MG | por tbl nob100x10mg | MCK | D |
| 10629 | LISINOPRIL-RATIOPHARM 5 MG | por tbl nob 100x5mg | MCK | D |
| 164.8 | C09AA04 | perindopril | p.o. | 4 | MG | 6,00 | |
| 164.9 | C09AA05 | ramipril do 2,5 mg v jedné tabletě včetně | p.o. | 2.5 | MG | 6,00 | |
| 13469 | RAMIL 1.25 | por tblnob30x1.25mg | LEX | CZ |
| 13470 | RAMIL 1.25 | por tblnob90x1.25mg | LEX | CZ |
| 13472 | RAMIL 2.5 | por tblnob 30x2.5mg | LEX | CZ |
| 13473 | RAMIL 2.5 | por tblnob 90x2.5mg | LEX | CZ |
| 164.10 | C09AA05 | ramipril nad 2,5 mg v jedné tabletě | p.o. | 2.5 | MG | 4,80 | |
| 13477 | RAMIL 10 | por tblnob 30x10mg | LEX | CZ |
| 13478 | RAMIL 10 | por tblnob 90x10mg | LEX | CZ |
| 164.11 | C09AA06 | quinapril do 15 mg v jedné tabletě včetně | p.o. | 15 | MG | 6,00 | |
|
| 164.12 | C09AA06 | quinapril nad 15 mg v jedné tabletě | p.o. | 15 | MG | 4,80 | |
|
| 164.13 | C09AA07 | benazepril | p.o. | 7.5 | MG | 6,00 | |
|
| 164.14 | C09AA08 | cilazapril | p.o. | 2.5 | MG | 6,00 | |
|
| 164.15 | C09AA09 | fosinopril | p.o. | 15 | MG | 4,80 | |
|
| 164.16 | C09AA10 | trandolapril | p.o. | 2 | MG | 6,00 | |
|
| 164.17 | C09AA11 | spirapril | p.o. | 6 | MG | 6,00 | |
|
| 164.18 | C09AA12 | delapril | p.o. | 30 | MG | 6,00 | |
|
| 164.19 | C09AA13 | moexipril | p.o. | 15 | MG | 6,00 | |
| |
| 164.20 | C09AA16 | imidapril do 5 mg v jedné tabletě včetně | p.o. | 5 | MG | 6,00 | |
|
| 164.21 | C09AA16 | imidapril nad 5 mg v jedné tabletě | p.o. | 5 | MG | 4,80 | |
| 165 | C09AA | inhibitory angiotenzin konvertujíciho enzymu | parent. | |
|---|
| 165.1 | C09AA02 | enalaprilát | parent. | 1.25 | MG | 26,30 | H |
| 62597 | ENAP I.V. | inj 5x1ml/1.25mg | KRK | SLO |
| 166 | C09BA | inhibitory angiotenzin konvertujícího enzymu v kombinaci s diuretiky | p.o. | |
|---|
| 166.1 | C09BA01 | kaptopril a diuretika | p.o. | 1 | DF | 4,78 | |
| 53252 | CAPTOHEXAL COMP.25/12.5 | tbl 100x25mg/12.5mg | SFS | D |
| 53250 | CAPTOHEXAL COMP.25/12.5 | tbl 20x25mg/12.5mg | SFS | D |
| 53251 | CAPTOHEXAL COMP.25/12.5 | tbl 50x25mg/12.5mg | SFS | D |
| 53245 | CAPTOHEXAL COMP.25/25 | tbl 100x25mg/25mg | SFS | D |
| 53242 | CAPTOHEXAL COMP.25/25 | tbl 20x25mg/25mg | SFS | D |
| 53243 | CAPTOHEXAL COMP.25/25 | tbl 50x25mg/25mg | SFS | D |
| 53249 | CAPTOHEXAL COMP.50/25 | tbl 100x50mg/25mg | SFS | D |
| 53246 | CAPTOHEXAL COMP.50/25 | tbl 20x50mg/25mg | SFS | D |
| 53248 | CAPTOHEXAL COMP.50/25 | tbl 50x50mg/25mg | SFS | D |
| 166.2 | C09BA02 | enalapril a diuretika | p.o. | 1 | DF | 4,37 | |
| 66506 | ENAP-H | por tbl nob 30 | KRK | SLO |
| 55429 | ENAP-HL | por tbl nob 30 | KRK | SLO |
| 166.3 | C09BA06 | quinapril s obsahem 10 mg v jedné tabletě a diuretikum | p.o. | 1 | DF | 4,47 | |
| | |
| 166.4 | C09BA06 | quinapril s obsahem 20 mg v jedné tabletě a diuretikum | p.o. | 1 | DF | 6,87 | |
| | |
| 166.5 | C09BA07 | benazepril a diuretika | p.o. | 1 | DF | 5,06 | |
| | | |
| 166.6 | C09BA08 | cilazapril a diuretika | p.o. | 1 | DF | 10,07 | |
| | |
| 166.7 | C09BB05 | felodipin a ramipril | p.o. | 1 | DF | 8,77 | |
| | |
| 166.8 | C09BB10 | trandolapril/verapamil | p.o. | 1 | DF | 9,75 | |
| 167 | C09CA | antagonisté angiotensinu II | p.o. | |
|---|
| 167.1 | C09CA01 | losartan do 50 mg v jedné tabletě včetně | p.o. | 50 | MG | 6,50 | |
| 10604 | LORISTA | por tblflm 28x50mg | KRK | SLO |
| 47610 | LORISTA | por tblflm 84x50mg | KRK | SLO |
| 10618 | LOZAP 12.5 | portblflm 30x12.5mg | LEX | CZ |
| 10620 | LOZAP 50 | por tbl flm 30x50mg | LEX | CZ |
| 167.2 | C09CA01 | losartan nad 50 mg v jedné tabletě včetně | p.o. | 50 | MG | 5,20 | |
| | | |
| 167.3 | C09CA02 | eprosartan | p.o. | 600 | MG | 6,50 | |
| | |
| 167.4 | C09CA03 | valsartan do 80 mg v jedné tabletě včetně | p.o. | 80 | MG | 6,50 | |
| | | |
| 167.5 | C09CA03 | valsartan nad 80 mg v jedné tabletě | p.o. | 80 | MG | 5,20 | |
| | |
| 167.6 | C09CA04 | irbesartan do 150 mg v jedné tabletě včetně | p.o. | 150 | MG | 9,00 | P |
| | |
| 167.7 | C09CA04 | irbesartan nad 150 mg v jedné tabletě | p.o. | 150 | MG | 7,20 | P |
Irbesartan is indicated in patients with:
(a) diabetic nephropathy from the microalbuminuria phase
(b) non-diabetic nephropathy with proteinuria greater than 1 g / 24 hours in patients intolerant to ACE inhibitors
| 167.8 | C09CA06 | kandesartan do 8 mg v jedné tabletě včetně | p.o. | 8 | MG | 6,50 | |
| | | |
| 167.9 | C09CA06 | kandesartan nad 8 mg v jedné tabletě | p.o. | 8 | MG | 5,20 | |
| | | |
| 167.10 | C09CA07 | telmisartan do 40 mg v jedné tabletě včetně | p.o. | 40 | MG | 6,50 | |
| | | |
| 167.11 | C09CA07 | telmisartan nad 40 mg v jedné tabletě | p.o. | 40 | MG | 5,20 | |
| | | |
| 167.12 | C09DA01 | losartan v kombinaci s thiazidy | p.o. | 1 | DF | 6,97 | |
| 03701 | LOZAP H | por tbl flm 28 | LEX | CZ |
| 167.13 | C09DA03 | valsartan v kombinaci s thiazidy s obsahem 80 mg valsartanu v jedné tabletě včetně | p.o. | 1 | DF | 6,97 | |
| | | |
| 167.14 | C09DA03 | valsartan v kombinaci s thiazidy s obsahem 160 mg valsartanu a 12,5 mg hydrochlorothiazidu v jedné tabletě včetně | p.o. | 1 | DF | 10,87 | |
| | | |
| 167.15 | C09DA03 | valsartan v kombinaci s thiazidy s obsahem 160 mg valsartanu a 25 mg hydrochlorothiazidu v jedné tabletě včetně | p.o. | 1 | DF | 11,34 | |
| 167.16 | C09DA06 | kandesartan v kombinaci s thiazidy s obsahem 8 mg kandesartanu v jedné tabletě | p.o. | 1 | DF | 6,97 | |
|
| 167.17 | C09DA06 | kandesartan v kombinaci s thiazidy s obsahem 16 mg kandesartanu v jedné tabletě | p.o. | 1 | DF | 10,87 | |
|
| 167.18 | C09DA07 | telmisartan v kombinaci s thiazidy s obsahem 40 mg telmisartanu v jedné tabletě | p.o. | 1 | DF | 6,97 | |
|
| 167.19 | C09DA07 | telmisartan v kombinaci s thiazidy s obsahem 80 mg telmisartanu v jedné tabletě | p.o. | 1 | DF | 10,87 | |
| 168 | C10AA | hypolipidemika ze skupiny statinů | p.o. | |
|---|
Simvastatin, lovastatin: treatment of patients with manifested atherosclerosis (secondary prevention) with isolated hypercholesterolaemia or mixed hyperlipidaemia with predominant hypercholesterolaemia can be prescribed with only one hypolipidemic (cannot be combined with statins and fibrates). In patients with diabetes mellitus with hypercholesterolaemia also indicated in primary prevention.
Treatment with atorvastatin, cerivastatin, fluvastatin and pravastatin is performed by a cardiologist, an intern, a diabetic or a physician working in a clinic for lipid metabolism disorders:
(a) treatment of patients with familial hypercholesterolaemia (atorvastatin 40 mg daily is paid only in the treatment of patients with isolated familial hypercholesterolaemia)
b) Treatment of patients with manifested atherosclerosis (secondary prevention) with isolated hypercholesterolaemia or combined hyperlipidaemia with predominant hypercholesterolaemia
(c) treatment of patients with accumulation of risk factors (high risk of cardiovascular events, expressed as an absolute 10-year risk of 20% or more) with isolated hypercholesterolaemia or combined hyperlipidaemia with predominant hypercholesterolaemia
| 168.1 | C10AA01 | simvastatin (do 10 mg v jedné tabletě včetně) | p.o. | 1 | DF | 10,00 | P |
| 59727 | SIMGAL 10 MG | por tbl flm 28x10mg | IVX | CZ |
| 10390 | SIMIREX 10 MG | por tbl flm 30x10mg | SYH | E |
| 10398 | SIMIREX 10 MG | por tbl flm 50x10mg | SYH | E |
| 58773 | SIMVACARD 10 | tbl obd 28x10mg | LEX | CZ |
| 31844 | SIMVASTATIN-RATIOPHARM 10 MG | por tbl flm 30x10mg | SYH | E |
| 31847 | SIMVASTATIN-RATIOPHARM 10 MG | por tbl flm100x10mg | SYH | E |
| 49919 | SIMVAX 10 | por tbl flm 28x10mg | SFS | D |
| 49923 | SIMVAX 10 | por tbl flm 28x10mg | SFS | D |
| 81479 | SIMVAX 10 | por tbl flm 28x10mg | GEA | DK |
| 97067 | SIMVAX 10 | por tbl flm 28x10mg | GEA | DK |
| 49920 | SIMVAX 10 | por tbl flm 30x10mg | SFS | D |
| 49924 | SIMVAX 10 | por tbl flm 30x10mg | SFS | D |
| 81480 | SIMVAX 10 | por tbl flm 30x10mg | GEA | DK |
| 97068 | SIMVAX 10 | por tbl flm 30x10mg | GEA | DK |
| 49921 | SIMVAX 10 | por tbl flm 50x10mg | SFS | D |
| 49925 | SIMVAX 10 | por tbl flm 50x10mg | SFS | D |
| 81481 | SIMVAX 10 | por tbl flm 50x10mg | GEA | DK |
| 97069 | SIMVAX 10 | por tbl flm 50x10mg | GEA | DK |
| 49922 | SIMVAX 10 | por tbl flm100x10mg | SFS | D |
| 49926 | SIMVAX 10 | por tbl flm100x10mg | SFS | D |
| 66024 | SIMVOR 10MG | tbl obd 30x10mg | RXY | IND |
| 58136 | VASILIP 10 | tbl obd 28x10mg | KRK | SLO |
| 95250 | VASILIP 10 | tbl obd 84x10mg | KRK | SLO |
| 168.2 | C10AA01 | simvastatin (nad 10 do 20 mg v jedné tabletě včetně) | p.o. | 1 | DF | 16,00 | P |
| 59728 | SIMGAL 20 MG | por tbl flm 28x20mg | IVX | CZ |
| 10422 | SIMIREX 20 MG | por tbl flm 30x20mg | SYH | E |
| 58775 | SIMVACARD 20 | tbl obd 28x20mg | LEX | CZ |
| 47731 | SIMVACARD 20 | tbl obd 84x20mg | LEX | CZ |
| 31851 | SIMVASTATIN-RATIOPHARM 20 MG | por tbl flm 30x20mg | SYH | E |
| 31856 | SIMVASTATIN-RATIOPHARM 20 MG | por tbl flm 100x20mg | SYH | E |
| 49911 | SIMVAX 20 | por tbl flm 28x20mg | SFS | D |
| 49915 | SIMVAX 20 | por tbl flm 28x20mg | SFS | D |
| 81483 | SIMVAX 20 | por tbl flm 28x20mg | GEA | DK |
| 97071 | SIMVAX 20 | por tbl flm 28x20mg | GEA | DK |
| 49912 | SIMVAX 20 | por tbl flm 30x20mg | SFS | D |
| 49916 | SIMVAX 20 | por tbl flm 30x20mg | SFS | D |
| 81484 | SIMVAX 20 | por tbl flm 30x20mg | GEA | DK |
| 97072 | SIMVAX 20 | por tbl flm 30x20mg | GEA | DK |
| 49913 | SIMVAX 20 | por tbl flm 50x20mg | SFS | D |
| 49917 | SIMVAX 20 | por tbl flm 50x20mg | SFS | D |
| 81485 | SIMVAX 20 | por tbl flm 50x20mg | GEA | DK |
| 97073 | SIMVAX 20 | por tbl flm 50x20mg | GEA | DK |
| 49914 | SIMVAX 20 | por tbl flm100x20mg | SFS | D |
| 49918 | SIMVAX 20 | por tbl flm100x20mg | SFS | D |
| 66026 | SIMVOR 20MG | tbl obd 30x20mg | RXY | IND |
| 58064 | VASILIP 20 | tbl obd 28x20mg | KRK | SLO |
| 95251 | VASILIP 20 | tbl obd 84x20mg | KRK | SLO |
| 168.3 | C10AA01 | simvastatin (nad 20 mg do 40mg v jedné tabletě včetně) | p.o. | 1 | DF | 25,60 | P |
| 59729 | SIMGAL 40 MG | por tbl flm 28x40mg | IVX | CZ |
| 10459 | SIMIREX 40 MG | por tbl flm 30x40mg | SYH | E |
| 58777 | SIMVACARD 40 | tbl obd 28x40mg | LEX | CZ |
| 31859 | SIMVASTATIN-RATIOPHARM 40 MG | por tbl flm 30x40mg | SYH | E |
| 49901 | SIMVAX 40 | por tbl flm 28x40mg | SFS | D |
| 49905 | SIMVAX 40 | por tbl flm 28x40mg | SFS | D |
| 81487 | SIMVAX 40 | por tbl flm 28x40mg | GEA | DK |
| 97075 | SIMVAX 40 | por tbl flm 28x40mg | GEA | DK |
| 49902 | SIMVAX 40 | por tbl flm 30x40mg | SFS | D |
| 49906 | SIMVAX 40 | por tbl flm 30x40mg | SFS | D |
| 81488 | SIMVAX 40 | por tbl flm 30x40mg | GEA | DK |
| 97076 | SIMVAX 40 | por tbl flm 30x40mg | GEA | DK |
| 49903 | SIMVAX 40 | por tbl flm 50x40mg | SFS | D |
| 49907 | SIMVAX 40 | por tbl flm 50x40mg | SFS | D |
| 81489 | SIMVAX 40 | por tbl flm 50x40mg | GEA | DK |
| 97077 | SIMVAX 40 | por tbl flm 50x40mg | GEA | DK |
| 49904 | SIMVAX 40 | por tbl flm100x40mg | SFS | D |
| 49908 | SIMVAX 40 | por tbl flm100x40mg | SFS | D |
| 66028 | SIMVOR 40MG | tbl obd 30x40mg | RXY | IND |
| 66028 | SIMVOR 40MG | tbl obd 30x40mg | RXY | IND |
| 42929 | VASILIP 40 | por tbl obd 28x40mg | KRK | SLO |
| 168.4 | C10AA01 | simvastatin (nad 40 mg v jedné tabletě) | p.o. | 1 | DF | 40,90 | P |
| | |
| 168.5 | C10AA02 | lovastatin (do 20 mg v jedné tabletě včetně) | p.o. | 1 | DF | 9,00 | P |
| 53286 | APO-LOVASTATIN 20 | tbl 100x20mg | APT | CND |
| 01300 | APO-LOVASTATIN 20 | tbl 30x20mg | APT | CND |
| 58799 | HOLETAR 20 | tbl 30x20mg | KRK | SLO |
| 53507 | MEDOSTATIN 20MG | tbl 100x20mg | MOE | CY |
| 53506 | MEDOSTATIN 20MG | tbl 30x20mg | MOE | CY |
| 168.6 | C10AA02 | lovastatin (nad 20 mg v jedné tabletě do 40 mg v jedné tabletě včetně) | p.o. | 1 | DF | 14,40 | P |
| 53287 | APO-LOVASTATIN 40 | tbl 100x40mg | APT | CND |
| 01254 | APO-LOVASTATIN 40 | tbl 30x40mg | APT | CND |
| 168.7 | C10AA03 | pravastatin (do 10 mg v jedné tabletě včetně) | p.o. | 1 | DF | 10,00 | P |
| | |
| 168.8 | C10AA03 | pravastatin (nad 10 mg do 20 mg v jedné tabletě včetně) | p.o. | 1 | DF | 16,00 | P |
| | |
| 168.9 | C10AA03 | pravastatin (nad 20 mg v jedné tabletě) | p.o. | 1 | DF | 25,60 | P |
| | |
| 168.10 | C10AA04 | fluvastatin (do 20 mg v jedné tabletě včetně) | p.o. | 1 | DF | 10,00 | P |
| | |
| 168.11 | C10AA04 | fluvastatin (nad 20 mg do 40 mgv jedné tabletě včetně) | p.o. | 1 | DF | 16,00 | P |
| | | |
| 168.12 | C10AA04 | fluvastatin (nad 40 MG v jedné tabletě ) | p.o. | 1 | DF | 27,50 | P |
| | |
| 168.13 | C10AA05 | atorvastatin (do 10 MG včetně v jedné tabletě) | p.o. | 1 | DF | 21,40 | P |
| | | |
| 168.14 | C10AA05 | atorvastatin (nad 10 MG do 20 MG v jedné tabletě včetně) | p.o. | 1 | DF | 34,20 | P |
| | |
| 168.15 | C10AA05 | atorvastatin (nad 20 MG do 40 MG v jedné tabletě včetně) | p.o. | 1 | DF | 54,70 | P |
| 169 | C10A | hypolipidemika ze skupiny fibrátů a některých dalších skupin | p.o. | |
|---|
| 169.1 | C10AB | klofibrát (etofylin) | p.o. | 0.5 | GM | 4,55 | |
| 49609 | DUOLIP FORTE | tbl obd 100x500mg | MCK | D |
| 169.2 | C10AB02 | bezafibrát | p.o. | 0.6 | GM | 6,50 | |
| | | |
| 169.3 | C10AB04 | gemfibrozil | p.o. | 1.2 | GM | 6,50 | |
| | | | |
| 169.4 | C10AB05 | fenofibrát | p.o. | 0.3 | GM | 6,50 | |
| | | |
| 169.5 | C10AB05 | fenofibrát (mikronisované lékové formy) | p.o. | 1 | DF | 8,10 | |
| 04143 | APO-FENO | por cpsdur 30x200mg | APT | CND |
| 04145 | APO-FENO | por cpsdur100x200mg | APT | CND |
| 32652 | FEBIRA 200 | por cps dur30x200mg | SLO | SK |
| 32653 | FEBIRA 200 | por cps dur60x200mg | SLO | SK |
| 32654 | FEBIRA 200 | por cps dur90x200mg | SLO | SK |
| 41797 | LIPIREX 200MG | por cps dur60x200mg | SGY | B |
| 99839 | LIPIREX S 160 MG | por cps dur60x160mg | SGY | B |
| 47872 | SUPRELIP | por cps dur30x200mg | CPW | H |
| 47873 | SUPRELIP | por cpsdur100x200mg | CPW | H |
| 169.6 | C10AB05 | fenofibrát (supramikronisované lékové formy) | p.o. | 1 | DF | 9,00 | |
| | | |
| 169.7 | C10AB08 | ciprofibrát | p.o. | 0.1 | GM | 8,10 | |
| | | |
| 169.8 | C10AD06 | acipimox | p.o. | 500 | MG | 11,15 | |
| 170 | C10AC | hypolipidemika ze skupiny pryskyřic | p.o. | |
|---|
Treatment is performed by a cardiologist, an intern or a physician working in a treatment centre for lipid disorders:
(a) the treatment of patients with high cholesterol hyperlipoproteinaemia;
(b) treatment of patients with pruritus during biliary cirrhosis.
| 170.1 | C10AC01 | cholestyramin | p.o. | 14 | GM | 31,09 | P |
| 170.2 | C10AC02 | colestipol | p.o. | 20 | GM | 59,39 | P |
| 94764 | COLESTID | plv 50x5gm | UPJ | B |
| 171 | D01AA | antimykotika pro lokální podání ze skupiny antibiotik | lok. | |
|---|
| 171.1 | D01AA01 | nystatin | lok. | 1 | GM | 2,66 | |
| 01069 | FUNGICIDIN LÉČIVA | ung 1x10gm | LEK | CZ |
| 171.2 | D01AA02 | natamycin | lok. | 1 | GM | 1,96 | |
| 172 | D01AC | antimykotika pro lokální podání ze skupiny derivátu imidazolu | lok. | |
|---|
| 172.1 | D01AC01 | klotrimazol do 20 g včetně | lok. | 1 | GM | 1,83 | |
| 65484 | CLOTRIMAZOL AL 1% | crm 1x20gm 1% | APA | D |
| 172.2 | D01AC01 | klotrimazol nad 20 g | lok. | 1 | GM | 1,57 | |
| 86397 | CLOTRIMAZOL AL 1% | crm 1x50gm 1% | APA | D |
| 172.3 | D01AC01 | klotrimazol tekuté lékové formy | lok. | 1 | GM | 2,54 | |
| | |
| 172.4 | D01AC02 | mikonazol | lok. | 1 | GM | 1,83 | |
| | |
| 172.5 | D01AC03 | ekonazol lékové formy krému | lok. | 1 | GM | 1,83 | |
| |
| 172.6 | D01AC03 | ekonazol (lékové formy tekuté, lipogelu a pasty) | lok. | 1 | GM | 3,52 | |
| | |
| 172.7 | D01AC05 | isokonazol | lok. | 1 | ML | 1,83 | |
| | |
| 172.8 | D01AC08 | ketokonazol | lok. | 1 | GM | 1,83 | |
| | |
| 172.9 | D01AC10 | bifonazol | lok. | 1 | GM | 2,49 | |
| 05969 | BIFONAZOL-SL CRM. | drmcrm 1x15gm/150mg | SLO | SK |
| 05976 | BIFONAZOL-SL SOL. | drm sol1x15ml/150mg | SLO | SK |
| 05977 | BIFONAZOL-SL SOL. | drm sol1x20ml/200mg | SLO | SK |
| 172.10 | D01AC11 | oxikonazol | lok. | 1 | GM | 2,49 | |
| | | | |
| 172.11 | D01AC12 | fenticonazol | lok. | 1 | GM | 1,83 | |
| | | |
| 172.12 | D01AC16 | flutrimazol, lékové forma krém a spray | lok. | 1 | GM | 4,70 | |
| | | |
| 172.13 | D01AC16 | flutrimazol, lékové forma gelu | lok. | 1 | GM | 3,06 | |
| | | |
| 172.14 | D01AC14 | sertakonazol | lok. | 1 | GM | 2,49 | |
| | | |
| 172.15 | D01AC20 | kombinace | lok. | 1 | GM | 1,83 | |
| | | |
| 172.16 | D01AC51 | clotrimazol/urea | lok. | 1 | GM | 1,83 | |
| | | |
| 172.17 | D01AC60 | bifonazol, kombinace | lok. | 1 | GM | 13,41 | P |
Treatment is administered by a dermatologist in onychomycosis, as documented by a culture test.
| 173 | D01AE | antimykotika pro lokální podání ostatních skupin | lok. | |
|---|
| 173.1 | D01AE | jiná antimykotika k zevnímu použití | lok. | 1 | ML | 0,78 | |
| 00799 | NITROFUNGIN | drm sol 1x25ml | GNO | CZ |
| 173.2 | D01AE04 | kyselina undecylenová | lok. | 1 | GM | 0,93 | |
|
| 173.3 | D01AE14 | ciclopirox | lok. | 1 | GM | 3,79 | |
| 76150 | BATRAFEN KRÉM | crm 1x20gm/200mg | HBS | SK |
| 76152 | BATRAFEN ROZTOK | liq 1x20ml | HBS | SK |
| 173.4 | D01AE15 | terbinafin | lok. | 1 | GM | 3,79 | |
| |
| 173.5 | D01AE16 | amorolfin | lok. | 1 | MG | 3,35 | |
|
| 173.6 | D01AE18 | tolnaftat | lok. | 1 | GM | 1,83 | |
| | |
| 173.7 | D01AE19 | tolciklát | lok. | 1 | GM | 1,83 | |
| | |
| 173.8 | D01AE20 | kombinace antimykotik (tolnaftat/cetrimid) | lok. | 1 | GM | 1,83 | |
| |
| 173.9 | D01AE20 | kombinace antimykotik (ostatní kombinace) | lok. | 1 | GM | 0,64 | |
| |
| 173.10 | D01AE | naftini hydrochlorid | lok. | 1 | GM | 2,93 | |
| 174 | D01BA | antimykotika pro celkové podání | p.o. | |
|---|
| 174.1 | D01BA01 | griseofulvin | p.o. | 0.5 | GM | 9,97 | |
| |
| 174.2 | D01BA02 | terbinafin do 125 mg v jedné tabletě včetně | p.o. | 0.25 | GM | 60,00 | P |
| 58429 | ONYCHON 125 | tbl 14x125mg bli | LEX | CZ |
| 30766 | ONYCHON 125 | tbl 14x125mg lah | LEX | CZ |
| 10144 | TERBISIL KID | por tblnob 14x125mg | GED | H |
| 174.3 | D01BA02 | terbinafin nad 125 mg v jedné tabletě včetně | p.o. | 0.25 | GM | 57,00 | P |
Treatment with terbinafine is performed by dermatologist:
(a) severe forms of dermatomycosis of selected dermatophytes based on culture or microscopic examination
(b) heavy forms of nail mycosis, if at least one of the following conditions applies:
• Disability of the whole nail plate
• Disability of at least four nail plates so that each of them has a disability that affects more than 30% for the free edge of the nail in a proximal direction
• thumbnail involvement of the lower limb
A positive microscopic finding and mycological culture sampling are a condition for initiating treatment ad (b).
| 175 | D02AB | emolliencia obsahující oxid zinečnatý | lok. | |
|---|
| 175.1 | D02AB | přípravky obsahující oxid zinečnatý (do 120 g v jednom balení včetně) | lok. | 1 | GM | 0,56 | |
| 88780 | SUSPENSIO ZINCI OXYD.CSL4 PROF. | sus 1x100gm | PSR | CZ |
| 176 | D02AC | emolliencia obsahující měkký parafin a tukové produkty | lok. | |
|---|
| 176.1 | D02AC | měkký parafin a tukové produkty (do 250 ml v 1 balení včetně) - tekuté lékové formy | lok. | 1 | ML | 0,59 | L/DER,PDD |
| 176.2 | D02AC | měkký parafin a tukové produkty (nad 250 ml v 1 balení) - tekuté lékové formy | lok. | 1 | ML | 0,43 | L/DER,PDD |
|
| 176.3 | D02AC | měkký parafin s polydekanolem (do 250 ml v 1 balení včetně) | lok. | 1 | ML | 0,65 | L/DER,PDD |
|
| 176.4 | D02AC | měkký parafin s polydekanolem (nad 250 ml v 1 balení) | lok. | 1 | ML | 0,47 | L/DER,PDD |
|
| 176.5 | D02AC | měkký parafin a tukové produkty (do 250 gm v 1 balení včetně) | lok. | 1 | GM | 0,59 | L/DER,PDD |
|
| 176.6 | D02AC | měkký parafin a tukové produkty (nad 250 gm v 1 balení) | lok. | 1 | GM | 0,43 | L/DER,PDD |
|
| 176.7 | D02AE01 | měkký parafin a tukové produkty s obsahem močoviny -tekuté lékové formy | lok. | 1 | ML | 0,50 | L/DER,PDD |
| 97153 | EXCIPIAL U HYDROLOTIO | drm eml 1x200ml | SEG | CH |
| 176.8 | D02AE51 | kombinace kyseliny salicylové s ureou | lok. | 1 | GM | 1,00 | |
| 177 | D02AX | jiná emolliencia a protektiva | lok. | |
|---|
| 177.1 | D02AX | jiná emolliencia a protektiva (do 50 g v balení včetně) | lok. | 1 | GM | 1,71 | |
|
| 177.2 | D02AX | jiná emolliencia a protektiva (nad 50 g v balení) | lok. | 1 | GM | 0,64 | |
|
| 177.3 | D03AX | jiná léčiva podporující tvorbu jizev (chlorofyl) | lok. | 1 | ML | 0,49 | |
|
| 177.4 | D03AX | jiná léčiva podporující zajizvení (kombinace celulosa + karboxycelulosa, na obsah karboxycelulosy) | lok. | 1 | GM | 15,40 | |
|
| 177.5 | D03AX | jiná léčiva podporující zajizvení (zinci hyaluronas -lékové formy gelu) | lok. | 1 | GM | 1,42 | |
|
| 177.6 | D03AX | jiná léčiva podporující zajizvení (zinci hyaluronas -lékové formy roztoku) | lok. | 1 | ML | 3,91 | |
|
| 177.7 | D03AX02 | dextranomer | lok. | 1 | GM | 3,91 | |
| 178 | D03BA | proteolytické enzymy | lok. | |
|---|
Treatment is performed by a surgeon, orthopaedic surgeon, gynecologist, otorhinolaryngologist or dermatologist:
(a) the treatment of leg ulcers,
(b) treatment of necrotic post-injury or post-operative wounds;
(c) treatment of necrotic wounds and decubits.
| 178.1 | D03BA | proteolytické enzymy (chymotrypsin) | lok. | 1 | GM | 79,28 | P |
|
| 178.2 | D03BA52 | proteolytické enzymy (kolagenáza - do 10 GM v jednom balení včetně) | lok. | 1 | GM | 18,57 | P |
|
| 178.3 | D03BA | proteolytické enzymy (plasmin/deoxiribonukleáza) | lok. | 1 | GM | 13,46 | P |
| 02594 | FIBROLAN MAST | ung 1x25gm | PDA | F |
| 178.4 | D03BA | proteolytické enzymy (trypsin/chymotrypsin) | lok. | 1 | GM | 28,84 | P |
| |
| 178.5 | D03BA52 | proteolytické enzymy (kolagenáza - nad 10 GM v jednom balení) | lok. | 1 | GM | 16,62 | P |
|
| 178.6 | D04AB01 | lidokain (lékové formy spreje, koncentrace 10%) | lok. | 1 | GM | 2,10 | O |
| 179 | D05AA | antipsoriatika ze skupiny dehtů a derivátů vitaminu D | lok. | |
|---|
Treatment of vitamin derivatives D in local pharmaceutical forms is operated by dermatologist:
(a) treatment for torpid localized psoriasis not responding to standard therapy of up to 100 g per week.
(b) in other cases only after approval by the medical insurance undertaking's medical examiner.
| 179.1 | D05AA | dehty | lok. | 1 | GM | 0,73 | |
| 66502 | ICHTOXYL | ung 1x30gm | HEO | CZ |
| 66262 | SALOXYL | ung 1x30gm | HEO | CZ |
| 85950 | SUSPENSIO VIŠNĚVSKI+PICE LIQUID | sus 1x1000gm | HEO | CZ |
| 05994 | UNGUENTUM ICHTHAMMOLI 10% H.-B. | drm ung 1x30gm | HEO | CZ |
| 55290 | UNGUENTUM ICHTHAMOLI 10% MVM | drm ung 1x100gm | MVM | CZ |
| 179.2 | D05AA | dehty (odbarvený dehet) | lok. | 1 | GM | 1,17 | |
|
| 179.3 | D05AD02 | methoxalen (0,15 % koncentrace) | lok. | 1 | ML | 4,15 | |
| 90618 | OXSORALEN | liq 1x50ml 0.15% | GER | A |
| 179.4 | D05AC01 | dithranol | lok. | 1 | GM | 3,91 | |
| | |
| 179.5 | D05AX02 | calcipotriol | lok. | 1 | GM | 9,00 | P |
| | |
| 179.6 | D05AX03 | calcitriol | lok. | 1 | GM | 9,00 | P |
| | |
| 179.7 | D05AX04 | tacalcitol | lok. | 1 | GM | 18,00 | P |
| | |
| 179.8 | D05AX05 | tazaroten | lok. | 1 | GM | 18,00 | P |
| 180 | D05BB | retinoidy pro celkové podání | p.o. | |
|---|
Treatment is performed by dermatologist:
(a) treatment for severe generalised forms of psoriasis not responding to other treatments;
b) other severe forms of keratinisation disorder not responding to any other treatment only after prior approval by a revision physician
| 180.1 | D05BB01 | etretinát | p.o. | 35 | MG | 81,14 | P |
| | |
| 180.2 | D05BB02 | acitretin | p.o. | 35 | MG | 81,14 | P |
| | |
| 180.3 | D05BA02 | methoxalen | p.o. | 10 | MG | 3,90 | L/DER |
| 03733 | OXSORALEN | cps 50x10mg | GER | A |
| 181 | D06AX | antibiotika k zevnímu použití | lok. | |
|---|
| 181.1 | D06AA | tetracyklin a deriváty | lok. | 1 | GM | 2,93 | |
|
| 181.2 | D06AX | neomycin/bacitracin (k přípravě roztoku) | lok. | 1 | ML | 3,83 | |
| 55759 | PAMYCON NA PŘÍPRAVU KAPEK | plv 1x1lahv | BTA | SK |
| 181.3 | D06AX | neomycin/bacitracin (zásyp do 2 g včetně) | lok. | 1 | GM | 13,69 | |
| |
| 181.4 | D06AX | neomycin/bacitracin (zásyp nad 2 do 5 g v jednom balení včetně) | lok. | 1 | GM | 7,63 | |
| |
| 181.5 | D06AX | neomycin/bacitracin (mast) | lok. | 1 | GM | 2,93 | |
| |
| 181.6 | D06AX | primycin | lok. | 1 | GM | 2,44 | |
| 181.7 | D06AX02 | chloramfenikol | lok. | 1 | GM | 2,88 | |
|
| 181.8 | D06AX09 | mupirocin (do 5 g v jednom balení včetně) | lok. | 1 | GM | 8,31 | |
|
| 181.9 | D06AX09 | mupirocin (nad 5 g v jednom balení) | lok. | 1 | GM | 5,18 | |
|
| 181.10 | D06AX | neomycin/bacitracin (zásyp nad 5 g v jednom balení) | lok. | 1 | GM | 2,44 | |
| 182 | D06BA | sulfonamidy s obsahem stříbrných solí k lokálnímu podání | lok. | |
|---|
| 182.1 | D06BA | sulfathiazin stříbrný (do 50 g v jednom balení včetně) | lok. | 1 | GM | 1,08 | L/DER,CHI |
|
| 182.2 | D06BA | sulfathiazin stříbrný (nad 50 g v jednom balení) | lok. | 1 | GM | 0,98 | L/DER,CHI |
|
| 182.3 | D06BA01 | sulfadiazin stříbrný (do 50 g v jednom balení včetně) | lok. | 1 | GM | 1,32 | L/DER,CHI |
|
| 182.4 | D06BA01 | sulfadiazin stříbrný (nad 50 g v jednom balení) | lok. | 1 | GM | 1,12 | L/DER,CHI |
|
| 182.5 | D06BA02 | sulfathiazol | lok. | 1 | GM | 0,98 | |
| 00899 | SULFATHIAZOL NEO-SLOVAKOFARMA | ung 1x20gm 5% | SLO | SK |
| 182.6 | D06BA03 | mafenid | lok. | 1 | GM | 0,98 | L/DER,CHI |
|
| 182.7 | D06BA51 | sulfadiazin stříbrný v kombinaci (léková forma náplasti) | lok. | 100 | CM2 | 13,49 | L/DER,CHI |
| |
| 182.8 | D06BA51 | sulfadiazin stříbrný v kombinaci (léková forma krému) | lok. | 1 | GM | 2,25 | L/DER,CHI |
| |
| 182.9 | D06BX01 | metronidazol | lok. | 1 | GM | 2,25 | L/DER,CHI |
| 183 | D07AA | kortikosteroidy třídy I, slabě účinné | lok. | |
|---|
| 183.1 | D07AA02 | hydrokortison | lok. | 1 | GM | 3,31 | |
| | |
| 183.2 | D07AA03 | prednisolon | lok. | 1 | GM | 3,18 | |
| 184 | D07AB | kortikosteroidy třídy II, středně účinné | lok. | |
|---|
| 184.1 | D07AB01 | klobetazon | lok. | 1 | GM | 3,08 | |
| |
| 184.2 | D07AB02 | hydrokortison butyrát | lok. | 1 | GM | 3,08 | |
| |
| 184.3 | D07AB03 | flumetason | lok. | 1 | GM | 3,08 | |
|
| 184.4 | D07AB07 | flupredniden | lok. | 1 | GM | 3,08 | |
| |
| 184.5 | D07AB09 | triamcinolon (lékové formy mastí a krémů) | lok. | 1 | GM | 2,55 | |
| |
| 184.6 | D07AB09 | triamcinolon (lékové formy lotia) | lok. | 1 | ML | 2,83 | |
| 66167 | TRIAMCINOLON-GALENA | drm sol 1x30gm | IVX | CZ |
| 184.7 | D07AB09 | triamcinolon (lékové formy spreje) | lok. | 1 | GM | 0,73 | |
|
| 184.8 | D07AB09 | triamcinolon (lékové formy tinktury) | lok. | 1 | ML | 0,98 | |
|
| 184.9 | D07AB10 | alclomethason | lok. | 1 | GM | 3,08 | |
| 184.10 | D07AB19 | dexamethason acetát | lok. | 1 | GM | 3,09 | |
| 02415 | DEXAMETHAZON LÉČIVA CRM | drm crm 1x10gm | LEX | CZ |
| 185 | D07AC | kortikosteroidy třídy III, účinné (fluorované) | lok. | |
|---|
| 185.1 | D07AC01 | betamethason dipropionát | lok. | 1 | GM | 2,49 | |
| 80206 | BELODERM | drm crm1x30gm 0.05% | BLU | CHO |
| 80204 | BELODERM | drm ung1x30gm 0.05% | BLU | CHO |
| 98034 | DIPROSONE | crm 1x30gm | SCH | B |
| 98032 | DIPROSONE | ung 1x30gm | SCH | B |
| 88489 | KUTERID | drm crm 1x20gm | LEK | SLO |
| 88495 | KUTERID | drm ung 1x20gm | LEK | SLO |
| 185.2 | D07AC01 | betamethason valerát | lok. | 1 | GM | 3,32 | |
|
| 185.3 | D07AC02 | fluklorolon | lok. | 1 | GM | 3,32 | |
|
| 185.4 | D07AC04 | fluocinolon gel | lok. | 1 | GM | 2,44 | |
|
| 185.5 | D07AC04 | fluocinolon mast a krém (koncentrace do 0,025% včetně) | lok. | 1 | GM | 2,93 | |
|
| 185.6 | D07AC04 | fluocinolon mast a krém (koncentrace nad 0,025%) | lok. | 1 | GM | 3,91 | |
|
| 185.7 | D07AC04 | fluocinolon lotio (koncentrace do 0,025% včetně) | lok. | 1 | GM | 2,93 | |
|
| 185.8 | D07AC04 | fluocinolon lotio (koncentrace nad 0,025%) | lok. | 1 | GM | 3,91 | |
| 44743 | GELARGIN FORTE LOT | lot 1x50gm/100mg | LEX | CZ |
| 185.9 | D07AC06 | diflukortolon | lok. | 1 | GM | 3,42 | |
| | |
| 185.10 | D07AC08 | fluocinonid | lok. | 1 | GM | 2,93 | |
| | |
| 185.11 | D07AC12 | halometason | lok. | 1 | GM | 3,27 | |
| | |
| 185.12 | D07AC17 | flutikason | lok. | 1 | GM | 3,42 | |
| 186 | D07AC | kortikosteroidy třídy III, účinné (nefluorované) | lok. | |
|---|
| 186.1 | D07AC09 | budesonid | lok. | 1 | GM | 3,18 | L/DER |
| |
| 186.2 | D07AC13 | mometazon do 10g v 1 balení včetně | lok. | 1 | GM | 6,70 | L/DER,ALG,PDD |
| |
| 186.3 | D07AC13 | mometazon nad 10g v jednom balení | lok. | 1 | GM | 5,00 | L/DER,ALG,PDD |
|
| 186.4 | D07AC14 | methylprednisoloni aceponas | lok. | 1 | GM | 5,87 | L/DER,ALG,PDD |
| |
| 186.5 | D07AC18 | prednikarbat (do 10 g v 1 balení včetně) | lok. | 1 | GM | 6,70 | L/DER,ALG,PDD |
| 83154 DERMATOP | crm 1x10gm/25mg | HBS | SK |
| 83156 DERMATOP | ung 1x10gm/25mg | HBS | SK |
| 186.6 | D07AC18 | prednikarbat (nad 10 g v 1 balení) | lok. | 1 | GM | 5,87 | L/DER,ALG,PDD |
| 187 | D07AD | kortikosteroidy třídy IV, vysoce účinné | lok. | |
|---|
| 187.1 | D07AD01 | klobetasol | lok. | 1 | GM | 4,40 | L/DER |
| | |
| 187.2 | D07AD02 | halcinonid | lok. | 1 | ML | 4,41 | L/DER |
| 97020 | BETACORTON | drm sol 1x100ml | SEG | CH |
| 97019 | BETACORTON | drm sol 1x25ml | SEG | CH |
| 188 | D07BB | kortikosteroidy, středně účinné, kombinace s antiseptiky | lok. | |
|---|
| 188.1 | D07BA01 | prednisolon/cloroxin | lok. | 1 | GM | 1,96 | |
|
| 188.2 | D07BB01 | flumetason a antiseptika | lok. | 1 | GM | 3,32 | |
|
| 188.3 | D07BB03 | triamcinolon a antiseptika (lékové formy pěny) | lok. | 1 | GM | 1,42 | |
|
| 188.4 | D07BB03 | triamcinolon a antiseptika (lékové formy spreje) | lok. | 1 | GM | 0,59 | |
|
| 188.5 | D07BB03 | triamcinolon a antiseptika (lékové formy tinktury) | lok. | 1 | ML | 1,60 | |
| 02827 | TRIAMCINOLON-GALENA | drm gtt sol 1x10ml | IVX | CZ |
| 188.6 | D07BB03 | triamcinolon a antiseptika (lékové formy mastí a krémů) | lok. | 1 | GM | 1,87 | |
|
| 188.7 | D07BA01 | prednisolon/hexamidin diisothionát | lok. | 1 | GM | 1,96 | |
|
| 188.8 | D07CC01 | betamethason a gentamycin | lok. | 1 | GM | 2,50 | L/DER |
| 189 | D07X | kortikosteroidy, jiné kombinace | lok. | |
|---|
| 189.1 | D07XA01 | hydrokortison | lok. | 1 | ML | 1,96 | |
| |
| 189.2 | D07XA02 | prednisolon/kyselina salicylová | lok. | 1 | ML | 1,32 | |
|
| 189.3 | D07XB01 | flumetason/dehet | lok. | 1 | GM | 4,40 | |
| |
| 189.4 | D07XB01 | flumethason pivalat/kyselina salicylová | lok. | 1 | GM | 2,93 | |
|
| 189.5 | D07XB02 | triamcinolon | lok. | 1 | GM | 1,87 | |
|
| 189.6 | D07XC | diflucortolon/isoconasol | lok. | 1 | GM | 2,61 | |
| |
| 189.7 | D07XC01 | betamethason (lékové formy mastí a krémů) | lok. | 1 | GM | 2,61 | |
| 85864 | BELOSALIC | drm ung 1x30gm | BLU | CHO |
| 189.8 | D07XC01 | betamethason (lékové formy tinktur) | lok. | 1 | ML | 2,61 | |
| |
| 189.9 | D07XD | halcinonid/kyselina salicylová | lok. | 1 | ML | 3,57 | |
|
| 189.10 | D07XD | halcinonid/močovina | lok. | 1 | GM | 3,57 | |
|
| 189.11 | D07CA01 | hydrocortison a antibiotika (lékové formy mastí a krémů) | lok. | 1 | GM | 1,96 | |
| |
| 189.12 | D07CA01 | hydrocortison a antibiotika (tekuté lékové formy) | lok. | 1 | ML | 1,96 | |
| 190 | D08A | antiseptika a desinficiencia | lok. | |
|---|
| 190.1 | D08AC02 | chlorhexidin | lok. | 1000 | ML | 178,70 | |
|
| 190.2 | D08AD | kyselina boritá (lékové formy mastí) | lok. | 1 | GM | 0,43 | |
| 65998 | UNG.AC.BORICI 3% HERB.-BOFARMA | ung 1x1000gm (dÓza) | HEO | CZ |
| 65997 | UNG.AC.BORICI 3% HERB.-BOFARMA | ung 1x500gm (dÓza) | HEO | CZ |
| 190.3 | D08AD | kyselina boritá (lékové formy roztoků) | lok. | 10 | GM | 1,32 | |
|
| 190.4 | D08AG02 | polyvidon-jód (do 200 ml včetně roztoku v jednom balení) | lok. | 1 | ML | 0,98 | |
| 46054 | BRAUNOL | liq 1x100ml | BMB | CH |
| 02981 | JODISOL ROZTOK | liq 1x80gm | SDH | CZ |
| 96605 | JODISOL SPRAY S MECH.ROZPRAŠOV. | drm spr sol1x75gm | SDH | CZ |
| 190.5 | D08AG02 | polyvidon-jód (nad 200 ml roztoku v jednom balení) | lok. | 1 | ML | 0,49 | |
| 62317 | BETADINE | liq 1x1000ml | EGI | H |
| 62319 | BETADINE | liq chir 1x1000ml | EGI | H |
| 80553 | BRAUNOL | liq 1x1000ml | BMB | CH |
| 46055 | BRAUNOL | liq 1x250ml | BMB | CH |
| 46056 | BRAUNOL | liq 1x500ml | BMB | CH |
| 02983 | JODISOL ROZTOK | liq 1x760gm | SDH | CZ |
| 190.6 | D08AG02 | polyvidon-jód (do 200 g masti v jednom balení včetně) | lok. | 1 | GM | 1,96 | |
| 84421 | BRAUNOVIDON MAST | ung 1x100gm-tuba | BMB | CH |
| 190.7 | D08AG02 | polyvidon-jód nad 200 g masti v jednom balení) | lok. | 1 | GM | 0,98 | |
| 46052 | BRAUNOVIDON MAST | ung 1x250gm-kelímek | BMB | CH |
| 84422 | BRAUNOVIDON MAST | ung 1x250gm-pe tuba | BMB | CH |
| 190.8 | D08AH | kloroxin | lok. | 1 | GM | 0,78 | |
|
| 190.9 | D08AJ | bromid benzododecinia (tinktura a roztok do 50 ml v jednom balení včetně) | lok. | 1 | ML | 0,29 | |
|
| 190.10 | D08AJ | bromid benzododecinia (tinktura a roztok nad 50 ml v jednom balení) | lok. | 1 | ML | 0,29 | H |
| 58237 | AJATIN PROFARMA TINKTURA | tct 1x1000ml | PSR | CZ |
| 190.11 | D08AJ | chlorid karbetopendecinia (tinktura 50 ml v jednom balení včetně) | lok. | 1 | ML | 0,29 | |
| 191 | D08AX | jiná antiseptika a desinficiencia | lok. | |
|---|
| 191.1 | D08AX | hexamidin/chlorhexidin | lok. | 1 | ML | 121,37 | H |
| | |
| 191.2 | D08AX | noxytiolin | lok. | 2.5 | GM | 492,11 | H |
| | |
| 191.3 | D08AX | noxytiolin/tetrakain | lok. | 2.5 | GM | 492,11 | H |
| | |
| 191.4 | D08AX | taurolidin | lok. | 1 | GM | 94,48 | H |
| 192 | D10A | lokálně podávaná léčiva k léčbě akne | lok. | |
|---|
| 192.1 | D10AD01 | tretinoin (lékové formy krémů a gelů do koncentrace 0,05% včetně) | lok. | 1 | GM | 3,75 | |
| 66170 | LOCACID | crm 1x30gm 0.05% | PFH | F |
| 192.2 | D10AD01 | tretinoin (lékové formy krémů a gelů koncentrace nad 0,05%) | lok. | 1 | GM | 4,40 | |
| 97573 | RETIN-A KRÉM 0.025% | drm crm 1x30gm | CIL | CH |
| 192.3 | D10AD01 | tretinoin (lékové formy roztoků do koncentrace 0,05% včetně) | lok. | 1 | ML | 4,00 | |
| 64956 | AIROL | lot 1x50ml 0.05% | PRH | F |
| 192.4 | D10AD01 | tretinoin (lékové formy roztoků koncentrace nad 0,05%) | lok. | 1 | ML | 4,40 | |
|
| 192.5 | D10AD03 | adapalen - léková forma krémů a gelů | lok. | 1 | GM | 4,00 | |
|
| 192.6 | D10AD54 | isotretinoin a erythromycin v kombinaci | lok. | 1 | GM | 2,93 | |
|
| 192.7 | D10AE01 | benzoyl peroxid (lékové formy krémů a gelů) | lok. | 1 | GM | 1,42 | |
| 47279 | ECLARAN 5 | drm gel 1x45gm | PFG | F |
| 192.8 | D10AE01 | benzoyl peroxid (lékové formy roztoků a lotií) | lok. | 1 | ML | 0,39 | |
|
| 192.9 | D10AE01 | benzoyl peroxid (koncentrace 20%) | lok. | 1 | ML | 2,54 | |
|
| 192.10 | D10AF01 | klindamycin | lok. | 1 | ML | 1,96 | |
|
| 192.11 | D10AF02 | erythromycin (lékové formy krémů a mastí) | lok. | 1 | GM | 2,93 | |
|
| 192.12 | D10AF02 | erythromycin (lékové formy roztoků) do 60 ml včetně v jednom balení | lok. | 1 | ML | 2,13 | |
| 98204 | ERYFLUID | sol 1x30ml | PFH | F |
| 192.13 | D10AF02 | erythromycin (lékové formy roztoků) nad 60 ml v jednom balení | lok. | 1 | ML | 1,72 | |
| 75285 | ERYFLUID | sol 1x100ml | PFH | F |
| 192.14 | D10AF52 | erythromycin v kombinaci | lok. | 1 | ML | 2,93 | |
|
| 192.15 | D10AX03 | kyselina azelaová | lok. | 1 | GM | 1,96 | |
| 193 | D10B | celkově podávaná léčiva k léčbě akné | p.o. | |
|---|
| 193.1 | D10BA01 | isotretinoin (do 10 MG včetně v jedné kapsli ) | p.o. | 30 | MG | 83,53 | X |
| 11685 | ROACCUTANE 10MG | cps 30x10mg | HLR | CH |
| 193.2 | D10BA01 | isotretinoin (nad 10 MG v jedné kapsli) | p.o. | 30 | MG | 75,39 | X |
| 91843 | ROACCUTANE 20MG | cps 30x20mg | HLR | CH |
| 194 | D11AX | jiná dermatologika | lok. | |
|---|
| 194.1 | D11AX | celulóza (lékové formy zásypů) | lok. | 1 | GM | 9,78 | L/DER |
| |
| 194.2 | D11AX | pimecrolimus | lok. | 1 | GM | 32,00 | P |
Treatment with pimecrolim is indicated by a dermatoenerologist in children 3 months to 6 years of age for acute and subacute manifestations of atopic dermatitis without wetting and superinfection in the face and neck, which last for at least 14 days when using emolients. The maximum duration of continuous administration is 6 months.
| 194.3 | D11AX14 | tacrolimus v koncentraci 0,03% | lok. | 1 | GM | 32,00 | P |
| | |
| 194.4 | D11AX14 | tacrolimus v koncentraci 0,1% | lok. | 1 | GM | 35,00 | P |
Treatment of atopic dermatitis with Tacrolimus is administered by a dermatologist in patients who have failed to receive treatment with or are not tolerated by conventional therapy in the following indications:
(a) for children 2-6 years of age who have moderate or severe atopic dermatitis on the head and neck (Rajka and Langeland classification: moderate form = 4.5-7,5 points, severe form = 8-9 points);
(b) in children over 6 years of age and in adults suffering from severe atopic dermatitis on the head and neck (8-9 points of the above classification).
| 194.5 | D11AF | fluorouracil (lékové formy roztoků) | lok. | 1 | ML | 16,51 | L/DER |
| 60890 | VERRUMAL | liq 1x13ml | HEM | D |
| 194.6 | D11AF | fluorouracil (lékové formy mastí) | lok. | 1 | GM | 13,15 | L/DER,ONK |
| |
| 194.7 | D06BB04 | podophylotoxin | lok. | 1 | GM | 15,00 | L/DER |
| 195 | G01AA | vaginálně podávaná antimykotika a antibiotika | vag. | |
|---|
Treatment with vaginal clindamycin is performed by a gynaecologist:
(a) the treatment of bacterial vaginosis during pregnancy,
Comments 0